1
Yale Endocrinology
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste 4th Floor Multispecialty Care Center
New Haven, CT 06511
1 of 4
- Yale EndocrinologySmilow Cancer Hospital at Yale New Haven35 Park Street, Ste 4th Floor Multispecialty Care CenterNew Haven, CT 06511
- Yale Endocrinology & MetabolismYale New Haven Hospital20 York StreetNew Haven, CT 06510
- Yale Diabetes CenterDana Clinic Building789 Howard Avenue, Ste 2nd FloorNew Haven, CT 06519
- Yale Endocrinology & MetabolismYale Health Center55 Lock StreetNew Haven, CT 06511
Silvio Inzucchi, MD
Endocrinology, Diabetes Medicine & Management
Telehealth is available
Patient type treated
Adult
Accepting new patients
Yes
Referral required
From patients or physicians
Board Certified in
Endocrinology Diabetes & Metabolism and Internal Medicine
Biography
Silvio E. Inzucchi, MD, director of the Yale Medicine Diabetes Center, treats patients who suffer from diabetes as well as pituitary and adrenal disorders. “Endocrinology is fascinating, and we are usually able to help patients improve their quality of life through multidisciplinary care and academic approaches to endocrine conditions,” he says.
Dr. Inzucchi is a professor or medicine (endocrinology) at Yale School of Medicine and the clinical director of the section of endocrinology. In his research, Dr. Inzucchi, studies the cardiovascular effects of diabetes medications and glucose management in the hospital. Named a “top doctor” locally and nationally, Dr. Inzucchi has also received Yale’s David J. Leffell Prize for Clinical Excellence. The prize is given to individuals who demonstrate the highest level of clinical expertise, commitment to teaching and compassion for patients.
He says he has developed an effective personal approach to treating patients, carefully honed over 30 years at Yale. It includes being on top of the latest advances, but also responding to each patient’s individual needs. “I like to try to draw people out in terms of who they are, what’s important to them, their life experiences and their family. Such an approach resonates with patients because they don’t want to be seen as a patient, they want to be treated as a person,” he says.
Titles
- Professor of Medicine (Endocrinology)
Education & Training
- MDHarvard University (1985)
- BSFordham University (1981)
Languages Spoken
- English
- Italiano (Italian)
Additional Information
Board Certifications
- AB of Internal Medicine, Endocrinology Diabetes & Metabolism (1995, recertified: 2017)
- AB of Internal Medicine, Internal Medicine (1988)
Publications
- Magvanjav O, MacLeod RS, Balasubramanian P, Mekala K, Peter PR, Inzucchi SE, Majumdar SK. Iodine for the Outpatient Management of Graves' Disease: A Case Series of 7 Patients. AACE Endocrinol Diabetes 2025, 13: 83-87. PMID: 41641309, DOI: 10.1016/j.aed.2025.10.015.
- Pop-Busui R, Rosin S, Butera N, Krause-Steinrauf H, Abou Assi H, Garg R, Inzucchi S, Katona A, McGill J, Mudaliar S, Schade D, Seaquist E, Tiktin M, Soliman E, Green J, Crandall J, McKee M, Behringer-Massera S, Brown-Friday J, Xhori E, Ballentine-Cargill K, Duran S, Estrella H, Gonzalez de la torre S, Lukin J, Phillips L, Burgess E, Olson D, Rhee M, Wilson P, Raines T, Boers J, Costello J, Maher-Albertelli M, Mungara R, Savoye L, White C, Gullett C, Holloway L, Morehead F, Person S, Sibymon M, Tanukonda S, Adams C, Ross A, Balasubramanyam A, Gaba R, Gonzalez Hattery E, Ideozu A, Jimenez J, Montes G, Wright C, Hollander P, Roe E, Jackson A, Smiley A, Burt P, Estrada L, Chionh K, Ismail-Beigi F, Falck-Ytter C, Sayyed Kassem L, Sood A, Tiktin M, Kulow T, Newman C, Stancil K, Cramer B, Iacoboni J, Kononets M, Sanders C, Tucker L, Werner A, Maxwell A, McPhee G, Patel C, Colosimo L, Krol A, Goland R, Pring J, Alfano L, Kringas P, Hausheer C, Tejada J, Gumpel K, Kirpitch A, Schneier H, Green J, AbouAssi H, Chatterjee R, Feinglos M, English Jones J, Khan S, Kimpel J, Zimmer R, Furst M, Satterwhite B, Thacker C, Evans Kreider K, Mariash C, Mather K, Ismail H, Lteif A, Mullen M, Hamilton T, Patel N, Riera G, Jackson M, Pirics V, Aguillar D, Howard D, Hurt S, Bergenstal R, Carlson A, Martens T, Johnson M, Hill R, Hyatt J, Jensen C, Madden M, Martin D, Willis H, Konerza W, Yang S, Kleeberger K, Passi R, Fortmann S, Herson M, Mularski K, Glauber H, Prihoda J, Ash B, Carlson C, Ramey P, Schield E, Torgrimson-Ojerio B, Arnold K, Kauffman B, Panos E, Sahnow S, Bays K, Berame K, Cook J, Ghioni D, Gluth J, Schell K, Criscola J, Friason C, Jones S, Nazarov S, Barzilay J, Rassouli N, Puttnam R, Ojoawo B, Nelson R, Curtis M, Hollis B, Sanders-Jones C, Stokes K, El-Haqq Z, Kolli A, Tran T, Wexler D, Larkin M, Meigs J, Chambers B, Dushkin A, Rocchio G, Yepes M, Steiner B, Dulin H, Cayford M, Chu K, DeManbey A, Hillard M, Martin K, Thangthaeng N, Gurry L, Kochis R, Raymond E, Ripley V, Stevens C, Park J, Aroda V, Ghazi A, Magee M, Ressing A, Loveland A, Hamm M, Hurtado M, Kuhn A, Leger J, Manandhar L, Mwicigi F, Sanchez O, Young T, Garg R, Lagari-Libhaber V, Florez H, Valencia W, Marks J, Casula S, Oropesa-Gonzalez L, Hue L, Cuadot A, Nieto-Martinez R, Riccio Veliz A, Gutt M, Kendal Y, Veciana B, Ahmann A, Aby-Daniel D, Joarder F, Morimoto V, Sprague C, Yamashita D, Cady N, Rivera-Eschright N, Kirchhoff P, Morales Gomez B, Adducci J, Goncharova A, Hox S, Petrovitch H, Matwichyna M, Jenkins V, Broadwater L, Ishii R, Bermudez N, Hsia D, Cefalu W, Greenway F, Waguespack C, King E, Fry G, Dragg A, Gildersleeve B, Arceneaux J, Haynes N, Thomassie A, Pavlionis M, Bourgeois B, Hazlett C, Mudaliar S, Henry R, Boeder S, Pettus J, Diaz E, Garcia-Acosta D, Maggs S, DeLue C, Stallings A, Castro E, Hernandez S, Krakoff J, Curtis J, Killean T, Khalid M, Joshevama E, Diaz E, Martin D, Tsingine K, Karshner T, Albu J, Pi-Sunyer F, Frances S, Maggio C, Ellis E, Bastawrose J, Gong X, Banerji M, August P, Lee M, Lorber D, Brown N, Josephson D, Thomas L, Tsovian M, Cherian A, Jacobson M, Mishko M, Kirkman M, Buse J, Diner J, Dostou J, Machineni S, Young L, Bergamo K, Goley A, Kerr J, Largay J, Guarda S, Cuffee J, Culmer D, Fraser R, Almeida H, Coffer S, Debnam E, Kiker L, Morton S, Josey K, Fuller G, Garvey W, Cherrington A, Dyer D, Lawson M, Griffith O, Agne A, McCullars S, Cohen R, Craig J, Rogge M, Burton K, Kersey K, Wilson C, Lipp S, Vonder Meulen M, Adkins C, Onadeko T, Rasouli N, Baker C, Schroeder E, Razzaghi M, Lyon C, Penaloza R, Underkofler C, Lorch R, Douglass S, Steiner S, Sivitz W, Cline E, Knosp L, McConnell J, Lowe T, Herman W, Pop-Busui R, Tan M, Martin C, Waltje A, Katona A, Goodhall L, Eggleston R, Kuo S, Bojescu S, Bule S, Kessler N, LaSalle E, Whitley K, Seaquist E, Bantle A, Harindhanavudhi T, Kumar A, Redmon B, Bantle J, Coe M, Mech M, Taddese A, Lesne L, Smith S, Desouza C, Kuechenmeister L, Shivaswamy V, Burbach S, Rodriguez M, Seipel K, Alfred A, Morales A, Eggert J, Lord G, Taylor W, Tillson R, Schade D, Adolphe A, Burge M, Duran-Valdez E, Martinez J, Bancroft A, Kunkel S, Ali Jamaleddin Ahmad F, Hernandez McGinnis D, Pucchetti B, Scripsick E, Zamorano A, DeFronzo R, Cersosimo E, Abdul-Ghani M, Triplitt C, Juarez D, Garza R, Verastiqui H, Wright K, Puckett C, Raskin P, Rhee C, Abraham S, Jordan L, Sao S, Morton L, Smith O, Osornio Walker L, Schnurr-Breen L, Ayala R, Kreymer R, Sturgess D, Utzschneider K, Kahn S, Alarcon-Casas Wright L, Boyko E, Tsai E, Trence D, Trikudanathan S, Fattaleh B, Montgomery B, Atkinson K, Kozedub A, Concepcion T, Moak C, Prikhodko N, Rhothisen S, Elasy T, Martin S, Shackelford L, Goidel R, Hinkle N, Lovell C, Myers J, Lipps Hogan J, McGill J, Salam M, Schweiger T, Kissel S, Recklein C, Clifton M, Tamborlane W, Camp A, Gulanski B, Inzucchi S, Pham K, Alguard M, Gatcomb P, Lessard K, Perez M, Iannone L, Magenheimer E, Montosa A, Cefalu W, Fradkin J, Burch H, Bremer A, Nathan D, Lachin J, Kahn S, Krause-Steinrauf H, Larkin M, Tiktin M, Wexler D, Burch H, Younes N, Bebu I, Butera N, Buys C, Fagan A, Gao Y, Ghosh A, Gramzinski M, Hall S, Kazemi E, Legowski E, Liu H, Suratt C, Tripputi M, Arey A, Backman M, Bethepu J, Lund C, Mangat Dhaliwal P, McGee P, Mesimer E, Ngo L, Steffes M, Seegmiller J, Saenger A, Arends V, Gabrielson D, Conner T, Warren S, Day J, Huminik J, Scrymgeour A, Soliman E, Pokharel Y, Zhang Z, Campbell C, Hu J, Keasler L, Hensley S, Li Y, Herman W, Kuo S, Martin C, Waltje A, Mihalcea R, Min D, Perez-Rosas V, Prosser L, Resnicow K, Ye W, Shao H, Zhang P, Luchsinger J, Sanchez D, Assuras S, Groessl E, Sakha F, Chong H, Hillery N. Differences in Prevalence and Incidence of Electrocardiogram Abnormalities and Cardiovascular Autonomic Neuropathy Among Randomized Glucose-Lowering Treatments in Early Type 2 Diabetes: The Glycemia Reduction Approaches in Diabetes (GRADE) Cohort. Diabetes Care 2025, 48: 1960-1970. PMID: 40986645, PMCID: PMC12583396, DOI: 10.2337/dc25-1087.
- Berg D, Patel S, Haller P, Cange A, Palazzolo M, Bellavia A, Kuder J, Desai A, Inzucchi S, McMurray J, O’Meara E, Verma S, Bělohlávek J, Drożdż J, Merkely B, Ogunniyi M, Drasnar T, Izzo J, Sarman B, McGinty J, Ramanathan K, Mulkay A, Przybylski A, Ruff C, O’Donoghue M, Murphy S, Sabatine M, Wiviott S, Committees and Investigators O. Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure. Circulation 2025, 152: 1411-1422. PMID: 40884036, DOI: 10.1161/circulationaha.125.076575.
- Lee M, Sattar N, Pop-Busui R, Deanfield J, Emerson S, Inzucchi S, Mann J, Marx N, Mulvagh S, Poulter N, Badve S, Pratley R, Perkovic V, Buse J, McGuire D. Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials. Diabetes Care 2025, 48: 846-859. PMID: 40156846, DOI: 10.2337/dc25-0241.
- Marx N, Deanfield J, Mann J, Arechavaleta R, Bain S, Bajaj H, Tanggaard K, Birkenfeld A, Buse J, Davicevic-Elez Z, Desouza C, Emerson S, Engelmann M, Hovingh G, Inzucchi S, Jhund P, Mulvagh S, Pop-Busui R, Poulter N, Rasmussen S, Tu S, McGuire D, Group O. Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial. Circulation 2025, 151: 1639-1650. PMID: 40156843, PMCID: PMC12144549, DOI: 10.1161/circulationaha.125.074545.
- Butt J, De Boer R, Hernandez A, Inzucchi S, Kosiborod M, Koeber L, Lam C, Martinez F, Ponikowski P, Sabatine M, Shah S, Vaduganathan M, Jhund P, Solomon S, Mcmurray J. Effects of dapagliflozin in heart failure according to duration of type 2 diabetes: a patient-level meta-analysis of DAPA-HF and DELIVER. European Heart Journal 2024, 45: ehae666.1097. DOI: 10.1093/eurheartj/ehae666.1097.
- Selvaraj S, Patel S, Sauer A, McGarrah R, Jones P, Kwee L, Windsor S, Ilkayeva O, Muehlbauer M, Newgard C, Borlaug B, Kitzman D, Shah S, Margulies K, Husain M, Inzucchi S, McGuire D, Lanfear D, Javaheri A, Umpierrez G, Mentz R, Sharma K, Kosiborod M, Shah S. Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction. Circulation Heart Failure 2024, 17: e011980. PMID: 39421941, PMCID: PMC11634023, DOI: 10.1161/circheartfailure.124.011980.
- Pabon M, Vaduganathan M, Claggett B, Chatur S, Siqueira S, Marti‐Castellote P, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Desai A, Jhund P, McMurray J, Solomon S, Vardeny O. In‐hospital course of patients with heart failure with improved ejection fraction in the DELIVER trial. European Journal Of Heart Failure 2024, 26: 2532-2540. PMID: 39300780, PMCID: PMC11683867, DOI: 10.1002/ejhf.3410.
- Butt J, Shen L, Inzucchi S, Docherty K, Jhund P, Martinez F, Sabatine M, Vaduganathan M, Solomon S, McMurray J, Committees and Investigators D. Dapagliflozin in Heart Failure, Type 2 Diabetes, and Neuropathy A Meta-Analysis of DAPA-HF and DELIVER. JACC Heart Failure 2024, 12: 1946-1948. PMID: 39269393, DOI: 10.1016/j.jchf.2024.07.017.
- Abdin A, Kondo T, Böhm M, Jhund P, Claggett B, Vaduganathan M, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Desai A, Køber L, Sabatine M, Petersson M, Bachus E, Solomon S, McMurray J, Committees and Investigators O. Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA‐HF and DELIVER. European Journal Of Heart Failure 2024, 26: 1952-1963. PMID: 39016033, DOI: 10.1002/ejhf.3350.
- Lassen M, Ostrominski J, Inzucchi S, Claggett B, Kulac I, Jhund P, de Boer R, Hernandez A, Kosiborod M, Lam C, Martinez F, Shah S, Desai A, Petersson M, Langkilde A, Docherty K, McMurray J, Solomon S, Vaduganathan M. Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose‐lowering therapy: A pre‐specified analysis of the DELIVER trial. European Journal Of Heart Failure 2024, 26: 1539-1548. PMID: 38745498, DOI: 10.1002/ejhf.3269.
- Yang M, Kondo T, Talebi A, Jhund P, Docherty K, Claggett B, Vaduganathan M, Bachus E, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Solomon S, McMurray J. Dapagliflozin and quality of life measured using the EuroQol 5‐dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction. European Journal Of Heart Failure 2024, 26: 1524-1538. PMID: 38700986, DOI: 10.1002/ejhf.3263.
- McDowell K, Kondo T, Talebi A, Teh K, Bachus E, de Boer R, Campbell R, Claggett B, Desai A, Docherty K, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Simpson J, Vaduganathan M, Jhund P, Solomon S, McMurray J. Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction. JAMA Cardiology 2024, 9: 457-465. PMID: 38536153, PMCID: PMC10974691, DOI: 10.1001/jamacardio.2024.0284.
- Rivier C, Acosta J, Leasure A, Forman R, Sharma R, de Havenon A, Spatz E, Inzucchi S, Kernan W, Falcone G, Sheth K. Secondary Prevention in Patients With Stroke Versus Myocardial Infarction: Analysis of 2 National Cohorts. Journal Of The American Heart Association 2024, 13: e033322. PMID: 38639369, PMCID: PMC11179946, DOI: 10.1161/jaha.123.033322.
- Pabón M, Wang X, Lam C, O'Meara E, Vaduganathan M, Claggett B, Foà A, Lu H, Langkilde A, De Boer R, Desai A, Hernandez A, Inzucchi S, Jhund P, Kosiborod M, Martinez F, Shah S, Petersson M, McMurray J, Solomon S, Vardeny O. Sex Differences in Heart Failure With Improved Ejection Fraction The DELIVER Trial. JACC Heart Failure 2024, 12: 1119-1122. PMID: 38661586, DOI: 10.1016/j.jchf.2024.03.011.
- Patel S, Kang Y, Im K, Neuen B, Anker S, Bhatt D, Butler J, Cherney D, Claggett B, Fletcher R, Herrington W, Inzucchi S, Jardine M, Mahaffey K, McGuire D, McMurray J, Neal B, Packer M, Perkovic V, Solomon S, Staplin N, Vaduganathan M, Wanner C, Wheeler D, Zannad F, Zhao Y, Heerspink H, Sabatine M, Wiviott S. Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis. Circulation 2024, 149: 1789-1801. PMID: 38583093, PMCID: PMC11149938, DOI: 10.1161/circulationaha.124.069568.
- Butt J, Jhund P, Docherty K, Claggett B, Vaduganathan M, Bachus E, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Solomon S, McMurray J. Dapagliflozin and Timing of Prior Heart Failure Hospitalization A Patient-Level Meta-Analysis of DAPA-HF and DELIVER. JACC Heart Failure 2024, 12: 1586-1599. PMID: 38573262, DOI: 10.1016/j.jchf.2024.01.018.
- Vaduganathan M, Claggett B, Kulac I, Johansen N, Reza N, Jhund P, De Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Desai A, Petersson M, Langkilde A, McMurray J, Solomon S. DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE ACROSS A RANGE OF LEFT VENTRICULAR HYPERTROPHY IN THE DELIVER TRIAL. Journal Of The American College Of Cardiology 2024, 83: 320. DOI: 10.1016/s0735-1097(24)02310-6.
- Kondo T, Mogensen U, Talebi A, Gasparyan S, Campbell R, Docherty K, de Boer R, Inzucchi S, Køber L, Kosiborod M, Martinez F, Sabatine M, Bengtsson O, Sjöstrand M, Vaduganathan M, Solomon S, Jhund P, McMurray J. Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial. Journal Of The American College Of Cardiology 2024, 83: 1973-1986. PMID: 38537918, DOI: 10.1016/j.jacc.2024.03.385.
- Peikert A, Vaduganathan M, Claggett B, Kulac I, Foà A, Desai A, Jhund P, Carberry J, Lam C, Kosiborod M, Inzucchi S, Martinez F, de Boer R, Hernandez A, Shah S, Køber L, Ponikowski P, Sabatine M, Petersson M, Langkilde A, McMurray J, Solomon S. Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant‐level pooled analysis of DAPA‐HF and DELIVER. European Journal Of Heart Failure 2024, 26: 912-924. PMID: 38487939, DOI: 10.1002/ejhf.3184.
- Vardeny O, Desai A, Jhund P, Fang J, Claggett B, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Mc Causland F, Petrie M, Vaduganathan M, McMurray J, Solomon S. Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction. JAMA Cardiology 2024, 9: 283-289. PMID: 38265835, PMCID: PMC10809142, DOI: 10.1001/jamacardio.2023.5318.
- Green J, Everett B, Ghosh A, Younes N, Krause-Steinrauf H, Barzilay J, Desouza C, Inzucchi S, Pokharel Y, Schade D, Scrymgeour A, Tan M, Utzschneider K, Mudaliar S, Crandall J, McKee M, Behringer-Massera S, Brown-Friday J, Xhori E, Ballentine-Cargill K, Duran S, Estrella H, Gonzalez de la Torre S, Lukin J, Phillips L, Burgess E, Olson D, Rhee M, Wilson P, Raines T, Boers J, Costello J, Maher-Albertelli M, Mungara R, Savoye L, White C, Gullett C, Holloway L, Morehead F, Person S, Sibymon M, Tanukonda S, Adams C, Ross A, Balasubramanyam A, Gaba R, Gonzalez Hattery E, Ideozu A, Jimenez J, Montes G, Wright C, Hollander P, Roe E, Jackson A, Smiley A, Burt P, Estrada L, Chionh K, Ismail-Beigi F, Falck-Ytter C, Sayyed Kassem L, Sood A, Tiktin M, Kulow T, Newman C, Stancil K, Cramer B, Iacoboni J, Kononets M, Sanders C, Tucker L, Werner A, Maxwell A, McPhee G, Patel C, Colosimo L, Krol A, Goland R, Pring J, Alfano L, Kringas P, Hausheer C, Tejada J, Gumpel K, Kirpitch A, Schneier H, AbouAssi H, Chatterjee R, Feinglos M, English Jones J, Khan S, Kimpel J, Zimmer R, Furst M, Satterwhite B, Thacker C, Evans Kreider K, Mariash C, Mather K, Ismail H, Lteif A, Mullen M, Hamilton T, Patel N, Riera G, Jackson M, Pirics V, Aguillar D, Howard D, Hurt S, Bergenstal R, Carlson A, Martens T, Johnson M, Hill R, Hyatt J, Jensen C, Madden M, Martin D, Willis H, Konerza W, Yang S, Kleeberger K, Passi R, Fortmann S, Herson M, Mularski K, Glauber H, Prihoda J, Ash B, Carlson C, Ramey P, Schield E, Torgrimson-Ojerio B, Arnold K, Kauffman B, Panos E, Sahnow S, Bays K, Berame K, Cook J, Ghioni D, Gluth J, Schell K, Criscola J, Friason C, Jones S, Nazarov S, Rassouli N, Puttnam R, Ojoawo B, Nelson R, Curtis M, Hollis B, Sanders-Jones C, Stokes K, El-Haqq Z, Kolli A, Tran T, Wexler D, Larkin M, Meigs J, Chambers B, Dushkin A, Rocchio G, Yepes M, Steiner B, Dulin H, Cayford M, Chu K, DeManbey A, Hillard M, Martin K, Thangthaeng N, Gurry L, Kochis R, Raymond E, Ripley V, Stevens C, Park J, Aroda V, Ghazi A, Magee M, Ressing A, Loveland A, Hamm M, Hurtado M, Kuhn A, Leger J, Manandhar L, Mwicigi F, Sanchez O, Young T, Garg R, Lagari-Libhaber V, Florez H, Valencia W, Marks J, Casula S, Oropesa-Gonzalez L, Hue L, Cuadot A, Nieto-Martinez R, Riccio Veliz A, Gutt M, Kendal Y, Veciana B, Ahmann A, Aby-Daniel D, Joarder F, Morimoto V, Sprague C, Yamashita D, Cady N, Rivera-Eschright N, Kirchhoff P, Morales Gomez B, Adducci J, Goncharova A, Hox S, Petrovitch H, Matwichyna M, Jenkins V, Broadwater L, Ishii R, Bermudez N, Hsia D, Cefalu W, Greenway F, Waguespack C, King E, Fry G, Dragg A, Gildersleeve B, Arceneaux J, Haynes N, Thomassie A, Pavlionis M, Bourgeois B, Hazlett C, Henry R, Boeder S, Pettus J, Diaz E, Garcia-Acosta D, Maggs S, DeLue C, Stallings A, Castro E, Hernandez S, Krakoff J, Curtis J, Killean T, Khalid M, Joshevama E, Diaz E, Martin D, Tsingine K, Karshner T, Albu J, Pi-Sunyer F, Frances S, Maggio C, Ellis E, Bastawrose J, Gong X, Banerji M, August P, Lee M, Lorber D, Brown N, Josephson D, Thomas L, Tsovian M, Cherian A, Jacobson M, Mishko M, Kirkman M, Buse J, Diner J, Dostou J, Machineni S, Young L, Bergamo K, Goley A, Kerr J, Largay J, Guarda S, Cuffee J, Culmer D, Fraser R, Almeida H, Coffer S, Debnam E, Kiker L, Morton S, Josey K, Fuller G, Garvey W, Cherrington A, Dyer D, Lawson M, Griffith O, Agne A, McCullars S, Cohen R, Craig J, Rogge M, Burton K, Kersey K, Wilson C, Lipp S, Vonder Meulen M, Adkins C, Onadeko T, Rasouli N, Baker C, Schroeder E, Razzaghi M, Lyon C, Penaloza R, Underkofler C, Lorch R, Douglass S, Steiner S, Sivitz W, Cline E, Knosp L, McConnell J, Lowe T, Herman W, Pop-Busui R, Martin C, Waltje A, Katona A, Goodhall L, Eggleston R, Kuo S, Bojescu S, Bule S, Kessler N, LaSalle E, Whitley K, Seaquist E, Bantle A, Harindhanavudhi T, Kumar A, Redmon B, Bantle J, Coe M, Mech M, Taddese A, Lesne L, Smith S, Kuechenmeister L, Shivaswamy V, Burbach S, Rodriguez M, Seipel K, Alfred A, Morales A, Eggert J, Lord G, Taylor W, Tillson R, Adolphe A, Burge M, Duran-Valdez E, Martinez J, Bancroft A, Kunkel S, Ali Jamaleddin Ahmad F, Hernandez McGinnis D, Pucchetti B, Scripsick E, Zamorano A, DeFronzo R, Cersosimo E, Abdul-Ghani M, Triplitt C, Juarez D, Mullen M, Garza R, Verastiqui H, Wright K, Puckett C, Raskin P, Rhee C, Abraham S, Jordan L, Sao S, Morton L, Smith O, Osornio Walker L, Schnurr-Breen L, Ayala R, Kreymer R, Sturgess D, Kahn S, Alarcon-Casas Wright L, Boyko E, Tsai E, Trence D, Trikudanathan S, Fattaleh B, Montgomery B, Atkinson K, Kozedub A, Concepcion T, Moak C, Prikhodko N, Rhothisen S, Elasy T, Martin S, Shackelford L, Goidel R, Hinkle N, Lovell C, Myers J, Lipps Hogan J, McGill J, Salam M, Schweiger T, Kissel S, Recklein C, Clifton M, Tamborlane W, Camp A, Gulanski B, Pham K, Alguard M, Gatcomb P, Lessard K, Perez M, Iannone L, Magenheimer E, Montosa A, Cefalu W, Fradkin J, Burch H, Bremer A, Nathan D, Lachin J, Buse J, Kahn S, Larkin M, Tiktin M, Wexler D, Burch H, Bremer A, Lachin J, Bebu I, Butera N, Buys C, Fagan A, Gao Y, Gramzinski M, Hall S, Kazemi E, Legowski E, Liu H, Suratt C, Tripputi M, Arey A, Backman M, Bethepu J, Lund C, Mangat Dhaliwal P, McGee P, Mesimer E, Ngo L, Steffes M, Seegmiller J, Saenger A, Arends V, Gabrielson D, Conner T, Warren S, Day J, Huminik J, Soliman E, Zhang Z, Campbell C, Hu J, Keasler L, Hensley S, Li Y, Herman W, Kuo S, Martin C, Waltje A, Mihalcea R, Min D, Perez-Rosas V, Prosser L, Resnicow K, Ye W, Shao H, Zhang P, Luchsinger J, Sanchez D, Assuras S, Groessl E, Sakha F, Chong H, Hillery N, Abdouch I, Bahtiyar G, Brantley P, Broyles F, Canaris G, Copeland P, Craine J, Fein W, Gliwa A, Hope L, Lee M, Meiners R, Meiners V, O’Neal H, Park J, Sacerdote A, Sledge Jr E, Soni L, Steppel-Reznik J, Turchin A. Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study). Circulation 2024, 149: 993-1003. PMID: 38344820, PMCID: PMC10978227, DOI: 10.1161/circulationaha.123.066604.
- Levy J, Adeyina O, Robert S, Rimmer R, Inzucchi S, Rutherford H, Omay B. Increased Anxiety and Depression after Sellar Surgery: Is Oxytocin the Culprit?? Journal Of Neurological Surgery Part B Skull Base 2024, 85: s1-s398. DOI: 10.1055/s-0044-1780103.
- Mc Causland F, Claggett B, Vaduganathan M, Desai A, Jhund P, Vardeny O, Fang J, de Boer R, Docherty K, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Saraiva J, McGrath M, Shah S, Verma S, Langkilde A, Petersson M, McMurray J, Solomon S. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiology 2024, 9: 144-152. PMID: 37952176, PMCID: PMC10641768, DOI: 10.1001/jamacardio.2023.4664.
- Chang J, Javaheri A, Sauer A, Windsor S, Fu Z, Jones P, Margulies K, Lanfear D, Nassif M, Husain M, Inzucchi S, McGuire D, Pitt B, Scirica B, Kosiborod M. Cardiac And Kidney Benefits Of Dapagliflozin Are Associated With ApoM Levels In Patients With Heart Failure With Reduced Ejection Fraction. Journal Of Cardiac Failure 2024, 30: 236. DOI: 10.1016/j.cardfail.2023.10.284.
- Butt J, Jering K, DE Boer R, Claggett B, Desai A, Hernandez A, Inzucchi S, Jhund P, Køber L, Kosiborod M, Lam C, Martinez F, Ponikowski P, Sabatine M, Shah S, Vaduganathan M, Langkilde A, Bengtsson O, Petersson M, Sjöstrand M, Wilderäng U, Solomon S, McMurray J. Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER. Journal Of Cardiac Failure 2023, 30: 436-448. PMID: 38104937, DOI: 10.1016/j.cardfail.2023.08.027.
- Wang X, Lam C, Vaduganathan M, Kondo T, Yang M, Han Y, Pham V, Chiang C, Kitakaze M, Miao Z, Jhund P, Desai A, Inzucchi S, de Boer R, Martinez F, Kosiborod M, Hernandez A, Claggett B, Langkilde A, McMurray J, Solomon S. Effects of Dapagliflozin in Patients in Asia A Post Hoc Subgroup Analysis From the DELIVER Trial. JACC Asia 2023, 4: 108-118. PMID: 38371292, PMCID: PMC10866733, DOI: 10.1016/j.jacasi.2023.10.005.
- Tan X, Liang Y, Rajpura J, Yedigarova L, Noone J, Xie L, Inzucchi S, de Havenon A. Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease. Cardiovascular Diabetology 2023, 22: 319. PMID: 37985992, PMCID: PMC10662529, DOI: 10.1186/s12933-023-02051-8.
- Kondo T, Vaduganathan V, Hernandez A, Lam C, Inzucchi S, Martinez F, De Boer R, Kosiborod M, Desai A, Kober L, Ponikowski P, Sabatine M, Shah S, Solomon S, Mcmurray J. Efficacy of dapagliflozin according to geographic regions in patients with heart failure: a patient-level pooled analysis of DAPA-HF and DELIVER. European Heart Journal 2023, 44: ehad655.979. DOI: 10.1093/eurheartj/ehad655.979.
- Butt J, Lu H, Kondo T, Bachus E, De Boer R, Hernandez A, Inzucchi S, Jhund P, Kosiborod M, Lam C, Martinez F, Shah S, Vaduganathan M, Solomon S, Mcmurray J. Effects of dapagliflozin in heart failure with preserved ejection fraction and chronic obstructive pulmonary disease: an analysis of the DELIVER trial. European Heart Journal 2023, 44: ehad655.949. DOI: 10.1093/eurheartj/ehad655.949.
- Chatur S, Vaduganathan M, Claggett B, Desai A, Docherty K, Jhund P, De Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Mcmurray J, Solomon S. Effect of dapagliflozin on outpatient worsening heart failure in patients with mildly reduced or preserved ejection fraction: the DELIVER trial. European Heart Journal 2023, 44: ehad655.751. DOI: 10.1093/eurheartj/ehad655.751.
- Kondo T, Butt J, Curtain J, Jhund P, Docherty K, Claggett B, Vaduganathan M, Bachus E, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Solomon S, McMurray J. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER. Circulation Heart Failure 2023, 16: e010898. PMID: 37886880, DOI: 10.1161/circheartfailure.123.010898.
- Kondo T, Gasparyan S, Jhund P, Bengtsson O, Claggett B, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Køber L, Lam C, Langkilde A, Martinez F, Petersson M, Ponikowski P, Sabatine M, Shah S, Sjostrand M, Wilderang U, Vaduganathan M, Solomon S, McMurray J. Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER Trials. NEJM Evidence 2023, 2: evidoa2300042. PMID: 38320525, DOI: 10.1056/evidoa2300042.
- Ostrominski J, Vaduganathan M, Selvaraj S, Claggett B, Miao Z, Desai A, Jhund P, Kosiborod M, Lam C, Inzucchi S, Martinez F, de Boer R, Hernandez A, Shah S, Petersson M, Langkilde A, McMurray J, Solomon S. Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial. Circulation 2023, 148: 1945-1957. PMID: 37830208, DOI: 10.1161/circulationaha.123.065254.
- Bhatt A, Kosiborod M, Claggett B, Miao Z, Vaduganathan M, Lam C, Hernandez A, Martinez F, Inzucchi S, Shah S, de Boer R, Jhund P, Desai A, Fang J, Han Y, Comin‐Colet J, Drożdż J, Vardeny O, Merkely B, Lindholm D, Peterson M, Langkilde A, McMurray J, Solomon S. Impact of COVID‐19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial. European Journal Of Heart Failure 2023, 25: 2177-2188. PMID: 37771274, DOI: 10.1002/ejhf.3043.
- Peikert A, Bart B, Vaduganathan M, Claggett B, Kulac I, Kosiborod M, Desai A, Jhund P, Lam C, Inzucchi S, Martinez F, de Boer R, Hernandez A, Shah S, Petersson M, Langkilde A, McMurray J, Solomon S, Vardeny O. Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF The DELIVER Trial. JACC Heart Failure 2023, 12: 631-644. PMID: 37767674, DOI: 10.1016/j.jchf.2023.09.007.
- Butt J, Lu H, Kondo T, Bachus E, de Boer R, Inzucchi S, Jhund P, Kosiborod M, Lam C, Martinez F, Vaduganathan M, Solomon S, McMurray J. Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER. European Journal Of Heart Failure 2023, 25: 2078-2090. PMID: 37634087, DOI: 10.1002/ejhf.3000.
- Chatur S, Vaduganathan M, Claggett B, Cunningham J, Docherty K, Desai A, Jhund P, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Petersson M, Langkilde A, McMurray J, Solomon S. Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial. Circulation 2023, 148: 1735-1745. PMID: 37632455, PMCID: PMC10664793, DOI: 10.1161/circulationaha.123.066506.
- Chatur S, Vaduganathan M, Claggett B, Mc Causland F, Desai A, Jhund P, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Sabatine M, Kober L, Ponikowski P, Merkely B, Petersson M, Langkilde A, McMurray J, Solomon S. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function. Journal Of The American College Of Cardiology 2023, 82: 1854-1863. PMID: 37634707, DOI: 10.1016/j.jacc.2023.08.026.
- Kondo T, Wang X, Yang M, Jhund P, Claggett B, Vaduganathan M, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Langkilde A, Petersson M, Zaozerska N, Bachus E, Solomon S, McMurray J. Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure. Journal Of The American College Of Cardiology 2023, 82: 1014-1026. PMID: 37610398, DOI: 10.1016/j.jacc.2023.05.056.
- Balasubramanian P, Kernan W, Sheth K, Ofstad A, Rosenstock J, Wanner C, Zinman B, Mattheus M, Marx N, Inzucchi S. Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials. Stroke 2023, 54: 2013-2021. PMID: 37449424, PMCID: PMC10358436, DOI: 10.1161/strokeaha.122.042053.
- Peikert A, Chandra A, Kosiborod M, Claggett B, Desai A, Jhund P, Lam C, Inzucchi S, Martinez F, de Boer R, Hernandez A, Shah S, Janssens S, Bělohlávek J, Borleffs C, Dobreanu D, Langkilde A, Bengtsson O, Petersson M, McMurray J, Solomon S, Vaduganathan M. Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiology 2023, 8: 684-690. PMID: 37208998, PMCID: PMC10200027, DOI: 10.1001/jamacardio.2023.1342.
- Wexler D, de Boer I, Ghosh A, Younes N, Bebu I, Inzucchi S, McGill J, Mudaliar S, Schade D, Steffes M, Tamborlane W, Tan M, Ismail-Beigi F, Crandall J, McKee M, Beringher-Massera S, Brown-Friday J, Xhori E, Ballentine-Cargill K, Duran S, Estrella H, Gonzalez de la torre S, Lukin J, Phillips L, Burgess E, Olson D, Rhee M, Wilson P, Raines T, Boers J, Costello J, Maher-Albertelli M, Mungara R, Savoye L, White C, Gullett C, Holloway L, Morehead F, Person S, Sibymon M, Tanukonda S, Adams C, Ross A, Balasubramanyam A, Gaba R, Gonzalez E, Ideozu A, Jimenez J, Montes G, Wright C, Hollander P, Roe E, Jackson A, Smiley A, Burt P, Estrada L, Chionh K, Ismail-Beigi F, Falck-Ytter C, Sayyed Kassem L, Sood A, Tiktin M, Cramer B, Iacoboni J, Kononets M, Kulow T, Newman C, Stancil K, Sanders C, Tucker L, Werner A, Krol A, McPhee G, Patel C, Colosimo L, Maxwell A, Goland R, Pring J, Alfano L, Kringas P, Hausheer C, Tejada J, Gumpel K, Kirpitch A, Schneier H, Green J, AbouAssi H, Chatterjee R, Feinglos M, English Jones J, Khan S, Kimpel J, Zimmer R, Furst M, Satterwhite B, Thacker C, Evans Kreider K, Mariash C, Mather K, Ismail H, Lteif A, Mullen M, Hamilton T, Patel N, Riera G, Jackson M, Pirics V, Howard D, Aguillar D, Hurt S, Bergenstal R, Carlson A, Martens T, Johnson M, Hill R, Hyatt J, Jensen C, Madden M, Martin D, Willis H, Konerza W, Yang S, Passi R, Kleeberger K, Fortmann S, Herson M, Mularski K, Glauber H, Prihoda J, Ash B, Carlson C, Ramey P, Schield E, Torgrimson-Ojerio B, Arnold K, Kauffman B, Panos E, Sahnow S, Bays K, Cook J, Gluth J, Ghioni D, Schell K, Criscola J, Friason C, Jones S, Nazarov S, Barzilay J, Rassouli N, Puttnam R, Ojoawo O, Nelson R, Curtis M, Hollis B, Sanders-Jones C, Stokes K, El-Haqq Z, Kolli A, Tran T, Wexler D, Larkin M, Meigs J, Chambers B, Dushkin A, Rocchio G, Yepes M, Steiner B, Dulin H, Cayford M, DeManbey A, Hillard M, Martin K, Thangthaeng N, Gurry L, Kochis R, Raymond E, Ripley V, Stevens C, Park J, Aroda V, Ghazi A, Magee M, Ressing A, Loveland A, Hamm M, Hurtado M, Kuhn A, Leger J, Manandhar L, Mwicigi F, Sanchez O, Young T, Garg R, Lagari-Libhaber V, Florez H, Valencia W, Mark J, Casula S, Oropesa-Gonzalez L, Hue L, Cuadot A, Nieto-Martinez R, Riccio Veliz A, Gutt M, Kendal Y, Veciana B, Ahmann A, Aby-Daniel D, Joarder F, Morimoto V, Sprague C, Yamashita D, Cady N, Rivera-Eschright N, Kirchhoff P, Morales Gonzalez B, Adducci J, Goncharova A, Hox S, Petrovich H, Matwichyna M, Jenkins V, Broadwater L, Ishii R, Bermudez N, Hsia D, Cefalu W, Greenway F, Waguespack C, King E, Fry G, Dragg A, Gildersleeve B, Arceneaux J, Haynes N, Thomassie A, Pavlionis M, Bourgeois B, Hazlett C, Mudaliar S, Robert H, Boeder S, Pettus J, Diaz E, Garcia-Acosta D, Maggs S, DeLue C, Stallings A, Castro E, Hernandez S, Krakoff J, Curtis J, Killean T, Khalid M, Joshevama E, Diaz E, Martin D, Tsingine K, Karshner T, Albu J, Pi-Sunyer F, Frances S, Maggio C, Ellis E, Bastawrose J, Gong X, Banerji M, August P, Lee M, Lorber D, Necole M. B, Josephson D, Thomas L, Tsovian M, Cherian A, Jacobson M, Mishko M, Kirkman S, Buse J, Dostou J, Machineni S, Young L, Bergamo K, Goley A, Kerr J, Largay J, Guarda S, Cuffee J, Culmer D, Fraser R, Almeida H, Coffer S, Debnam E, Kiker L, Morton S, Josey K, Fuller G, Garvey W, Cherrington A, Dyer D, Lawson M, Griffith O, Agne A, McCullars S, Cohen R, Craig J, Rogge M, Burton K, Kersey K, Wilson C, Lipp S, Vonder Meulen M, Adkins C, Onadeko T, Rasouli N, Baker C, Schroeder E, Razzaghi M, Lyon C, Penaloza R, Underkofler C, Lorch R, Douglass S, Steiner S, Sivitz W, Cline E, Knosp L, McConnell J, Lowe T, Herman W, Pop-Busui R, Tan M, Martin C, Waltje A, Katona A, Goodhall L, Eggleston R, Kuo S, Bojescu S, Bule S, Kessler N, LaSalle E, Whitley K, Seaquist E, Bantle A, Harindhanavudhi T, Kumar A, Redmon B, Bantle J, Coe M, Mech M, Taddese A, Lesne L, Smith S, Desouza C, Kuechenmeister L, Shivaswamv V, Burbach S, Rodriguez M, Seipel K, Alfred A, Morales A, Eggert J, Lord G, Taylor W, Tillson R, Schade D, Adolphe A, Burge M, Duran-Valdez E, Martinez J, Bancroft A, Kunkel S, Jamaleddin Ahmad F, Hernandez McGinnis D, Pucchetti B, Scripsick E, Zamorano A, DeFronzo R, Cersosimo E, Abdul-Ghani M, Triplitt C, Juarez D, Garza R, Verastiqui H, Wright K, Puckett C, Raskin P, Rhee C, Abraham S, Jordan L, Sao S, Morton L, Smith O, Osornio Walker L, Schnurr-Breen L, Ayala R, Kreymer R, Sturgess D, Utzschneider K, Kahn S, Alarcon-Casas Wright L, Boyko E, Tsiai E, Trence D, Trikudanathan S, Fattaleh B, Montgomery B, Atkinson K, Kozedub A, Concepcion T, Moak C, Prikhodko N, Rhothisen S, Elasy T, Martin S, Shackelford L, Goidel R, Hinkle N, Lovell C, Myers J, Lipps Hogan J, McGill J, Salam M, Schweiger T, Kissel S, Recklein C, Clifton M, Tamborlane W, Camp A, Gulanski B, Inzucchi S, Pham K, Alguard M, Gatcomb P, Lessard K, Perez M, Iannone L, Magenheimer E, Montosa A, Cefalu W, Fradkin J, Burch H, Bremer A, Nathan D, Lachin J, Krause-Steinrauf H, Younes N, Bebu I, Butera N, Buys C, Fagan A, Gao Y, Ghosh A, Gramzinski M, Hall S, Kazemi E, Legowski E, Liu H, Suratt C, Tripputi M, Arey A, Backman M, Bethepu J, Lund C, Mangat Dhaliwal P, McGee P, Mesimer E, Ngo L, Steffes M, Seegmiller J, Saenger A, Arends V, Gabrielson D, Conner T, Warren S, Day J, Huminik J, Scrymgeour A, Soliman E, Pokharel Y, Zhang Z, Campbell C, Hu J, Keasler L, Hensley S, Li Y, Mihalcea R, Min D, Perez-Rosas V, Prosser L, Resnicow K, Ye W, Shao H, Zhang P, Luchsinger J, Sanchez D, Assuras S, Groessl E, Sakha F, Chong H, Hillery N, Abdouch I, Bahityar G, Brantley P, Broyles F, Canaris G, Copeland P, Craine J, Fein W, Gliwa A, Hope L, Lee M, Meiners R, Meiners V, O'Neal H, Park J, Sacerdote A, Sledge E, Soni L, Steppel-Reznik J, Turchin A. Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes. JAMA Internal Medicine 2023, 183: 705-714. PMID: 37213109, PMCID: PMC10203973, DOI: 10.1001/jamainternmed.2023.1487.
- Butt J, Docherty K, Kosiborod M, Inzucchi S, Køber L, Langkilde A, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjöstrand M, Solomon S, Jhund P, McMurray J. Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction. JACC Heart Failure 2023, 11: 1411-1423. PMID: 37318419, DOI: 10.1016/j.jchf.2023.04.016.
- Chatur S, Cunningham J, Vaduganathan M, Mc Causland F, Claggett B, Desai A, Miao Z, Jhund P, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Petersson M, Langkilde A, McMurray J, Solomon S. Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trial. European Journal Of Heart Failure 2023, 25: 1170-1175. PMID: 37212168, DOI: 10.1002/ejhf.2915.
- Chatur S, Kondo T, Claggett B, Docherty K, Miao Z, Desai A, Jhund P, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Petersson M, Langkilde A, McMurray J, Solomon S, Vaduganathan M. Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: Insights from DELIVER and DAPA‐HF. European Journal Of Heart Failure 2023, 25: 1364-1371. PMID: 37210608, DOI: 10.1002/ejhf.2912.
- Bhatt A, Kosiborod M, Vaduganathan M, Claggett B, Miao Z, Kulac I, Lam C, Hernandez A, Martinez F, Inzucchi S, Shah S, de Boer R, Jhund P, Desai A, Petersson M, Langkilde A, McMurray J, Solomon S. Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant‐level pooled analysis from the DAPA‐HF and DELIVER trials. European Journal Of Heart Failure 2023, 25: 981-988. PMID: 37211977, DOI: 10.1002/ejhf.2909.
- Peter P, Inzucchi S. Tailoring the Treatment of Type 2 Diabetes Mellitus to the Individual. Contemporary Cardiology 2023, 1043-1070. DOI: 10.1007/978-3-031-13177-6_37.
- Jhund P, Claggett B, Talebi A, Butt J, Gasparyan S, Wei L, McCaw Z, Wilderäng U, Bengtsson O, Desai A, Petersson M, Langkilde A, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Vaduganathan M, Solomon S, McMurray J. Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiology 2023, 8: 554-563. PMID: 37099283, PMCID: PMC10134044, DOI: 10.1001/jamacardio.2023.0711.
- Ostrominski J, Thierer J, Claggett B, Miao Z, Desai A, Jhund P, Kosiborod M, Lam C, Inzucchi S, Martinez F, de Boer R, Hernandez A, Shah S, Petersson M, Langkilde A, McMurray J, Solomon S, Vaduganathan M. Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JACC Heart Failure 2023, 11: 1491-1503. PMID: 37226448, DOI: 10.1016/j.jchf.2023.05.015.
- Chatur S, Vaduganathan M, Claggett B, Vardeny O, Desai A, Jhund P, de Boer R, Lam C, Kosiborod M, Shah S, Martinez F, Inzucchi S, Hernandez A, Haddad T, Mitter S, Miao Z, Petersson M, Langkilde A, McMurray J, Solomon S. Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. European Heart Journal 2023, 44: 2930-2943. PMID: 37220093, PMCID: PMC10484057, DOI: 10.1093/eurheartj/ehad283.
- Butt J, Kondo T, Yang M, Jhund P, Docherty K, Vaduganathan M, Claggett B, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Shah S, Zaozerska N, Wilderäng U, Bengtsson O, Solomon S, McMurray J. Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. European Heart Journal 2023, 44: 2170-2183. PMID: 37220172, PMCID: PMC10290876, DOI: 10.1093/eurheartj/ehad276.
- Bhatt A, Lindholm D, Nilsson A, Zaozerska N, Claggett B, Vaduganathan M, Kosiborod M, Lam C, Hernandez A, Martinez F, Inzucchi S, Shah S, de Boer R, Desai A, Jhund P, Langkilde A, Petersson M, McMurray J, Solomon S. Operational challenges and mitigation measures during the COVID-19 pandemic–Lessons from DELIVER. American Heart Journal 2023, 263: 133-140. PMID: 37220822, PMCID: PMC10200275, DOI: 10.1016/j.ahj.2023.05.013.
- Peikert A, Goyal P, Vaduganathan M, Claggett B, Kulac I, Miao Z, Vardeny O, Kosiborod M, Desai A, Jhund P, Lam C, Inzucchi S, Martinez F, de Boer R, Hernandez A, Shah S, Petersson M, Langkilde A, McMurray J, Solomon S. Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status. JACC Heart Failure 2023, 11: 1380-1393. PMID: 37294244, DOI: 10.1016/j.jchf.2023.05.014.
- Nassif M, Windsor S, Gosch K, Borlaug B, Husain M, Inzucchi S, Kitzman D, McGuire D, Pitt B, Scirica B, Shah S, Umpierrez G, Austin B, Lamba S, Khumri T, Sharma K, Kosiborod M. Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials. Circulation Heart Failure 2023, 16: e009837. PMID: 37203441, PMCID: PMC10348645, DOI: 10.1161/circheartfailure.122.009837.
- McGuire D, Busui R, Deanfield J, Inzucchi S, Mann J, Marx N, Mulvagh S, Poulter N, Engelmann M, Hovingh G, Ripa M, Gislum M, Brown‐Frandsen K, Buse J. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial. Diabetes Obesity And Metabolism 2023, 25: 1932-1941. PMID: 36945734, DOI: 10.1111/dom.15058.
- Nargesi A, Clark C, Aminorroaya A, Chen L, Liu M, Reddy A, Amodeo S, Oikonomou E, Suchard M, McGuire D, Lin Z, Inzucchi S, Khera R. Persistence on Novel Cardioprotective Antihyperglycemic Therapies in the United States. The American Journal Of Cardiology 2023, 196: 89-98. PMID: 37012183, PMCID: PMC11007258, DOI: 10.1016/j.amjcard.2023.03.002.
- Butt J, Docherty K, Claggett B, Desai A, Petersson M, Langkilde A, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Køber L, Lam C, Martinez F, Ponikowski P, Sabatine M, Shah S, Vaduganathan M, Jhund P, Solomon S, McMurray J. Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid–Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout. JAMA Cardiology 2023, 8: 386-393. PMID: 36811901, PMCID: PMC9947801, DOI: 10.1001/jamacardio.2022.5608.
- Wojeck B, Inzucchi S, Qin L, Yaggi H. Polysomnographic predictors of incident diabetes and pre-diabetes: an analysis of the DREAM study. Journal Of Clinical Sleep Medicine 2023, 19: 703-710. PMID: 36689314, PMCID: PMC10071389, DOI: 10.5664/jcsm.10414.
- Vardeny O, Fang J, Desai A, Jhund P, Claggett B, Vaduganathan M, de Boer R, Hernandez A, Lam C, Inzucchi S, Martinez F, Kosiborod M, DeMets D, O’Meara E, Zieroth S, Comin-Colet J, Drozdz J, Chiang C, Kitakaze M, Petersson M, Lindholm D, Langkilde A, McMurray J, Solomon S. Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. Nature Medicine 2023, 29: 3269-3269. PMID: 36932245, PMCID: PMC10719083, DOI: 10.1038/s41591-023-02302-x.
- Kondo T, Jering K, Borleffs C, de Boer R, Claggett B, Desai A, Dobreanu D, Inzucchi S, Hernandez A, Janssens S, Jhund P, Kosiborod M, Lam C, Langkilde A, Martinez F, Petersson M, Vinh P, Vaduganathan M, Solomon S, McMurray J. Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial. Circulation 2023, 147: 1067-1078. PMID: 36876483, DOI: 10.1161/circulationaha.122.062918.
- Athonvarangkul D, Wang K, Deng Y, Inzucchi S, Mayerson A. Improved extremity tissue oxygenation with short-term exposure to textiles embedded with far infrared light emitting thermoactive particles in patients with diabetes mellitus. Diabetes And Vascular Disease Research 2023, 20: 14791641231170282. PMID: 37073436, PMCID: PMC10123901, DOI: 10.1177/14791641231170282.
- McMurray J, Docherty K, Jhund P, Claggett B, De Boer R, Hernandez A, Inzucchi S, Kober L, Kosiborod M, Lam C, Martinez F, Ponikowski P, Sabatine M, Shah S, Langkilde A, Petersson M, Solomon S. THE EFFECT OF DAPAGLIFLOZIN ON INSULIN INITIATION OR INTENSIFICATION IN PATIENTS IN HEART FAILURE AND DIABETES: A POOLED ANALYSIS OF DAPA-HF AND DELIVER. Journal Of The American College Of Cardiology 2023, 81: 278. DOI: 10.1016/s0735-1097(23)00722-2.
- Haider S, Templeton K, Omay S, Inzucchi S. Primary hypothyroidism presenting as neuropsychiatric symptoms and pituitary enlargement in a young woman: illustrative case. Journal Of Neurosurgery Case Lessons 2023, 5: case22496. PMID: 36794728, PMCID: PMC10550602, DOI: 10.3171/case22496.
- Butt J, Docherty K, Claggett B, Desai A, Fang J, Petersson M, Langkilde A, de Boer R, Cabrera Honorio J, Hernandez A, Inzucchi S, Kosiborod M, Køber L, Lam C, Martinez F, Ponikowski P, Sabatine M, Vardeny O, O'Meara E, Saraiva J, Shah S, Vaduganathan M, Jhund P, Solomon S, McMurray J. Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum. JACC Heart Failure 2023, 11: 375-388. PMID: 36881399, DOI: 10.1016/j.jchf.2022.11.014.
- Suthahar N, Wang K, Zwartkruis V, Bakker S, Inzucchi S, Meems L, Eijgenraam T, Ahmadizar F, Sijbrands E, Gansevoort R, Kieneker L, van Veldhuisen D, Kavousi M, de Boer R. Associations of relative fat mass, a new index of adiposity, with type-2 diabetes in the general population. European Journal Of Internal Medicine 2023, 109: 73-78. PMID: 36604231, DOI: 10.1016/j.ejim.2022.12.024.
- Brandt‐Jacobsen N, Jürgens M, Hasbak P, Gæde P, Rossing P, Rasmussen J, Andersen C, Forman J, Faber J, Inzucchi S, Gustafsson F, Schou M, Kistorp C. Reduction of cardiac adipose tissue volume with short‐term empagliflozin treatment in patients with type 2 diabetes: A substudy from the SIMPLE randomized clinical trial. Diabetes Obesity And Metabolism 2023, 25: 844-855. PMID: 36484428, PMCID: PMC10107109, DOI: 10.1111/dom.14933.
- Balasubramanian P, Inzucchi S. Chapter 13 Sodium-glucose Co-transporter-2 inhibitors: a new era of cardioprotection and renoprotection. 2023, 337-363. DOI: 10.1016/b978-0-323-99991-5.00006-1.
- Mc Causland F, Claggett B, Vaduganathan M, Desai A, Jhund P, de Boer R, Docherty K, Fang J, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Saraiva J, McGrath M, Shah S, Verma S, Langkilde A, Petersson M, McMurray J, Solomon S. Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiology 2023, 8: 56-65. PMID: 36326604, PMCID: PMC9634592, DOI: 10.1001/jamacardio.2022.4210.
- Kernan W, Forman R, Inzucchi S. Caring for Patients With Diabetes in Stroke Neurology. Stroke 2022, 54: 894-904. PMID: 36541212, DOI: 10.1161/strokeaha.122.038163.
- Vardeny O, Fang J, Desai A, Jhund P, Claggett B, Vaduganathan M, de Boer R, Hernandez A, Lam C, Inzucchi S, Martinez F, Kosiborod M, DeMets D, O’Meara E, Zieroth S, Comin-Colet J, Drozdz J, Chiang C, Kitakaze M, Petersson M, Lindholm D, Langkilde A, McMurray J, Solomon S. Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. Nature Medicine 2022, 28: 2504-2511. PMID: 36522606, PMCID: PMC9800271, DOI: 10.1038/s41591-022-02102-9.
- Kosiborod M, Bhatt A, Claggett B, Vaduganathan M, Kulac I, Lam C, Hernandez A, Martinez F, Inzucchi S, Shah S, de Boer R, Jhund P, Desai A, Fang J, Han Y, Comin-Colet J, Vardeny O, Lindholm D, Wilderäng U, Bengtsson O, McMurray J, Solomon S. Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction. Journal Of The American College Of Cardiology 2022, 81: 460-473. PMID: 36526515, DOI: 10.1016/j.jacc.2022.11.006.
- Ghazi L, O'Connor K, Yamamoto Y, Fuery M, Sen S, Samsky M, Riello R, Huang J, Olufade T, McDermott J, Inzucchi S, Velazquez E, Wilson F, Desai N, Ahmad T. Pragmatic trial of messaging to providers about treatment of acute heart failure: The PROMPT-AHF trial. American Heart Journal 2022, 257: 111-119. PMID: 36493842, DOI: 10.1016/j.ahj.2022.12.002.
- Alameddine D, Satam K, Slade M, Wang H, Mena-Hurtado C, Turner J, Inzucchi S, Chaar C. Predictors of Major Adverse Limb Events After Infrainguinal Bypass in Patients with Diabetes. American Heart Journal 2022, 254: 241. DOI: 10.1016/j.ahj.2022.10.026.
- Wojeck B, Inzucchi S, Neeland I, Mancuso J, Frederich R, Masiukiewicz U, Cater N, McGuire D, Cannon C, Yaggi H. Ertugliflozin and Incident Obstructive Sleep Apnea: An Analysis from the VERTIS CV Trial. Sleep Medicine 2022, 100: s249-s250. DOI: 10.1016/j.sleep.2022.05.671.
- Inzucchi S, Claggett B, Vaduganathan M, Desai A, Jhund P, de Boer R, Hernandez A, Kosiborod M, Lam C, Martinez F, Shah S, Verma S, Han Y, Kerr Saraiva J, Bengtsson O, Petersson M, Langkilde A, McMurray J, Solomon S. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet Diabetes & Endocrinology 2022, 10: 869-881. PMID: 36372069, DOI: 10.1016/s2213-8587(22)00308-4.
- Adamson C, Welsh P, Docherty K, de Boer R, Diez M, Drożdż J, Dukát A, Inzucchi S, Køber L, Kosiborod M, Ljungman C, Martinez F, Ponikowski P, Sabatine M, Morrow D, Lindholm D, Hammarstedt A, Boulton D, Greasley P, Langkilde A, Solomon S, Sattar N, McMurray J, Jhund P. IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction Findings From DAPA-HF. JACC Heart Failure 2022, 11: 291-304. PMID: 36592046, DOI: 10.1016/j.jchf.2022.09.004.
- Yang M, Butt J, Kondo T, Jering K, Docherty K, Jhund P, de Boer R, Claggett B, Desai A, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Langkilde A, Martinez F, Petersson M, Shah S, Vaduganathan M, Wilderäng U, Solomon S, McMurray J. Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. European Journal Of Heart Failure 2022, 24: 2307-2319. PMID: 36342375, PMCID: PMC11497302, DOI: 10.1002/ejhf.2722.
- Wang X, Vaduganathan M, Claggett B, Hegde S, Pabon M, Kulac I, Vardeny O, O’Meara E, Zieroth S, Katova T, McGrath M, Pouleur A, Jhund P, Desai A, Inzucchi S, Kosiborod M, de Boer R, Kober L, Sabatine M, Martinez F, Ponikowski P, Shah S, Hernandez A, Langkilde A, McMurray J, Solomon S, Lam C. Sex Differences in Characteristics, Outcomes and Treatment Response with Dapagliflozin across the Range of Ejection Fraction in Patients with Heart Failure: Insights from DAPA-HF and DELIVER. Circulation 2022, 147: 624-634. PMID: 36342789, PMCID: PMC9974767, DOI: 10.1161/circulationaha.122.062832.
- Baigent C, Emberson J, Haynes R, Herrington W, Judge P, Landray M, Mayne K, Ng S, Preiss D, Roddick A, Staplin N, Zhu D, Anker S, Bhatt D, Brueckmann M, Butler J, Cherney D, Green J, Hauske S, Haynes R, Heerspink H, Herrington W, Inzucchi S, Jardine M, Liu C, Mahaffey K, McCausland F, McGuire D, McMurray J, Neal B, Neuen B, Packer M, Perkovic V, Sabatine M, Solomon S, Vaduganathan M, Wanner C, Wheeler D, Wiviott S, Zannad F. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. The Lancet 2022, 400: 1788-1801. PMID: 36351458, PMCID: PMC7613836, DOI: 10.1016/s0140-6736(22)02074-8.
- Brandt-Jacobsen N, Jürgens M, Hasbak P, Gæde P, Rossing P, Rasmussen J, Andersen C, Forman J, Faber J, Inzucchi S, Gustafsson F, Schou M, Kistorp C. ODP154 Reduction of Cardiac Adipose Tissue Volume with Short-Term Empagliflozin in Patients with Type 2 Diabetes: Results from the SIMPLE Randomized Clinical Trial. Journal Of The Endocrine Society 2022, 6: a245-a245. PMCID: PMC9624604, DOI: 10.1210/jendso/bvac150.504.
- Adamson C, Welsh P, Morrow D, Docherty K, Hammarstedt A, Inzucchi S, Kober L, Kosiborod M, Martinez F, Ponikowski P, Sabatine M, Solomon S, Sattar N, Jhund P, McMurray J. Outcomes related to IGFBP-7 in patients with heart failure and reduced ejection fraction and effects of dapagliflozin: findings from DAPA-HF. European Heart Journal 2022, 43: ehac544.913. DOI: 10.1093/eurheartj/ehac544.913.
- Kondo T, Jhund P, Abraham W, Rouleau J, Packer M, Desai A, Kober L, Solomon S, Zile M, Inzucchi S, Kosiborod M, Sabatine M, Ponikowski P, Martinez F, McMurray J. Stroke in patients with heart failure and reduced ejection fraction without atrial fibrillation: external validation of a risk model. European Heart Journal 2022, 43: ehac544.869. DOI: 10.1093/eurheartj/ehac544.869.
- Yeoh S, Docherty K, Jhund P, Hammarstedt A, Inzucchi S, Kober L, Kosiborod M, Martinez F, Ponikowski P, Solomon S, Sattar N, Welsh P, Sabatine M, Morrow D, McMurray J. Relationship between endothelin-1, heart failure with reduced ejection fraction and dapagliflozin: findings from DAPA-HF. European Heart Journal 2022, 43: ehac544.833. DOI: 10.1093/eurheartj/ehac544.833.
- Selvaraj S, Vaduganathan M, Claggett B, Miao Z, Fang J, Vardeny O, Desai A, Shah S, Lam C, Martinez F, Inzucchi S, de Boer R, Petersson M, Langkilde A, McMurray J, Solomon S. Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction DELIVER. JACC Heart Failure 2022, 11: 76-89. PMID: 36599553, DOI: 10.1016/j.jchf.2022.09.002.
- Levine L, Heard A, Ignatiev J, Inzucchi S. S2229 Acquired Dextrocardia?: A Striking Consequence of Sigmoid Volvulus. The American Journal Of Gastroenterology 2022, 117: e1505-e1505. DOI: 10.14309/01.ajg.0000865556.38714.d8.
- Balasubramanian P, Wanner C, Ferreira J, Ofstad A, Elsaesser A, Zinman B, Inzucchi S. Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition? 2022, 48-52. DOI: 10.37987/1997-9894.2022.5-6(261-2).271666.
- Logeay F, Zaoui P, Inzucchi S, Zinman B, Steubl D, Ofstad A, Wanner C, Mattheus M. Effet d’empagliflozine sur le changement (aggravation/amélioration) de groupe de risque d’IRC selon KDIGO : évalué dans EMPA-REG-OUTCOME. Néphrologie & Thérapeutique 2022, 18: 355. DOI: 10.1016/j.nephro.2022.07.180.
- Myhre P, Vaduganathan M, Claggett B, Miao Z, Jhund P, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Desai A, Lindholm D, Petersson M, Langkilde A, McMurray J, Solomon S. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JACC Heart Failure 2022, 10: 902-913. PMID: 36114137, DOI: 10.1016/j.jchf.2022.08.007.
- Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O’Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilderäng U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. The New England Journal Of Medicine 2022, 387: 1089-1098. PMID: 36027570, DOI: 10.1056/nejmoa2206286.
- Aroda V, Krause-Steinrauf H, Kazemi E, Buse J, Gulanski B, Florez H, Ahmann A, Loveland A, Kuhn A, Lonier J, Wexler D, Crandall J, McKee M, Behringer-Massera S, Brown-Friday J, Xhori E, Ballentine-Cargill K, Duran S, Estrella H, Gonzalez de la torre S, Lukin J, Phillips L, Burgess E, Olson D, Rhee M, Wilson P, Raines T, Boers J, Costello J, Maher-Albertelli M, Mungara R, Savoye L, White C, Gullett C, Holloway L, Morehead F, Person S, Sibymon M, Tanukonda S, Adams C, Ross A, Balasubramanyam A, Gaba R, Gonzalez Hattery E, Ideozu A, Jimenez J, Montes G, Wright C, Hollander P, Roe E, Jackson A, Smiley A, Burt P, Estrada L, Chionh K, Ismail-Beigi F, Falck-Ytter C, Sayyed Kassem L, Sood A, Tiktin M, Kulow T, Newman C, Stancil K, Cramer B, Iacoboni J, Kononets M, Sanders C, Tucker L, Werner A, Maxwell A, McPhee G, Patel C, Colosimo L, Krol A, Goland R, Pring J, Alfano L, Kringas P, Hausheer C, Tejada J, Gumpel K, Kirpitch A, Schneier H, Green J, AbouAssi H, Chatterjee R, Feinglos M, English Jones J, Khan S, Kimpel J, Zimmer R, Furst M, Satterwhite B, Thacker C, Evans Kreider K, Mariash C, Mather K, Ismail H, Lteif A, Mullen M, Hamilton T, Patel N, Riera G, Jackson M, Pirics V, Aguillar D, Howard D, Hurt S, Bergenstal R, Carlson A, Martens T, Johnson M, Hill R, Hyatt J, Jensen C, Madden M, Martin D, Willis H, Konerza W, Yang S, Kleeberger K, Passi R, Fortmann S, Herson M, Mularski K, Glauber H, Prihoda J, Ash B, Carlson C, Ramey P, Schield E, Torgrimson-Ojerio B, Arnold K, Kauffman B, Panos E, Sahnow S, Bays K, Berame K, Cook J, Ghioni D, Gluth J, Schell K, Criscola J, Friason C, Jones S, Nazarov S, Barzilay J, Rassouli N, Puttnam R, Ojoawo B, Nelson R, Curtis M, Hollis B, Sanders-Jones C, Stokes K, El-Haqq Z, Kolli A, Tran T, Wexler D, Larkin M, Meigs J, Chambers B, Dushkin A, Rocchio G, Yepes M, Steiner B, Dulin H, Cayford M, Chu K, DeManbey A, Hillard M, Martin K, Thangthaeng N, Gurry L, Kochis R, Raymond E, Ripley V, Stevens C, Park J, Aroda V, Ghazi A, Magee M, Ressing A, Loveland A, Hamm M, Hurtado M, Kuhn A, Leger J, Manandhar L, Sanchez O, Young T, Mofor F, Garg R, Lagari-Libhaber V, Florez H, Valencia W, Marks J, Casula S, Oropesa-Gonzalez L, Hue L, Cuadot A, Nieto-Martinez R, Riccio Veliz A, Gutt M, Kendal Y, Veciana B, Ahmann A, Aby-Daniel D, Joarder F, Morimoto V, Sprague C, Yamashita D, Cady N, Rivera-Eschright N, Kirchhoff P, Morales Gomez B, Adducci J, Goncharova A, Hox S, Petrovitch H, Matwichyna M, Jenkins V, Broadwater L, Ishii R, Bermudez N, Hsia D, Cefalu W, Greenway F, Waguespack C, King E, Fry G, Dragg A, Gildersleeve B, Arceneaux J, Haynes N, Thomassie A, Pavlionis M, Bourgeois B, Hazlett C, Mudaliar S, Henry R, Boeder S, Pettus J, Diaz E, Garcia-Acosta D, Maggs S, DeLue C, Stallings A, Castro E, Hernandez S, Krakoff J, Curtis J, Killean T, Khalid M, Joshevama E, Diaz E, Martin D, Tsingine K, Karshner T, Albu J, Pi-Sunyer F, Frances S, Maggio C, Ellis E, Bastawrose J, Gong X, Banerji M, August P, Lee M, Lorber D, Brown N, Josephson D, Thomas L, Tsovian M, Cherian A, Jacobson M, Mishko M, Kirkman M, Buse J, Dostou J, Machineni S, Young L, Bergamo K, Goley A, Kerr J, Largay J, Guarda S, Cuffee J, Culmer D, Fraser R, Almeida H, Coffer S, Debnam E, Kiker L, Morton S, Josey K, Fuller G, Garvey W, Cherrington A, Dyer D, Lawson M, Griffith O, Agne A, McCullars S, Cohen R, Craig J, Rogge M, Burton K, Kersey K, Wilson C, Lipp S, Vonder Meulen M, Adkins C, Onadeko T, Rasouli N, Baker C, Schroeder E, Razzaghi M, Lyon C, Penaloza R, Underkofler C, Lorch R, Douglass S, Steiner S, Sivitz W, Cline E, Knosp L, McConnell J, Lowe T, Herman W, Pop-Busui R, Tan M, Martin C, Waltje A, Katona A, Goodhall L, Eggleston R, Kuo S, Bojescu S, Bule S, Kessler N, LaSalle E, Whitley K, Seaquist E, Bantle A, Harindhanavudhi T, Kumar A, Redmon B, Bantle J, Coe M, Mech M, Taddese A, Lesne L, Smith S, Desouza C, Kuechenmeister L, Shivaswamy V, Burbach S, Rodriguez M, Seipel K, Alfred A, Morales A, Eggert J, Lord G, Taylor W, Tillson R, Schade D, Adolphe A, Burge M, Duran-Valdez E, Martinez J, Bancroft A, Kunkel S, Ali Jamaleddin Ahmad F, Hernandez McGinnis D, Pucchetti B, Scripsick E, Zamorano A, DeFronzo R, Cersosimo E, Abdul-Ghani M, Triplitt C, Juarez D, Mullen M, Garza R, Verastiqui H, Wright K, Puckett C, Raskin P, Rhee C, Abraham S, Jordan L, Sao S, Morton L, Smith O, Osornio Walker L, Schnurr-Breen L, Ayala R, Kreymer R, Sturgess D, Utzschneider K, Kahn S, Alarcon-Casas L, Wright L, Boyko E, Tsai E, Trence D, Trikudanathan S, Fattaleh B, Montgomery B, Atkinson K, Kozedub A, Concepcion T, Moak C, Prikhodko N, Rhothisen S, Elasy T, Martin S, Shackelford L, Goidel R, Hinkle N, Lovell C, Myers J, Lipps Hogan J, McGill J, Salam M, Schweiger T, Kissel S, Recklein C, Clifton M, Tamborlane W, Camp A, Gulanski B, Inzucchi S, Pham K, Alguard M, Gatcomb P, Lessard K, Perez M, Iannone L, Magenheimer E, Montosa A, Burch H, Bremer A, Fradkin J, Nathan D, Lachin J, Krause-Steinrauf H, Younes N, Backman M, Bebu I, Butera N, Buys C, Fagan Murphy A, Gao Y, Ghosh A, Gramzinski M, Kazemi E, Hall S, Legowski E, Suratt C, Tripputi M, Arey A, Bethepu J, Lund C, Mangat Dhaliwal P, McGee P, Mesimer E, Ngo L, Steffes M, Seegmiller J, Saenger A, Arends V, Gabrielson D, Conner T, Warren S, Day J, Huminik J, Scrymgeour A, Soliman E, Pokharel Y, Zhang Z, Campbell C, Hu J, Keasler L, Hensley S, Li Y, Herman W, Kuo S, Martin C, Waltje A, Mihalcea R, Min D, Perez-Rosas V, Prosser L, Resnicow K, Ye W, Shao H, Zhang P, Luchsinger J, Sanchez D, Assuras S, Groessl E, Sakha F, Chong H, Hillery N, Everett B, Abdouch I, Bahtiyar G, Brantley P, Broyles F, Canaris G, Copeland P, Craine J, Fein W, Gliwa A, Hope L, Lee M, Meiners R, Meiners V, O’Neal H, Park J, Sacerdote A, Sledge E, Soni L, Steppel-Reznik J, Turchin A, Brooks-Worrell B, Hampe C, Newgard C, Palmer J, Shojaie A, Higgins J, Fischer L, Golden S, Gonzalez J, Naik A, Walker E, Doner Lotenberg L, Gallivan J, Lim J, Tuncer D, Behringer-Massera S. Clinical and Metabolic Characterization of Adults With Type 2 Diabetes by Age in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) Cohort. Diabetes Care 2022, 45: 1512-1521. PMID: 40315175, PMCID: PMC9375440, DOI: 10.2337/dc21-2659.
- INZUCCHI S, BHATT D, PITT B, SZAREK M, CANNON C, LEWIS J, RIDDLE M, KOSIBOROD M, CHERNEY D, DWYER J, SCIRICA B, BAILEY C, BANKS P, DIAZ R, RAY K, UDELL J, LOPES R, LEITER L, STEG P. 864-P: Glycemic Control across eGFR Categories with the Dual SGLT1 and 2 Inhibitor Sotagliflozin in SCORED. Diabetes 2022, 71 DOI: 10.2337/db22-864-p.
- Sharma A, Inzucchi S, Testani J, Ofstad A, Fitchett D, Mattheus M, Verma S, Zannad F, Wanner C, Kraus B, Wagner-Golbs A. Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2022, 17: s31-s32. DOI: 10.1055/s-0042-1746295.
- Ferreira J, Inzucchi S, Zinman B, Mattheus M, Meinicke T, Steubl D, Wanner C, Gotsch U. Effects of empagliflozin on uric acid levels and gout: observations from the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2022, 17: s62-s62. DOI: 10.1055/s-0042-1746380.
- Anam A, Inzucchi S. Newer Glucose-Lowering Medications and Potential Role in Metabolic Management of PCOS. 2022, 527-553. DOI: 10.1007/978-3-030-92589-5_26.
- Sharma A, Inzucchi S, Testani J, Ofstad A, Fitchett D, Mattheus M, Verma S, Zannad F, Wanner C, Kraus B. Association Of Kidney And Cardiovascular Outcomes: Insights From The Empagliflozin Cardiovascular Outcome Event Trial In Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) Trial. Journal Of Cardiac Failure 2022, 28: s103. DOI: 10.1016/j.cardfail.2022.03.262.
- Docherty K, Anand I, Chiang C, Chopra V, Desai A, Kitakaze M, Verma S, Vinh P, Inzucchi S, Køber L, Kosiborod M, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjöstrand M, Solomon S, Langkilde A, Jhund P, McMurray J. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. JACC Asia 2022, 2: 139-153. PMID: 36339117, PMCID: PMC9627879, DOI: 10.1016/j.jacasi.2022.02.004.
- Leasure A, Acosta J, Schwartz A, Forman R, Sharma R, de Havenon A, Falcone G, Inzucchi S, Kernan W, Sheth K. WORSE VASCULAR RISK FACTOR CONTROL IN PATIENTS WITH STROKE COMPARED TO PATIENTS WITH MYOCARDIAL INFARCTION. Journal Of The American College Of Cardiology 2022, 79: 1504. DOI: 10.1016/s0735-1097(22)02495-0.
- Brooks-Worrell B, Hampe C, Hattery E, Palomino B, Zangeneh S, Utzschneider K, Kahn S, Larkin M, Johnson M, Mather K, Younes N, Rasouli N, Desouza C, Cohen R, Park J, Florez H, Valencia W, Shojaie A, Palmer J, Balasubramanyam A, Crandall J, McKee M, Brown-Friday J, Xhori E, Ballentine-Cargill K, Duran S, Lukin J, Beringher S, Gonzalez de la Torre S, Phillips L, Burgess E, Olson D, Rhee M, Wilson P, Raines T, Costello J, Gullett C, Maher-Albertelli M, Morehead F, Mungara R, Person S, Savoye L, Sibymon M, Tanukonda S, White C, Holloway L, Adams C, Ross A, Balasubramanyam A, Gonzalez Hattery E, Gaba R, Montes G, Wright C, Hollander P, Roe E, Uy A, Burt P, Estrada L, Chionh K, Ismail-Beigi F, Falck-Ytter C, Sayyed Kassem L, Sood A, Tiktin M, Cramer B, Iacoboni J, Kononets M, Kulow T, Newman C, Stancil K, Sanders C, Tucker L, Werner A, Krol A, McPhee G, Patel C, Colosimo L, Goland R, Pring J, Kringas P, Tejada J, Hausheer C, Schneier H, Gumpel K, Kirpitch A, Green J, AbouAssi H, Chatterjee R, Feinglos M, English Jones J, Khan S, Kimpel J, Zimmer R, Furst M, Satterwhite B, Thacker C, Evans Kreider K, Mather K, Lteif A, Hamilton T, Patel N, Riera G, Jackson M, Pirics V, Howard D, Aguillar D, Hurt S, Bergenstal R, Carlson A, Martens T, Johnson M, Hill R, Hyatt J, Jensen C, Madden M, Martin D, Willis H, Konerza W, Passi R, Kleeberger K, Fortmann S, Herson M, Mularski K, Glauber H, Prihoda J, Ash B, Carlson C, Ramey P, Schield E, Torgrimson-Ojerio B, Arnold K, Kauffman B, Panos E, Sahnow S, Bays K, Cook J, Gluth J, Sasaki D, Schell K, Criscola J, Friason C, Jones S, Nazarov S, Barzilay J, Rassouli N, Puttnam R, Curtis M, Stokes K, Hollis B, Sanders-Jones C, Nelson R, El-Haqq Z, Kolli A, Tran T, Wexler D, Larkin M, Meigs J, Dushkin A, Rocchio G, Chambers B, Yepes M, Steiner B, Dulin H, Cayford M, DeManbey A, Gurry L, Hillard M, Martin K, Stevens C, Thangthaeng N, Kochis R, Raymond E, Ripley V, Park J, Aroda V, Ghazi A, Loveland A, Hurtado M, Kuhn A, Mofor F, Florez H, Valencia W, Marks J, Oropesa-Gonzalez L, Riccio Veliz A, Nieto-Martinez R, Gutt M, Ahmann A, Aby-Daniel D, Joarder F, Morimoto V, Sprague C, Yamashita D, Cady N, Kirchhoff P, Rivera-Eschright N, Adducci J, Morales Gomez B, Goncharova A, Hox S, Petrovitch H, Matwichyna M, Jenkins V, Bermudez N, Ishii R, Hsia D, Cefalu W, Greenway F, Waguespack C, King E, Haynes N, Thomassie A, Bourgeois B, Hazlett C, Henry R, Mudaliar S, Boeder S, Pettus J, Diaz E, DeLue C, Castro E, Hernandez S, Krakoff J, Curtis J, Killean T, Joshevama E, Diaz E, Martin D, Karshner T, Albu J, Pi-Sunyer F, Frances S, Maggio C, Ellis E, Bastawrose J, Gong X, Banerji M, August P, Lorber D, Brown N, Josephson D, Thomas L, Tsovian M, Cherian A, Jacobson M, Mishko M, Kirkman M, Bergamo K, Buse J, Dostou J, Young L, Goley A, Kerr J, Largay J, Guarda S, Cuffee J, Culmer D, Fraser R, Almeida H, Coffer S, Debnam E, Kiker L, Morton S, Josey K, Fuller G, Garvey W, Cherrington A, Golson D, Griffith O, Robertson M, Agne A, McCullars S, Cohen R, Craig J, Kersey K, Rogge M, Wilson C, Burton K, Lipp S, Vonder Meulen M, Rasouli N, Schroeder E, Steiner S, Baker C, Underkofler C, Douglass S, Sivitz W, Cline E, Knosp L, McConnell J, Lowe T, Herman W, Pop-Busui R, Tan M, Martin C, Waltje A, Goodhall L, Eggleston R, Kuo S, Bule S, Kessler N, LaSalle E, Seaquist E, Bantle A, Kumar A, Redmon B, Bantle J, Harindhanavudhi T, Coe M, Mech M, Taddese A, Lesne L, Smith S, Desouza C, Kuechenmeister L, Shivaswamy V, Morales A, Rodriguez M, Seipel K, Alfred A, Eggert J, Lord G, Taylor W, Tillson R, Schade D, Adolphe A, Burge M, Duran-Valdez E, Martinez J, Hernandez McGinnis D, Pucchetti B, Scripsick E, DeFronzo R, Cersosimo E, Abdul-Ghani M, Triplitt C, Verastiqui H, Garza R, Wright K, Puckett C, Raskin P, Rhee C, Abraham S, Jordan L, Sao S, Morton L, Smith O, Osornio Walker L, Schnurr-Breen L, Ayala R, Kraymer R, Sturgess D, Utzschneider K, Kahn S, Alarcon-Casas Wright L, Boyko E, Tsai E, Trence D, Fattaleh B, Montgomery B, Atkinson K, Concepcion T, Kozedub A, Moak C, Rhothisen S, Elasy T, Martin S, Shackelford L, Goidel R, Hinkle N, Lipps Hogan J, Lovell C, Myers J, McGill J, Salam M, Kissel S, Schweiger T, Recklein C, Tamborlane W, Gatcomb P, Camp A, Gulanski B, Inzucchi S, Pham K, Alguard M, Lessard K, Perez M, Magenheimer E, Montoza A, Nathan D, Lachin J, Buse J, Kahn S, Krause-Steinrauf H, Larkin M, Wexler D, Burch H, Linder B, Bremer A, Lachin J, Younes N, Backman M, Bebu I, Buys C, Fagan Murphy A, Gao Y, Gramzinski M, Hall S, Legowski E, Arey A, Bethepu J, Lund C, Mangat Dhaliwal P, McGee P, Mesimer E, Ngo L, Steffes M, Seegmiller J, Saenger A, Arends V, Gabrielson D, Conner T, Stuart W, Day J, Scrymgeour A, Soliman E, Zhang Z, Campbell C, Hu J, Keasler L, Hensley S, Li Y, Herman W, Martin C, Waltje A, Mihalcea R, Perez-Rosas V, Prosser L, Resnicow K, Ye W, Shao H, Zhang P, Luchsinger J, Sanchez D, Burch H, Bremer A, Linder B, Fradkin J, Groessl E, Chong H, Hillery N, Abdouch I, Brantley P, Broyles F, Canaris G, Copeland P, Craine J, Fein W, Lee M, Meiners R, Meiners V, O’Neal H, Park J, Sledge E, Steppel-Resnick J, Turchin A, Brooks-Worrell B, Hampe C, Palmer J, Shojaie A, Higgins J, Fischer L, Golden S, Gonzalez J, Naik A, Walker E, Doner Lotenberg L, Gallivan J, Lim J, Tuncer D, Behringer-Massera S. Islet Autoimmunity is Highly Prevalent and Associated With Diminished β-Cell Function in Patients With Type 2 Diabetes in the Grade Study. Diabetes 2022, 71: 1261-1271. PMID: 35061024, PMCID: PMC9375448, DOI: 10.2337/db21-0590.
- Ding Q, Qin L, Wojeck B, Inzucchi SE, Ibrahim A, Bravata DM, Strohl KP, Yaggi HK, Zinchuk AV. Polysomnographic Phenotypes of Obstructive Sleep Apnea and Incident Type 2 Diabetes: Results from the DREAM Study. Annals Of The American Thoracic Society 2021, 18: 2067-2078. PMID: 34185617, PMCID: PMC8641817, DOI: 10.1513/annalsats.202012-1556oc.
- Holt E, Inzucchi S. Update in Endocrinology. 2021, 105: i. DOI: 10.1016/s0025-7125(21)00125-5.
- Cowan L, Adamson C, Docherty K, Inzucchi S, Koeber L, Kosiborod M, Martinez F, Ponikowski P, Sabatine M, Solomon S, Bengtsson O, Sjostrand M, Langkilde A, Jhund P, McMurray J. Elevated markers of liver function are associated with poorer outcomes in HFREF: an analysis of DAPA-HF. European Heart Journal 2021, 42: ehab724.0911. DOI: 10.1093/eurheartj/ehab724.0911.
- Hadjadj S, Kahl S, Ofstad A, Zinman B, Wanner C, Schüler E, Inzucchi S, Roden M. Effets de l’empagliflozine sur les marqueurs de la stéatose et de la fibrose hépatique et lien avec les résultats cardiorénaux dans l’étude EMPA-REG OUTCOME. Annales D Endocrinologie 2021, 82: 269-270. DOI: 10.1016/j.ando.2021.08.045.
- Sharma A, Inzucchi S, Testani J, Ofstad A, Fitchett D, Mattheus M, Verma S, Zannad F, Wanner C, Kraus B. ASSOCIATION OF KIDNEY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL. Canadian Journal Of Cardiology 2021, 37: s62-s63. DOI: 10.1016/j.cjca.2021.07.130.
- Wanner C, Nangaku M, Kraus B, Zinman B, Mattheus M, Ohneberg K, Hajmessaoud N, Zaoui P, Schmoor C, Inzucchi S. Médiateurs de l’effet du traitement par empagliflozine sur les résultats rénaux dans l’essai EMPA-REG OUTCOME. Néphrologie & Thérapeutique 2021, 17: 339. DOI: 10.1016/j.nephro.2021.07.233.
- Luchsinger J, Younes N, Manly J, Barzilay J, Valencia W, Larkin M, Falck-Ytter C, Krause-Steinrauf H, Pop-Busui R, Florez H, Seaquist E, Crandall J, McKee M, Brown-Friday J, Xhori E, Ballentine-Cargill K, Duran S, Lukin J, Beringher S, Gonzalez de la torre S, Phillips L, Burgess E, Olson D, Rhee M, Wilson P, Raines T, Costello J, Gullett C, Maher-Albertelli M, Morehead F, Mungara R, Person S, Savoye L, Sibymon M, Tanukonda S, White C, Holloway L, Adams C, Ross A, Balasubramanyam A, Gonzalez E, Wright C, Hollander P, Roe E, Uy A, Burt P, Estrada L, Chionh K, Ismail-Beigi F, Falck-Ytter C, Sayyed Kassem L, Sood A, Tiktin M, Cramer B, Iacoboni J, Kononets M, Kulow T, Newman C, Stancil K, Sanders C, Tucker L, Werner A, Krol A, McPhee G, Patel C, Colosimo L, Goland R, Pring J, Kringas P, Tejada J, Hausheer C, Schneier H, Gumpel K, Kirpitch A, Green J, AbouAssi H, Chatterjee R, Feinglos M, English Jones J, Khan S, Kimpel J, Zimmer R, Furst M, Satterwhite B, Thacker C, Evans Kreider K, Mather K, Lteif A, Hamilton T, Patel N, Riera G, Jackson M, Pirics V, Howard D, Aguillar D, Hurt S, Bergenstal R, Carlson A, Martens T, Johnson M, Hill R, Hyatt J, Jensen C, Madden M, Martin D, Willis H, Konerza W, Passi R, Kleeberger K, Fortmann S, Herson M, Mularski K, Glauber H, Prihoda J, Ash B, Carlson C, Ramey P, Schield E, Torgrimson-Ojerio B, Arnold K, Kauffman B, Panos E, Sahnow S, Bays K, Cook J, Gluth J, Sasaki D, Schell K, Criscola J, Friason C, Jones S, Nazarov S, Barzilay J, Rassouli N, Puttnam R, Curtis M, Stokes K, Hollis B, Sanders-Jones C, Nelson R, El-Haqq Z, Kolli A, Tran T, Wexler D, Larkin M, Meigs J, Dushkin A, Rocchio G, Chambers B, Yepes M, Steiner B, Dulin H, Cayford M, DeManbey A, Gurry L, Hillard M, Martin K, Stevens C, Thangthaeng N, Kochis R, Raymond E, Ripley V, Park J, Aroda V, Ghazi A, Loveland A, Hurtado M, Kuhn A, Mofor F, Florez H, Valencia W, Marks J, Oropesa-Gonzalez L, Riccio Veliz A, Nieto-Martinez R, Gutt M, Ahmann A, Aby-Daniel D, Joarder F, Morimoto V, Sprague C, Yamashita D, Cady N, Kirchhoff P, Rivera- Eschright N, Adducci J, Morales Gomez B, Goncharova A, Hox S, Petrovitch H, Matwichyna M, Jenkins V, Bermudez N, Ishii R, Hsia D, Cefalu W, Greenway F, Waguespack C, King E, Haynes N, Thomassie A, Bourgeois B, Hazlett C, Henry R, Mudaliar S, Boeder S, Pettus J, Diaz E, DeLue C, Castro E, Hernandez S, Krakoff J, Curtis J, Killean T, Joshevama E, Diaz E, Martin D, Karshner T, Albu J, Pi-Sunyer F, Frances S, Maggio C, Ellis E, Bastawrose J, Gong X, Banerji M, August P, Lorber D, Brown N, Josephson D, Thomas L, Tsovian M, Cherian A, Jacobson M, Mishko M, Kirkman M, Bergamo K, Buse J, Dostou J, Young L, Goley A, Kerr J, Largay J, Guarda S, Cuffee J, Culmer D, Fraser R, Almeida H, Coffer S, Debnam E, Kiker L, Morton S, Josey K, Fuller G, Garvey W, Cherrington A, Golson D, Griffith O, Robertson M, Agne A, McCullars S, Cohen R, Craig J, Kersey K, Rogge M, Wilson C, Burton K, Lipp S, Vonder Meulen M, Rasouli N, Schroeder E, Steiner S, Baker C, Underkofler C, Douglass S, Sivitz W, Cline E, Knosp L, McConnell J, Lowe T, Herman W, Pop-Busui R, Tan M, Martin C, Waltje A, Goodhall L, Eggleston R, Kuo S, Bule S, Kessler N, LaSalle E, Seaquist E, Bantle A, Kumar A, Redmon B, Bantle J, Harindhanavudhi T, Coe M, Mech M, Taddese A, Lesne L, Smith S, Desouza C, Kuechenmeister L, Shivaswamy V, Morales A, Rodriguez M, Seipel K, Alfred A, Eggert J, Lord G, Taylor W, Tillson R, Schade D, Adolphe A, Burge M, Duran-Valdez E, Martinez J, Hernandez McGinnis D, Pucchetti B, Scripsick E, DeFronzo R, Cersosimo E, Abdul-Ghani M, Triplitt C, Verastiqui H, Garza R, Wright K, Puckett C, Raskin P, Rhee C, Abraham S, Jordan L, Sao S, Morton L, Smith O, Osornio Walker L, Schnurr-Breen L, Ayala R, Kraymer R, Sturgess D, Utzschneider K, Kahn S, Alarcon-Casas Wright L, Boyko E, Tsai E, Trence D, Fattaleh B, Montgomery B, Atkinson K, Concepcion T, Kozedub A, Moak C, Rhothisen S, Elasy T, Martin S, Shackelford L, Goidel R, Hinkle N, Lipps Hogan J, Lovell C, Myers J, McGill J, Salam M, Kissel S, Schweiger T, Recklein Carol Tamborlane W, Gatcomb P, Camp A, Gulanski B, Inzucchi S, Pham K, Alguard M, Lessard K, Perez M, Magenheimer E, Montoza A, Nathan D, Lachin J, Buse J, Kahn S, Krause-Steinrauf H, Larkin M, Tiktin M, Wexler D, Burch H, Linder B, Bremer A, Younes N, Backman M, Bebu I, Buys C, Fagan Murphy A, Gao Y, Gramzinski M, Hall S, Legowski E, Arey A, Bethepu J, Lund C, Mangat Dhaliwal P, McGee P, Mesimer E, Ngo L, Steffes M, Seegmiller J, Saenger A, Arends V, Gabrielson D, Conner T, Warren S, Day J, Scrymgeour A, Soliman E, Zhang Z, Campbell C, Hu J, Keasler L, Hensley S, Li Y, Herman W, Martin C, Waltje A, Kuo S, Mihalcea R, Perez-Rosas V, Prosser L, Resnicow K, Ye W, Shao H, Zhang P, Luchsinger J, Sanchez D, Burch H, Bremer A, Linder B, Fradkin J, Groessl E, Chong H, Hillery N, Abdouch I, Brantley P, Broyles F, Canaris G, Copeland P, Craine J, Fein W, Lee M, Meiners R, Meiners V, O’Neal H, Park J, Sledge E, Steppel-Resnick J, Turchin A, Brooks-Worrell B, Hampe C, Newgard C, Palmer J, Shojaie A, Higgins J, Fischer L, Golden S, Gonzalez J, Naik A, Walker E, Doner Lotenberg L, Gallivan J, Lim J, Tuncer D, Behringer-Massera S. Association of Glycemia, Lipids, and Blood Pressure With Cognitive Performance in People With Type 2 Diabetes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care 2021, 44: 2286-2292. PMID: 34285097, PMCID: PMC8740937, DOI: 10.2337/dc20-2858.
- ATHONVARANGKUL D, BAK L, ZHENG C, D’AMBROSI J, SINER J, HONIDEN S, INZUCCHI S. 873-P: Modified Insulin Infusion Protocol for COVID-19 Patients Is Safe and Effective for Controlling Hyperglycemia. Diabetes 2021, 70 DOI: 10.2337/db21-873-p.
- INZUCCHI S, WANNER C, FITCHETT D, ZINMAN B, ANKER S, MATTHEUS M, VEDIN O, HANTEL S, LUND S. 790-P: Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalization in EMPA-REG OUTCOME. Diabetes 2021, 70 DOI: 10.2337/db21-790-p.
- KAHL S, OFSTAD A, ZINMAN B, WANNER C, SCHUELER E, INZUCCHI S, RODEN M. 319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial. Diabetes 2021, 70 DOI: 10.2337/db21-319-or.
- Vaduganathan M, Sattar N, Fitchett D, George J, Ofstad A, Verma S, Mattheus M, Wanner C, Inzucchi, Zinman B, Butler J. Empagliflozin facilitates sustained insulin dose reductions in patients with type 2 diabetes and cardiovascular disease: the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2021, 16: s18-s19. DOI: 10.1055/s-0041-1727336.
- Fitchett D, Inzucchi, Zinman B, Wanner C, Anker S, Pocock S, Kaspers S, George J, Johansen O, Jamal W, Hantel S, Lund S. Empagliflozin reduces the total burden of cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2021, 16: s51. DOI: 10.1055/s-0041-1727464.
- Kraus B, Weir, Bakris G, Mattheus M, Cherney D, Sattar N, Heerspink H, Ritter I, von Eynatten M, Zinman B, Inzucchi, Wanner C, Koitka-Webe A. Cardiovascular and kidney implications of the initial response in estimated glomerular filtration rate to sodium glucose cotransporter-2 inhibition with empagliflozin: the ‘eGFR dip’ in EMPA-REG OUTCOME. Diabetologie Und Stoffwechsel 2021, 16: s52. DOI: 10.1055/s-0041-1727466.
- Inzucchi, Zinman B, Wanner C, Fitchett D, Anker S, Pocock S, Kaspers S, George J, Johansen O, Jamal W, Hantel S, Lund S. Empagliflozin Reduces the Total Burden of All-cause Hospitalisations and All-cause Mortality in the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2021, 16: s51-s52. DOI: 10.1055/s-0041-1727465.
- Ding Q, Qin L, Wojeck B, Inzucchi S, Ibrahim A, Bravata D, Strohl K, Yaggi H, Zinchuk A. Associations Between Polysomnographic Phenotypes of Obstructive Sleep Apnea and Incident Type 2 Diabetes. 2021, a4679-a4679. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4679.
- Wojeck B, Gossmann M, Zeidan A, Inzucchi S. Acute Myeloid Leukemia Leading to Central Diabetes Insipidus. Journal Of The Endocrine Society 2021, 5: a570-a571. PMCID: PMC8090637, DOI: 10.1210/jendso/bvab048.1163.
- Lupsa B, Inzucchi S. Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic Syndrome. Contemporary Endocrinology 2021, 9-25. DOI: 10.1007/978-3-030-67455-7_2.
- Hong CS, Omuro A, An Y, Inzucchi S, Kohli AA, McGuone D, Vining EM, Omay SB, Erson-Omay E. Sporadic adamantinomatous craniopharyngioma with double-hit somatic APC mutations. Neuro-Oncology Advances 2021, 3: vdab124. PMID: 34549183, PMCID: PMC8446933, DOI: 10.1093/noajnl/vdab124.
- Hamilton A, Inzucchi S, Wanner C, Fitchett D, Zinman B, Anker S, Mattheus M, Vedin O, Hantel S, Lund S. Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalisation in EMPA-REG OUTCOME. Heart Lung And Circulation 2021, 30: s221-s222. DOI: 10.1016/j.hlc.2021.06.281.
- Hamilton A, Fitchett D, Zinman B, Inzucchi S, Wanner C, Anker S, Pocock S, Kaspers S, Mattheus M, Vedin O, Hantel S, Lund S. Effect of Empagliflozin on Total Events of Myocardial Infarctions by Subtype in the EMPA-REG OUTCOME Trial. Heart Lung And Circulation 2021, 30: s220-s221. DOI: 10.1016/j.hlc.2021.06.278.
- Hamilton A, Sharma A, Inzucchi S, Testani J, Ofstad A, Fitchett D, Mattheus M, Verma S, Zannad F, Wanner C, Kraus B. Association of Kidney and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus: Insights From the EMPA-REG OUTCOME Trial. Heart Lung And Circulation 2021, 30: s212-s213. DOI: 10.1016/j.hlc.2021.06.259.
- Yaggi H, Eliasson B, Kasai T, Marx N, Zinman B, Inzucchi S, Wanner C, Zwiener I, Wojeck B, Neeland I, Johansen O. Obstructive sleep apnoe and cardiovascular, heart failure and mortality outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial. European Heart Journal 2020, 41: ehaa946.2883. DOI: 10.1093/ehjci/ehaa946.2883.
- Kristensen S, Docherty K, Jhund P, Bengtsson O, Demets D, Inzucchi S, Kober L, Kosiborod M, Langkilde A, Martinez F, Ponikowski P, Sabatine M, Sjostrand M, Solomon S, McMurray J. Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF. European Heart Journal 2020, 41: ehaa946.0939. DOI: 10.1093/ehjci/ehaa946.0939.
- Docherty K, Jhund P, Bengtsson O, Demets D, Inzucchi S, Kober L, Kosiborod M, Langkilde A, Lindholm D, Martinez F, Ponikowski P, Sabatine M, Sjostrand M, Solomon S, McMurray J. The effect of dapagliflozin across the spectrum of baseline risk: a post-hoc analysis of DAPA-HF. European Heart Journal 2020, 41: ehaa946.0931. DOI: 10.1093/ehjci/ehaa946.0931.
- Dewan P, Jhund P, Bengtsson O, Demets D, Inzucchi S, Kober L, Kosiborod M, Langkilde A, Lindholm D, Martinez F, Ponikowski P, Sabatine M, Sjostrand M, Solomon S, McMurray J. The effect of dapagliflozin in patients with HFrEF and COPD: a post-hoc analysis of DAPA-HF. European Heart Journal 2020, 41: ehaa946.0932. DOI: 10.1093/ehjci/ehaa946.0932.
- Verma S, Mazer C, Inzucchi S, Wanner C, Ofstad A, Johansen O, Zwiener I, George J, Butler J, Zinman B. Impact of polyvascular disease and renal dysfunction on cardiovascular outcomes in diabetes: post hoc analyses from EMPA-REG OUTCOME. European Heart Journal 2020, 41: ehaa946.3352. DOI: 10.1093/ehjci/ehaa946.3352.
- Kristensen S, Docherty K, Jhund P, Bengtsson O, Inzucchi S, Kosiborod M, Langkilde A, Martinez F, Ponikowski P, Sabatine M, Sjostrand M, Solomon S, McMurray J. Dapagliflozin Reduces the Risk of Hyperkalaemia in Patients with Heart Failure and Reduced Ejection Fraction: A Secondary Analysis from DAPA-HF. Journal Of The American Society Of Nephrology 2020, 31: 21-21. DOI: 10.1681/asn.20203110s121b.
- Docherty KF, Jhund PS, Anand I, Bengtsson O, Böhm M, de Boer RA, DeMets DL, Desai AS, Drozdz J, Howlett J, Inzucchi SE, Johanson P, Katova T, Køber L, Kosiborod MN, Langkilde AM, Lindholm D, Martinez FA, Merkely B, Nicolau J, O’Meara E, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Tereshchenko S, Verma S, McMurray JJV. Effect of Dapagliflozin on Outpatient Worsening of Patients with Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. Circulation 2020, 142: 1623-1632. PMID: 32883108, PMCID: PMC7580857, DOI: 10.1161/circulationaha.120.047480.
- Jackson AM, Dewan P, Anand IS, Bělohlávek J, Bengtsson O, de Boer RA, Böhm M, Boulton DW, Chopra VK, DeMets DL, Docherty KF, Dukát A, Greasley PJ, Howlett JG, Inzucchi SE, Katova T, Køber L, Kosiborod MN, Langkilde AM, Lindholm D, Ljungman CEA, Martinez FA, O’Meara E, Sabatine MS, Sjöstrand M, Solomon SD, Tereshchenko S, Verma S, Jhund PS, McMurray JJV. Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. Circulation 2020, 142: 1040-1054. PMID: 32673497, PMCID: PMC7664959, DOI: 10.1161/circulationaha.120.047077.
- LIPSKA K, DOYLE M, CENGIZ E, DROZDOWICZ B, GILL T, MURPHY T, INZUCCHI S. 380-P: Hypoglycemia among Nursing Home Residents with Diabetes Detected by Continuous Glucose Monitoring (CGM). Diabetes 2020, 69 DOI: 10.2337/db20-380-p.
- PRATLEY R, BAUER R, INZUCCHI S, KHUNTI K, KREINER E, LAURSEN P, MEIER J. 927-P: Effect of Oral Semaglutide with or without Background SGLT2i in Patients with T2D: Subgroup Analysis of PIONEER 4. Diabetes 2020, 69 DOI: 10.2337/db20-927-p.
- VADUGANATHAN M, SATTAR N, FITCHETT D, OFSTAD A, BRUECKMANN M, GEORGE J, VERMA S, MATTHEUS M, WANNER C, INZUCCHI S, ZINMAN B, BUTLER J. 30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME. Diabetes 2020, 69 DOI: 10.2337/db20-30-or.
- VERMA S, LEITER L, SHARMA A, ZINMAN B, MATTHEUS M, FITCHETT D, GEORGE J, OFSTAD A, WANNER C, INZUCCHI S. 28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME. Diabetes 2020, 69 DOI: 10.2337/db20-28-or.
- INZUCCHI S, DOCHERTY K, KOBER L, KOSIBOROD M, MARTINEZ F, PONIKOWSKI P, SABATINE M, SOLOMON S, BELOHLAVEK J, BÖHM M, CHIANG C, DE BOER R, DIEZ M, DUKAT A, LJUNGMAN C, VERMA S, DEMETS D, BENGTSSON O, LANGKILDE A, SJÖSTRAND M, JHUND P, MCMURRAY J. 271-OR: ADA Presidents’ Select Abstract: Effect of Dapagliflozin on the Incidence of Diabetes: A Prespecified Exploratory Analysis from DAPA-HF. Diabetes 2020, 69 DOI: 10.2337/db20-271-or.
- BAK L, FANDEL T, BOZZO J, DEWITT M, CHEN P, PANDO R, FERRO L, KAPLAN R, HENDRICKSON K, AMPORT S, SUSSMAN L, INZUCCHI S. 23-OR: EHR-Based Blood Glucose Alerts Improve Inpatient Glycemic Control at a Large Academic Medical Center. Diabetes 2020, 69 DOI: 10.2337/db20-23-or.
- INZUCCHI S, KRAUS B, WEIR M, BAKRIS G, MATTHEUS M, CHERNEY D, SATTAR N, HEERSPINK H, RITTER I, EYNATTEN M, ZINMAN B, WANNER C, KOITKA-WEBER A. 132-LB: Implications of Initial EGFR Response to Empagliflozin Treatment Effects. Diabetes 2020, 69 DOI: 10.2337/db20-132-lb.
- INZUCCHI S, ZINMAN B, WANNER C, FITCHETT D, ANKER S, POCOCK S, KASPERS S, GEORGE J, JOHANSEN O, JAMAL W, HANTEL S, LUND S. 131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome. Diabetes 2020, 69 DOI: 10.2337/db20-131-lb.
- NEELAND I, ELIASSON B, KASAI T, MARX N, ZINMAN B, INZUCCHI S, WANNER C, ZWIENER I, WOJECK B, YAGGI H, JOHANSEN O. 1128-P: Empagliflozin and Obstructive Sleep Apnea (OSA): Exploratory Analysis from the EMPA-REG OUTCOME Trial. Diabetes 2020, 69 DOI: 10.2337/db20-1128-p.
- DOCHERTY K, INZUCCHI S, KOSIBOROD M, KOBER L, LANGKILDE A, MARTINEZ F, BENGTSSON O, DEMETS D, SJÖSTRAND M, SABATINE M, SOLOMON S, JHUND P, MCMURRAY J. 1112-P: Does Background T2D Therapy Modify the Benefits of Dapagliflozin in Heart Failure? Analysis of the DAPA-HF Trial. Diabetes 2020, 69 DOI: 10.2337/db20-1112-p.
- Kraus B, Weir M, Bakris G, Mattheus M, Cherney D, Sattar N, Heerspink H, Ritter I, Von Eynatten M, Zinman B, Inzucchi S, Wanner C, Koitka-Weber A. LB005KIDNEY IMPLICATIONS OF THE INITIAL EGFR RESPONSE TO SGLT2 INHIBITION WITH EMPAGLIFLOZIN: THE ‘EGFR DIP’ IN EMPA-REG OUTCOME. Nephrology Dialysis Transplantation 2020, 35: gfaa146.lb005. DOI: 10.1093/ndt/gfaa146.lb005.
- Inzucchi S, Davies M, Khunti K, Trivedi P, George J, Zwiener I, Johansen O, Sattar N. MON-645 Association of Baseline Cardio-Metabolic Parameters on the Treatment Effects of Empagliflozin When Added to Metformin in Patients with T2D. Journal Of The Endocrine Society 2020, 4: mon-645. PMCID: PMC7209010, DOI: 10.1210/jendso/bvaa046.414.
- Athonvarangkul D, Hosier H, Wojeck B, Inzucchi S. SAT-258 Surprising Transformation of a Microprolactinoma to a Macroprolactinoma. Journal Of The Endocrine Society 2020, 4: sat-258. PMCID: PMC7207434, DOI: 10.1210/jendso/bvaa046.1057.
- Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett J, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Vinh PN, Schou M, Tereshchenko S, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Johanson P, Greasley PJ, Boulton D, Bengtsson O, Jhund PS, McMurray JJV. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA: The Journal Of The American Medical Association 2020, 323: 1353-1368. PMID: 32219386, PMCID: PMC7157181, DOI: 10.1001/jama.2020.1906.
- Buse J, Caprio S, Cefalu W, Ceriello A, Del Prato S, Inzucchi S, McLaughlin S, Phillips G, Robertson R, Rubino F, Kahn R, Kirkman M. Partial remission of diabetes mellitus (type 1 or type 2). 2020 DOI: 10.32388/d002ka.
- Buse J, Caprio S, Cefalu W, Ceriello A, Del Prato S, Inzucchi S, McLaughlin S, Phillips G, Robertson R, Rubino F, Kahn R, Kirkman M. Complete remission of diabetes mellitus (type 1 or type 2). 2020 DOI: 10.32388/bg3azp.
- Buse J, Caprio S, Cefalu W, Ceriello A, Del Prato S, Inzucchi S, McLaughlin S, Phillips G, Robertson R, Rubino F, Kahn R, Kirkman M. Remission of diabetes mellitus (type 1 or type 2). 2020 DOI: 10.32388/2q5q1f.
- Sivitz W, Phillips L, Wexler D, Fortmann S, Camp A, Tiktin M, Perez M, Craig J, Hollander P, Cherrington A, Aroda V, Tan M, Krakoff J, Rasouli N, Butera N, Younes N, Crandall J, Diane McKee M, Brown-Friday J, Xhori E, Ballentine-Cargill K, Duran S, Lukin J, Beringher S, Gonzalez de la torre S, Phillips L, Burgess E, Olson D, Rhee M, Wilson P, Stephanie Raines T, Costello J, Gullett C, Maher-Albertelli M, Morehead F, Mungara R, Person S, Savoye L, Sibymon M, Tanukonda S, Ann White C, Holloway L, Adams C, Ross A, Balasubramanyam A, Gonzalez E, Wright C, Hollander P, Roe E, Uy A, Burt P, Estrada L, Chionh K, Ismail-Beigi F, Falck-Ytter C, Sayyed Kassem L, Sood A, Tiktin M, Cramer B, Iacoboni J, Kononets M, Kulow T, Newman C, Stancil K, Sanders C, Tucker L, Werner A, Krol A, McPhee G, Patel C, Colosimo L, Goland R, Pring J, Kringas P, Tejada J, Hausheer C, Schneier H, Gumpel K, Kirpitch A, Green J, AbouAssi H, Chatterjee R, Feinglos M, English Jones J, Khan S, Kimpel J, Zimmer R, Furst M, Satterwhite B, Thacker C, Evans Kreider K, Mather K, Lteif A, Hamilton T, Patel N, Riera G, Jackson M, Pirics V, Howard D, Aguillar D, Hurt S, Bergenstal R, Carlson A, Martens T, Johnson M, Hill R, Hyatt J, Jensen C, Madden M, Martin D, Willis H, Konerza W, Passi R, Kleeberger K, Fortmann S, Herson M, Mularski K, Glauber H, Prihoda J, Ash B, Carlson C, Anne Ramey P, Schield E, Torgrimson-Ojerio B, Arnold K, Kauffman B, Panos E, Sahnow S, Bays K, Cook J, Gluth J, Sasaki D, Schell K, Criscola J, Friason C, Jones S, Nazarov S, Barzilay J, Rassouli N, Puttnam R, Curtis M, Stokes K, Hollis B, Sanders-Jones C, Nelson R, El-Haqq Z, Kolli A, Tran T, Wexler D, Mary L, Meigs J, Dushkin A, Rocchio G, Chambers B, Yepes M, Steiner B, Dulin H, Cayford M, DeManbey A, Gurry L, Hillard M, Martin K, Stevens C, Thangthaeng N, Kochis R, Raymond E, Ripley V, Park J, Aroda V, Ghazi A, Loveland A, Hurtado M, Kuhn A, Mofor F, Florez H, Valencia W, Marks J, Oropesa-Gonzalez L, Riccio Veliz A, Nieto-Martinez R, Gutt M, Ahmann A, Aby-Daniel D, Joarder F, Morimoto V, Sprague C, Yamashita D, Cady N, Kirchhoff P, Rivera-Eschright N, Adducci J, Gomez B, Goncharova A, Hox S, Petrovitch H, Matwichyna M, Jenkins V, Bermudez N, Ishii R, Hsia D, Cefalu W, Greenway F, Waguespack C, King E, Haynes N, Thomassie A, Bourgeois B, Hazlett C, Henry R, Mudaliar S, Boeder S, Pettus J, Diaz E, DeLue C, Castro E, Hernandez S, Krakoff J, Curtis J, Killean T, Joshevama E, Diaz E, Martin D, Karshner T, Albu J, Pi-Sunyer F, Frances S, Maggio C, Ellis E, Bastawrose J, Gong X, Ann Banerji M, August P, Lorber D, Brown N, Josephson D, Thomas L, Tsovian M, Cherian A, Jacobson M, Mishko M, Kirkman M, Bergamo K, Buse J, Dostou J, Young L, Goley A, Kerr J, Largay J, Guarda S, Cuffee J, Culmer D, Fraser R, Almeida H, Coffer S, Debnam E, Kiker L, Morton S, Josey K, Fuller G, Garvey W, Cherrington A, Golson D, Griffith O, Catherine Robertson M, Agne A, McCullars S, Cohen R, Craig J, Kersey K, Rogge M, Wilson C, Burton K, Lipp S, Vonder Meulen M, Rasouli N, Schroeder E, Steiner S, Baker C, Underkofler C, Douglass S, Sivitz W, Cline E, Knosp L, McConnell J, Lowe T, Herman W, Pop-Busui R, Tan M, Martin C, Waltje A, Goodhall L, Eggleston R, Kuo S, Bule S, Kessler N, LaSalle E, Seaquist E, Bantle A, Kumar A, Redmon B, Bantle J, Harindhanavudhi T, Coe M, Mech M, Taddese A, Lesne L, Smith S, Desouza C, Kuechenmeister L, Shivaswamy V, Laura Morales A, Rodriguez M, Seipel K, Alfred A, Eggert J, Lord G, Taylor W, Tillson R, Schade D, Adolphe A, Burge M, Duran-Valdez E, Martinez J, McGinnis D, Pucchetti B, Scripsick E, DeFronzo R, Cersosimo E, Abdul-Ghani M, Triplitt C, Verastiqui H, Irene Garza R, Wright K, Puckett C, Raskin P, Rhee C, Abraham S, Fan Jordan L, Sao S, Morton L, Smith O, Osornio Walker L, Schnurr-Breen L, Ayala R, Brian Kraymer R, Sturgess D, Utzschneider K, Kahn S, Alarcon-Casas Wright L, Boyko E, Tsai E, Trence D, Fattaleh B, Montgomery B, Atkinson K, Concepcion T, Kozedub A, Moak C, Rhothisen S, Elasy T, Martin S, Shackelford L, Goidel R, Hinkle N, Lipps Hogan J, Lovell C, Myers J, McGill J, Salam M, Kissel S, Schweiger T, Recklein C, Tamborlane W, Gatcomb P, Camp A, Gulanski B, Inzucchi S, Pham K, Alguard M, Lessard K, Perez M, Magenheimer E, Montoza A, Nathan D, Lachin J, Buse J, Kahn S, Krause-Steinrauf H, Larkin M, Tiktin M, Wexler D, Burch H, Linder B, Bremer A, Lachin J, Krause-Steinrauf H, Younes N, Backman M, Bebu I, Buys C, Fagan Murphy A, Gao Y, Gramzinski M, Hall S, Legowski E, Arey A, Bethepu J, Lund C, Mangat Dhaliwal P, McGee P, Mesimer E, Ngo L, Steffes M, Seegmiller J, Saenger A, Arends V, Gabrielson D, Conner T, Warren S, Day J, Scrymgeour A, Soliman E, Zhang Z, Campbell C, Hu J, Keasler L, Hensley S, Li Y, Herman W, Martin C, Waltje A, Kuo S, Mihalcea R, Perez-Rosas V, Prosser L, Resnicow K, Ye W, Shao H, Zhang P, Luchsinger J, Sanchez D, Burch H, Bremer A, Linder B, Fradkin J, Groessl E, Chong H, Hillery N, Abdouch I, Brantley P, Broyles F, Canaris G, Copeland P, Craine J, Fein W, Lee M, Meiners R, Meiners V, O’Neal H, Park J, Sledge E, Steppel-Resnick J, Turchin A, Brooks-Worrell B, Hampe C, Newgard C, Palmer J, Shojaie A, Higgins J, Fischer L, Golden S, Gonzalez J, Naik A, Walker E, Doner Lotenberg L, Gallivan J, Lim J, Tuncer D, Behringer-Massera S. Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. Diabetes Care 2020, 43: 940-947. PMID: 32139384, PMCID: PMC7171946, DOI: 10.2337/dc19-1769.
- Docherty K, Jackson A, Inzucchi S, Jhund P, Kober L, Kosiborod M, Langkilde A, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjoestrand M, Solomon S, Desai A, Diez M, Howlett J, Ljungman C, O'Meara E, Petrie M, Schou M, Pham V, McMurray J. CONSISTENT BENEFIT OF DAPAGLIFLOZIN ACCORDING TO BACKGROUND THERAPY IN PATIENTS WITH HFREF: AN ANALYSIS OF THE DAPA-HF TRIAL. Journal Of The American College Of Cardiology 2020, 75: 656. DOI: 10.1016/s0735-1097(20)31283-3.
- Jhund P, Adamson C, Inzucchi S, Kosiborod M, Langkilde A, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjoestrand M, Solomon S, McMurray J. EFFECT OF TREATMENT WITH DAPAGLIFLOZIN IS CONSISTENT ACROSS THE RANGE OF BODY MASS INDEX IN PATIENTS WITH HFREF: AN ANALYSIS OF THE DAPA-HF TRIAL. Journal Of The American College Of Cardiology 2020, 75: 673. DOI: 10.1016/s0735-1097(20)31300-0.
- Køber L, Docherty K, Inzucchi S, Jhund P, Kosiborod M, Langkilde A, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjoestrand M, Solomon S, McMurray J. DAPAGLIFLOZIN IMPROVES OUTCOMES IRRESPECTIVE OF NT-PROBNP CONCENTRATION IN PATIENTS WITH HFREF: AN ANALYSIS OF THE DAPA-HF TRIAL. Journal Of The American College Of Cardiology 2020, 75: 675. DOI: 10.1016/s0735-1097(20)31302-4.
- McMurray J, Boehm M, Serenelli M, Inzucchi S, Jhund P, Kober L, Kosiborod M, Langkilde A, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjoestrand M, Solomon S. EFFECT OF TREATMENT WITH DAPAGLIFLOZIN ACCORDING TO BASELINE SYSTOLIC BLOOD PRESSURE IN PATIENTS WITH HFREF: AN ANALYSIS OF THE DAPA-HF TRIAL. Journal Of The American College Of Cardiology 2020, 75: 849. DOI: 10.1016/s0735-1097(20)31476-5.
- Verma S, Mazer C, Inzucchi S, Wanner C, Ofstad A, Johansen O, Zwiener I, George J, Butler J, Zinman B. THE ASSOCIATION BETWEEN POLYVASCULAR DISEASE AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME. Journal Of The American College Of Cardiology 2020, 75: 1859. DOI: 10.1016/s0735-1097(20)32486-4.
- Verma S, Sharma A, Zinman B, Ofstad A, Fitchett D, Brueckmann M, Wanner C, Zwiener I, George J, Inzucchi S, Butler J, Mazer C. APPLICATION OF THE TIMI HEART FAILURE RISK SCORE TO THE EMPA-REG OUTCOME POPULATION. Journal Of The American College Of Cardiology 2020, 75: 1851. DOI: 10.1016/s0735-1097(20)32478-5.
- Inzucchi S, Khunti K, Fitchett D, Wanner C, Mattheus M, George J, Ofstad A, Zinman B. Consistent cardiovascular (CV) benefit of empagliflozin over the spectrum of CV risk factor control in EMPA-REG OUTCOME. Metabolism 2020, 104: 154125. DOI: 10.1016/j.metabol.2019.12.071.
- Murari K, Gossman M, Mahajan A, Erson Z, Inzucchi S, Omay S. A Case of the Use of Genomic Signatures in the Diagnosis of Cushing Disease. Journal Of Neurological Surgery Part B Skull Base 2020, 81: s1-s272. DOI: 10.1055/s-0040-1702681.
- Kosiborod M, Nassif M, Windsor S, Tang F, Khariton Y, Austin B, Umpierrez G, Lamba S, Katz S, Fong M, Husain M, Inzucchi S, Mcguire D, Pitt B, Scirica B. Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients with Heart Failure with Reduced Ejection Fraction with and without Diabetes - The Define-HF Trial. Journal Of Cardiac Failure 2019, 25: 937-938. DOI: 10.1016/j.cardfail.2019.11.005.
- McGuire D, Zinman B, Inzucchi S, Anker S, Wanner C, Kaspers S, Von Eynatten M, Johansen O, Elsasser U, Pocock S, Fitchett D, Jamal W, Hantel S, Lund S. P6270Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease. European Heart Journal 2019, 40: ehz746.0869. DOI: 10.1093/eurheartj/ehz746.0869.
- Verma S, Böhm M, Brueckmann M, Fitchett D, George J, Inzucchi S, Marx N, Mattheus M, Ofstad A, Slawik J, Wanner C, Zinman B. HEART FAILURE OUTCOMES IN PATIENTS WITH DIABETES WITH AND WITHOUT ATRIAL FIBRILLATION - DATA FROM THE EMPA-REG OUTCOME STUDY. Canadian Journal Of Cardiology 2019, 35: s197. DOI: 10.1016/j.cjca.2019.07.619.
- Verma S, Qiuhe J, Bhatt D, Mazer C, Al-Omran M, Inzucchi S, Wanner C, Ofstad A, Zwiener I, George J, Zinman B, Fitchett D. URIC ACID LEVELS PREDICT CARDIORENAL OUTCOMES AND CARDIOVASCULAR DEATH IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME. Canadian Journal Of Cardiology 2019, 35: s139. DOI: 10.1016/j.cjca.2019.07.554.
- Nassif ME, Windsor S, Tang F, Khariton Y, Husain M, Inzucchi SE, McGuire D, Pitt B, Scirica BM, Austin B, Drazner M, Fong M, Givertz MM, Gordon R, Jermyn R, Katz S, Lamba S, Lanfear D, LaRue S, Lindenfeld J, Malone M, Margulies K, Mentz R, Mutharasan RK, Pursley M, Umpierrez G, Kosiborod M, Malik A, Wenger N, Ogunniyi M, Vellanki P, Murphy B, Newman J, Hartupee J, Gupta C, Goldsmith M, Baweja P, Montero M, Gottlieb S, Costanzo M, Hoang T, Warnock A, Allen L, Tang W, Chen H, Cox J. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. Circulation 2019, 140: 1463-1476. PMID: 31524498, DOI: 10.1161/circulationaha.119.042929.
- Larkin M, Nathan D, Bebu I, Krause-Steinrauf H, Herman W, Higgins J, Tiktin M, Cohen R, Lund C, Bergenstal R, Johnson M, Arends V, Crandall J, McKee M, Brown-Friday J, Xhori E, Ballentine-Cargill K, Duran S, Lukin J, Beringher S, de la torre S, Phillips L, Burgess E, Olson D, Rhee M, Wilson P, Raines T, Costello J, Gullett C, Maher-Albertelli M, Morehead F, Mungara R, Person S, Savoye L, Sibymon M, Tanukonda S, White C, Holloway L, Adams C, Ross A, Balasubramanyam A, Gonzalez E, Wright C, Hollander P, Roe E, Uy A, Burt P, Estrada L, Chionh K, Ismail-Beigi F, Falck-Ytter C, Kassem L, Sood A, Cramer B, Iacoboni J, Kononets M, Kulow T, Newman C, Stancil K, Sanders C, Tucker L, Werner A, Krol A, McPhee G, Patel C, Colosimo L, Goland R, Pring J, Kringas P, Tejada J, Hausheer C, Schneier H, Gumpel K, Kirpitch A, Green J, AbouAssi H, Chatterjee R, Feinglos M, Jones J, Khan S, Kimpel J, Zimmer R, Furst M, Satterwhite B, Thacker C, Kreider K, Mather K, Lteif A, Hamilton T, Patel N, Riera G, Jackson M, Pirics V, Howard D, Aguillar D, Hurt S, Bergenstal R, Carlson A, Martens T, Johnson M, Hill R, Hyatt J, Jensen C, Madden M, Martin D, Willis H, Konerza W, Passi R, Kleeberger K, Fortmann S, Herson M, Mularski K, Glauber H, Prihoda J, Ash B, Carlson C, Ramey P, Schield E, Torgrimson-Ojerio B, Arnold K, Kauffman B, Panos E, Sahnow S, Bays K, Cook J, Gluth J, Sasaki D, Schell K, Criscola J, Friason C, Jones S, Nazarov S, Barzilay J, Rassouli N, Puttnam R, Curtis M, Stokes K, Hollis B, Sanders-Jones C, Nelson R, El-Haqq Z, Kolli A, Tran T, Wexler D, Meigs J, Dushkin A, Rocchio G, Chambers B, Yepes M, Steiner B, Dulin H, Cayford M, DeManbey A, Gurry L, Hillard M, Martin K, Stevens C, Thangthaeng N, Kochis R, Raymond E, Ripley V, Park J, Aroda V, Ghazi A, Loveland A, Hurtado M, Kuhn A, Mofor F, Florez H, Valencia W, Marks J, Oropesa-Gonzalez L, Riccio Veliz A, Nieto-Martinez R, Gutt M, Ahmann A, Aby-Daniel D, Joarder F, Morimoto V, Sprague C, Yamashita D, Cady N, Kirchhoff P, Rivera-Eschright N, Adducci J, Gomez B, Goncharova A, Hox S, Petrovitch H, Matwichyna M, Jenkins V, Bermudez N, Ishii R, Hsia D, Cefalu W, Greenway F, Waguespack C, King E, Haynes N, Thomassie A, Bourgeois B, Hazlett C, Henry R, Mudaliar S, Boeder S, Pettus J, Diaz E, DeLue C, Castro E, Hernandez S, Krakoff J, Curtis J, Killean T, Joshevama E, Diaz E, Martin D, Karshner T, Albu J, Pi-Sunyer F, Frances S, Maggio C, Ellis E, Bastawrose J, Gong X, Banerji M, August P, Lorber D, Brown N, Josephson D, Thomas L, Tsovian M, Cherian A, Jacobson M, Mishko M, Kirkman M, Bergamo K, Buse J, Dostou J, Young L, Goley A, Kerr J, Largay J, Guarda S, Cuffee J, Culmer D, Fraser R, Almeida H, Coffer S, Debnam E, Kiker L, Morton S, Josey K, Fuller G, Garvey W, Cherrington A, Golson D, Griffith O, Robertson M, Agne A, McCullars S, Craig J, Kersey K, Rogge M, Wilson C, Burton K, Lipp S, Meulen M, Rasouli N, Schroeder E, Steiner S, Baker C, Underkofler C, Douglass S, Sivitz W, Cline E, Knosp L, McConnell J, Lowe T, Pop-Busui R, Tan M, Martin C, Waltje A, Goodhall L, Eggleston R, Kuo S, Bule S, Kessler N, LaSalle E, Seaquist E, Bantle A, Kumar A, Redmon B, Bantle J, Harindhanavudhi T, Coe M, Mech M, Taddese A, Lesne L, Smith S, Desouza C, Kuechenmeister L, Shivaswamy V, Morales A, Rodriguez M, Seipel K, Alfred A, Eggert J, Lord G, Taylor W, Tillson R, Schade D, Adolphe A, Burge M, Duran-Valdez E, Martinez J, McGinnis D, Pucchetti B, Scripsick E, DeFronzo R, Cersosimo E, Abdul-Ghani M, Triplitt C, Verastiqui H, Garza R, Wright K, Puckett C, Raskin P, Rhee C, Abraham S, Jordan L, Sao S, Morton L, Smith O, Walker L, Schnurr-Breen L, Ayala R, Kraymer R, Sturgess D, Utzschneider K, Kahn S, Wright L, Boyko E, Tsai E, Trence D, Fattaleh B, Montgomery B, Atkinson K, Concepcion T, Kozedub A, Moak C, Rhothisen S, Elasy T, Martin S, Shackelford L, Goidel R, Hinkle N, Hogan J, Lovell C, Myers J, McGill J, Salam M, Kissel S, Schweiger T, Recklein C, Tamborlane W, Gatcomb P, Camp A, Gulanski B, Inzucchi S, Pham K, Alguard M, Lessard K, Perez M, Magenheimer E, Montoza A, Burch H, Bremer A, Linder B, Fradkin J, Lachin J, Kahn S, Burch H, Younes N, Backman M, Buys C, Murphy A, Gao Y, Gramzinski M, Hall S, Legowski E, Arey A, Bethepu J, Dhaliwal P, McGee P, Mesimer E, Ngo L, Steffes M, Seegmiller J, Saenger A, Gabrielson D, Conner T, Warren S, Day J, Scrymgeour A, Soliman E, Zhang Z, Campbell C, Hu J, Keasler L, Hensley S, Li Y, Herman W, Mihalcea R, Perez-Rosas V, Prosser L, Resnicow K, Ye W, Shao H, Zhang P, Luchsinger J, Sanchez D, Groessl E, Chong H, Hillery N, Abdouch I, Brantley P, Broyles F, Canaris G, Copeland P, Craine J, Fein W, Lee M, Meiners R, Meiners V, O'Neal H, Park J, Sledge E, Steppel-Resnick J, Turchin A, Higgins J. Rationale and Design for a GRADE Substudy of Continuous Glucose Monitoring. Diabetes Technology & Therapeutics 2019, 21: 682-690. PMID: 31393176, PMCID: PMC7207016, DOI: 10.1089/dia.2019.0202.
- INZUCCHI S, ZINMAN B, GEORGE J, MATTHEUS M, EYNATTEN M, WANNER C, HAUSKE S. 248-OR: Empagliflozin and Cardiorenal Outcomes in Patients with Nonproteinuric Kidney Disease in the EMPA-REG OUTCOME Trial. Diabetes 2019, 68 DOI: 10.2337/db19-248-or.
- INZUCCHI S, KHUNTI K, FITCHETT D, WANNER C, MATTHEUS M, GEORGE J, PERNILLE OFSTAD A, ZINMAN B. 19-LB: Consistent Cardiovascular (CV) Benefits from Empagliflozin across the Spectrum of CV Risk Factor Control: Post Hoc Analysis from EMPA-REG OUTCOME. Diabetes 2019, 68 DOI: 10.2337/db19-19-lb.
- ZINMAN B, FITCHETT D, MATTHEUS M, WANNER C, GEORGE J, VEDIN O, INZUCCHI S, JOHANSEN O. 159-LB: Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME. Diabetes 2019, 68 DOI: 10.2337/db19-159-lb.
- Inzucchi S, Wanner C, Hehnke U, Lee J, Kaspers S, Clark D, George J, Zinman B. Composite retinopathy outcome in patients treated with empagliflozin versus placebo in the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2019, 14: s53-s53. DOI: 10.1055/s-0039-1688261.
- Sambevski S, Fitchett D, Inzucchi S, Kaspers S, Pfarr E, George J, Zinman B. Empagliflozin reduces mortality and hospitalisation for heart failure in patients with or without a history of myocardial infarction or stroke at baseline. Diabetologie Und Stoffwechsel 2019, 14: s65-s66. DOI: 10.1055/s-0039-1688297.
- Wanner C, Cooper M, Inzucchi S, Zinman B, Zwiener I, Eynatten M, Koitka-Weber A. Empagliflozin Improves Kidney Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol and HbA1c. Diabetologie Und Stoffwechsel 2019, 14: s80-s80. DOI: 10.1055/s-0039-1688342.
- Gunawan F, Partridge C, Kosiborod M, Inzucchi S. SUN-149 Cardiologist vs. Endocrinologist Encounters in Patients with T2D and CVD: Potential Implications for Glucose-Lowering Therapy Use and Education. Journal Of The Endocrine Society 2019, 3: sun-149. PMCID: PMC6553036, DOI: 10.1210/js.2019-sun-149.
- Verma S, Ji Q, Bhatt D, Mazer C, Al-Omran M, Inzucchi S, Wanner C, Ofstad A, Zwiener I, George J, Zinman B, Fitchett D. THE ASSOCIATION BETWEEN URIC ACID LEVELS AND CARDIORENAL OUTCOMES AND DEATH IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME. Journal Of The American College Of Cardiology 2019, 73: 1754. DOI: 10.1016/s0735-1097(19)32360-5.
- Qamar A, Scirica B, Wiviott S, Fanola C, Im K, Inzucchi S, McGuire D, Keech A, Smith S, Murphy S, Perdomo C, Miao W, Patel T, Sabatine M, Bohula E, Group S. INTERINDIVIDUAL VARIABILITY IN WEIGHT LOSS WITH LORCASERIN: AN ANALYSIS FROM THE CAMELLIA-TIMI 61 STUDY. Journal Of The American College Of Cardiology 2019, 73: 1811. DOI: 10.1016/s0735-1097(19)32417-9.
- Fanola C, Bohula E, Weissman N, Wiviott S, Qamar A, Kuder J, Im K, Inzucchi S, McGuire D, Keech A, Smith S, Perdomo C, Miao W, Patel T, Sabatine M, Scirica B. PERSISTENCE OF VALVULOPATHY IN THE CAMELLIA-TIMI 61 TRIAL OF LORCASERIN IN OBESE OR OVERWEIGHT PATIENTS AT INCREASED CARDIOVASCULAR RISK. Journal Of The American College Of Cardiology 2019, 73: 2023. DOI: 10.1016/s0735-1097(19)32629-4.
- Butler J, Savarese G, Sattar N, Januzzi J, Verma S, Lund L, Fitchett D, Zeller C, George J, Brueckmann M, Ofstad A, Inzucchi S, Wanner C, Zinman B. EMPAGLIFLOZIN IS ASSOCIATED WITH A LOWER RISK OF POST-ACUTE HEART FAILURE RE-HOSPITALIZATION AND MORTALITY: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL. Journal Of The American College Of Cardiology 2019, 73: 663. DOI: 10.1016/s0735-1097(19)31271-9.
- Böhm M, Brueckmann M, Fitchett D, George J, Inzucchi S, Marx N, Mattheus M, Ofstad A, Slawik J, Verma S, Wanner C, Zinman B. Heart Failure Outcomes in Patients with Diabetes With and Without Atrial Fibrillation – Data From the EMPA-REG OUTCOME Study. Heart Lung And Circulation 2019, 28: s172. DOI: 10.1016/j.hlc.2019.06.091.
- Verma S, Mazer C, Fitchett D, Inzucchi S, George J, Pfarr E, Woerle H, Zinman B. 124 Empagliflozin Reduces Mortality and Hospitalization for Heart Failure in Patients with Type 2 Diabetes and Peripheral Artery Disease: A Sub-Analysis of the EMPA-REG OUTCOME Trial. Canadian Journal Of Diabetes 2018, 42: s43. DOI: 10.1016/j.jcjd.2018.08.129.
- Fitchett D, Inzucchi S, Sambevski S, Kaspers S, Pfarr E, George J, Zinman B. EMPAGLIFLOZIN REDUCES MORTALITY AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH OR WITHOUT A HISTORY OF MYOCARDIAL INFARCTION OR STROKE AT BASELINE. Canadian Journal Of Cardiology 2018, 34: s80-s81. DOI: 10.1016/j.cjca.2018.07.288.
- Verma S, Mazer C, Fitchett D, Inzucchi S, George J, Pfarr E, Woerle H, Zinman B. EMPAGLIFLOZIN REDUCES MORTALITY AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH TYPE 2 DIABETES AND PERIPHERAL ARTERY DISEASE: A SUB-ANALYSIS OF THE EMPA-REG OUTCOME TRIAL. Canadian Journal Of Cardiology 2018, 34: s81. DOI: 10.1016/j.cjca.2018.07.289.
- McGuire D, Zinman B, Inzucchi S, Anker S, Wanner C, Kaspers S, George J, Elsasser U, Woerle H, Lund S, Fitchett D. P5334Effect of empagliflozin on cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial. European Heart Journal 2018, 39: ehy566.p5334. DOI: 10.1093/eurheartj/ehy566.p5334.
- Fitchett D, Inzucchi S, Cannon C, McGuire D, Johansen O, Sambevski S, Hehnke U, George J, Zinman B. P1879Empagliflozin reduces mortality and hospitalisation for heart failure irrespective of cardiovascular risk score at baseline. European Heart Journal 2018, 39: ehy565.p1879. DOI: 10.1093/eurheartj/ehy565.p1879.
- INZUCCHI S, VISCOLI C, YOUNG L, GORMAN M, CONWIT R, SCHWARTZ G, KERNAN W. What Mediated Pioglitazone's Cardiovascular (CV) Benefit in the IRIS Trial? Diabetes 2018, 67 DOI: 10.2337/db18-17-lb.
- WANNER C, COOPER M, INZUCCHI S, ZINMAN B, HEHNKE U, EYNATTEN M, KOITKA-WEBER A. Empagliflozin Improves Renal Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol, and HbA1c. Diabetes 2018, 67 DOI: 10.2337/db18-524-p.
- RASOULI N, COHEN R, DEFRONZO R, INZUCCHI S, ISMAIL-BEIGI F, KAHN S, UTZSCHNEIDER K, LACHIN J, YOUNES N. Relationship between Baseline Phenotype and Measures of Insulin Sensitivity and Beta-Cell Responses in the GRADE Cohort. Diabetes 2018, 67 DOI: 10.2337/db18-1822-p.
- WONG N, SONG Y, ARNOLD S, SPERLING L, CANNON C, INZUCCHI S, KOSIBOROD M. Composite Cardiovascular Risk Factor Target Achievement and Its Indicators in U.S. Adults with Diabetes—The Diabetes Collaborative Registry. Diabetes 2018, 67 DOI: 10.2337/db18-1487-p.
- FITCHETT D, SCIRICA B, INZUCCHI S, CANNON C, MCGUIRE D, JOHANSEN O, SAMBEVSKI S, HEHNKE U, GEORGE J, ZINMAN B. Empagliflozin (EMPA) Reduces Mortality and Hospitalization for Heart Failure (HHF) Irrespective of Cardiovascular (CV) Risk Score at Baseline. Diabetes 2018, 67 DOI: 10.2337/db18-1123-p.
- Ruggenenti P, Inzucchi S, Zinman B, Hantel S, Koitka-Weber A, von Eynatten M, Wanner C. SP415EMPAGLIFLOZIN AND PROGRESSION OF CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES COMPLICATED BY NEPHROTIC-RANGE PROTEINURIA: INSIGHTS FROM THE EMPA-REG OUTCOME® TRIAL. Nephrology Dialysis Transplantation 2018, 33: i487-i487. DOI: 10.1093/ndt/gfy104.sp415.
- Fitchett D, Lee J, George J, Woerle H, Inzucchi. Empagliflozin reduces heart failure irrespective of control of blood pressure, low density lipoprotein cholesterol and HbA1c. Diabetologie Und Stoffwechsel 2018, 13: s52-s52. DOI: 10.1055/s-0038-1641913.
- Inzucchi, Fitchett D, Wanner C, George J, Woerle H, Zinman B. Reduction in cardiovascular death with empagliflozin is consistent across categories of baseline HbA1c and change in HbA1c: Results from EMPA-REG OUTCOME. Diabetologie Und Stoffwechsel 2018, 13: s51-s51. DOI: 10.1055/s-0038-1641909.
- Fitchett D, Inzucchi S, Sambevski S, Kaspers S, Pfarr E, George J, Zinman B. EMPAGLIFLOZIN REDUCES MORTALITY AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH OR WITHOUT A HISTORY OF MYOCARDIAL INFARCTION OR STROKE AT BASELINE. Journal Of The American College Of Cardiology 2018, 71: a1719. DOI: 10.1016/s0735-1097(18)32260-5.
- Fitchett D, McKnight J, Lee J, George J, Mattheus M, Woerle H, Inzucchi S. P4903Empagliflozin reduces heart failure irrespective of control of blood pressure, low density lipoprotein cholesterol and HbA1c. European Heart Journal 2017, 38: ehx493.p4903. DOI: 10.1093/eurheartj/ehx493.p4903.
- Chilton R, Gullestad L, Fitchett D, Inzucchi S, Mattheus M, Woerle H, Johansen O. 5935Effects of empagliflozin on cardiac and vascular hemodynamic markers by subgroups of age, sex and hypertension in patients with T2DM and high CV risk: EMPA-reg outcome. European Heart Journal 2017, 38: ehx493.5935. DOI: 10.1093/eurheartj/ehx493.5935.
- DeMauro-Jablonski S, Inzucchi S. Management of Diabetes and Hyperglycemia in the Hospital Setting. 2017, 983-998. DOI: 10.1007/978-3-319-18741-9_47.
- Jurišić-Eržen D, Johansen O, George J, Mattheus M, Zinman B, Inzucchi. Effect of empagliflozin when added to insulin in patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2017, 12: s1-s84. DOI: 10.1055/s-0037-1601614.
- Zinman B, Inzucchi, Lachin J, George J, Mattheus M, Woerle H, Fitchett D. Consistent effect of empagliflozin on cardiovascular death in subgroups by type of cardiovascular disease: results from EMPA-REG OUTCOME. Diabetologie Und Stoffwechsel 2017, 12: s1-s84. DOI: 10.1055/s-0037-1601787.
- Inzucchi S, Zinman B, McGinniss J, Schnee J, George J, Fitchett D. CONSISTENT EFFECT OF EMPAGLIFLOZIN ON COMPOSITE OUTCOMES RELATED TO HEART FAILURE: RESULTS FROM EMPA-REG OUTCOME. Journal Of The American College Of Cardiology 2017, 69: 1656. DOI: 10.1016/s0735-1097(17)35045-3.
- Arnold S, Inzucchi S, Tang F, McGuire D, Mehta S, Goyal A, Maddox T, Sperling L, Einhorn D, Wong N, Kosiborod M. USING THE DIABETES COLLABORATIVE REGISTRY (DCR) TO ESTIMATE THE POTENTIAL REAL-WORLD IMPACT OF THE LEADER TRIAL ON IMPROVING CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIABETES AT HIGH CARDIOVASCULAR RISK. Journal Of The American College Of Cardiology 2017, 69: 47. DOI: 10.1016/s0735-1097(17)33436-8.
- Inzucchi S, Matthews D. How to Use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies. 2016, 471-492. DOI: 10.1002/9781118924853.ch33.
- Fitchett D, Inzucchi S, Lachin J, Wanner C, Mattheus M, Johansen O, Woerle H, Broedl U, Zinman B. EFFECT OF EMPAGLIFLOZIN ON MORTALITY AND CAUSES OF DEATH IN PATIENTS WITH TYPE 2 DIABETES AT HIGH CARDIOVASCULAR RISK. Canadian Journal Of Cardiology 2016, 32: s122-s123. DOI: 10.1016/j.cjca.2016.07.182.
- Fitchett D, Zinman B, Lachin J, Mattheus M, George J, Johansen O, Inzucchi S. EFFECTS OF EMPAGLIFLOZIN ON OVERALL HEART FAILURE BURDEN IN EMPA-REG OUTCOME. Canadian Journal Of Cardiology 2016, 32: s175-s176. DOI: 10.1016/j.cjca.2016.07.272.
- Fitchett D, Zinman B, Lachin J, Mattheus M, George J, Johansen O, Inzucchi S. EFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR MORTALITY BY PREVALENT OR INCIDENT HEART FAILURE IN THE EMPA-REG OUTCOME TRIAL. Canadian Journal Of Cardiology 2016, 32: s90-s91. DOI: 10.1016/j.cjca.2016.07.124.
- Fitchett D, Inzucchi S, Lachin J, Wanner C, Mattheus M, Johansen O, Woerle H, Broedl U, Zinman B. 10 Effect of Empagliflozin on Mortality and Causes of Death in Patients with Type 2 Diabetes at High Cardiovascular Risk. Canadian Journal Of Diabetes 2016, 40: s4-s5. DOI: 10.1016/j.jcjd.2016.08.013.
- Lee D, Monteiro P, Clark D, Hantel S, Woerle H, Inzucchi S, Fitchett D. LBPS 02-52 EFFECT OF EMPAGLIFLOZIN ON HEART FAILURE OUTCOMES IN SUBGROUPS BY AGE. Journal Of Hypertension 2016, 34: e520. DOI: 10.1097/01.hjh.0000501423.64635.bd.
- Fitchett D, Inzucchi S, Lachin J, Wanner C, Mattheus M, Johansen O, Woerle H, Broedl U, Zinman B. EFFECT OF EMPAGLIFLOZIN ON MORTALITY AND CAUSES OF DEATH IN PATIENTS WITH TYPE 2 DIABETES AT HIGH CARDIOVASCULAR RISK. Journal Of The American College Of Cardiology 2016, 67: 1869. DOI: 10.1016/s0735-1097(16)31870-8.
- Moghissi E, Inzucchi S. 1: The Evolution of Glycemic Control in the Hospital Setting. 2016, 1-10. DOI: 10.2337/9781580406086.01.
- Peter P, Inzucchi S. 25: Continuous Glucose Monitoring in the Hospital. 2016, 323-335. DOI: 10.2337/9781580406086.25.
- Shuman J, Inzucchi S. Revisiting the Role of Intensive Glucose Control on Cardiovascular Outcomes. MD Conference Express 2015, 15: 4-7. DOI: 10.1177/1559897715581830.
- DeMauro-Jablonski S, Inzucchi S. Management of Diabetes and Hyperglycemia in the Hospital Setting. 2015, 1-16. DOI: 10.1007/978-3-319-20797-1_47-1.
- Lleva RR, Thomas P, Bozzo JE, Hendrickson KC, Inzucchi SE. Using the Glucometrics Website to Benchmark ICU Glucose Control Before and After the NICE-SUGAR Study. Journal Of Diabetes Science And Technology 2014, 8: 918-922. PMID: 25013157, PMCID: PMC4455376, DOI: 10.1177/1932296814540871.
- Lee G, Inzucchi S, Holt E. Endocrine Perturbations in Critical Illness. 2014, 247-272. DOI: 10.1007/978-1-4939-1121-9_14.
- Hoang QN, Pisani MA, Inzucchi S, Hu B, Honiden S. The prevalence of undiagnosed diabetes mellitus and the association of baseline glycemic control on mortality in the intensive care unit: A prospective observational study. Journal Of Critical Care 2014, 29: 1052-1056. PMID: 25092614, DOI: 10.1016/j.jcrc.2014.06.007.
- Zinman B, Inzucchi S, Lachin J, Wanner C, Ferrari R, Fitchett D, Bluhmki E, Kempthorne-Rawson J, Newman J, Johansen O, Woerle H, Broedl U. Baseline characteristics of participants enrolled in the empagliflozin cardiovascular outcome trial (EMPA-REG OUTCOME™) in patients with type 2 diabetes. Diabetologie Und Stoffwechsel 2014, 9 DOI: 10.1055/s-0034-1374995.
- Inzucchi S. Personalizing Diabetes Management. 2014, 59-64. DOI: 10.1210/mtp3.9781936704835.ch13.
- Lupsa B, Inzucchi S. Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic Syndrome. Contemporary Endocrinology 2013, 15-31. DOI: 10.1007/978-1-62703-697-9_2.
- Zinman B, Inzucchi S, Lachin J, Wanner C, Ferrari R, Bluhmki E, Hantel S, Johansen O, Woerle H, Broedl U. Design of the Empagliflozin Cardiovascular (CV) Outcome Event Trial in Type 2 Diabetes (T2D). Canadian Journal Of Diabetes 2013, 37: s29-s30. DOI: 10.1016/j.jcjd.2013.08.088.
- Inzucchi, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M, Peters A, Tsapas A, Wender R, Matthews. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379. Diabetes Care 2013, 36: 490-490. PMCID: PMC3554319, DOI: 10.2337/dc13-er02.
- Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M, Peters A, Tsapas A, Wender R, Matthews D. Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 56: 680-680. DOI: 10.1007/s00125-012-2785-9.
- Matthews D, Inzucchi S. Response to Comments on: Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379. Diabetes Care 2012, 35: e72-e73. PMCID: PMC3447838, DOI: 10.2337/dc12-1184.
- Matthews D, Inzucchi S, for the Position Statement Writing Group. ADA/EASD position statement of the treatment of type 2 diabetes: Reply to Rodbard HW and Jellinger PS [letter], Scheen AJ [letter] and Ceriello A, Gallo M, Gentile S et al [letter]. Diabetologia 2012, 55: 2856-2857. PMID: 22854891, DOI: 10.1007/s00125-012-2669-z.
- Buckley R, Inzucchi S. New ADA/EASD Position Statement Endorses a Patient-Centered Approach. MD Conference Express 2012, 12: 35-36. DOI: 10.1177/155989771210019.
- Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M, Peters A, Tsapas A, Wender R, Matthews D. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Spectrum 2012, 25: 154-171. DOI: 10.2337/diaspect.25.3.154.
- Inzucchi S, Rosenstock J, Umpierrez G. Diabetic Neuropathy. The Journal Of Clinical Endocrinology & Metabolism 2012, 97: 35a-35a. PMID: 22563114, DOI: 10.1210/jcem.97.5.zeg35a.
- Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M, Peters A, Tsapas A, Wender R, Matthews D. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 55: 1577-1596. PMID: 22526604, DOI: 10.1007/s00125-012-2534-0.
- Hage F, Wackers F, Bansal S, Chyun D, Young L, Inzucchi S, Iskandrian A. THE HEART RATE RESPONSE TO ADENOSINE AS A PREDICTOR OF ADVERSE CARDIAC OUTCOMES IN THE DETECTION OF ISCHEMIA IN ASYMPTOMATIC DIABETICS STUDY. Journal Of The American College Of Cardiology 2012, 59: e1162. DOI: 10.1016/s0735-1097(12)61163-2.
- Inzucchi S, Sherwin R. 237 Type 2 Diabetes Mellitus. 2012, 1489-1499. DOI: 10.1016/b978-1-4377-1604-7.00237-2.
- Inzucchi S, Sherwin R. 237 Type 2 Diabetes Mellitus. 2012, e95-e108. DOI: 10.1016/b978-1-4377-1604-7.00562-5.
- Inzucchi S, Sherwin R. 236 Type 1 Diabetes Mellitus. 2012, e78-e94. DOI: 10.1016/b978-1-4377-1604-7.00561-3.
- Inzucchi S, Sherwin R. 236 Type 1 Diabetes Mellitus. 2012, 1475-1489. DOI: 10.1016/b978-1-4377-1604-7.00236-0.
- Tandon S, Bansal S, Inzucchi S, Staib L, Davey J, Chyun D, Young L, Wackers F. SCREENING ASYMPTOMATIC PATIENTS WITH TYPE 2 DIABETES FOR SILENT MYOCARDIAL ISCHEMIA: IMPORTANT GENDER DIFFERENCES FROM THE DETECTION OF ISCHEMIA IN ASYMPTOMATIC DIABETICS (DIAD) STUDY. Journal Of The American College Of Cardiology 2011, 57: e745. DOI: 10.1016/s0735-1097(11)60745-6.
- Gore M, Inzucchi S, McGuire D. CHAPTER 21 Diabetes and Cardiovascular Disease. 2011, 345-370. DOI: 10.1016/b978-1-4377-1366-4.00021-4.
- Vinall M, Inzucchi S. Glucose Lowering: New Options. MD Conference Express 2010, 10: 35-35. DOI: 10.1177/155989771010023.
- Inzucchi S, Rosenstock J, Umpiérrez G. Control continuo de la glucosa. The Journal Of Clinical Endocrinology & Metabolism 2010, 95: e2-e2. DOI: 10.1210/jcem.95.10.9999.
- Inzucchi S, Rosenstock J, Umpierrez G. Continuous Glucose Monitoring. The Journal Of Clinical Endocrinology & Metabolism 2010, 95: e1-e1. DOI: 10.1210/jcem.95.10.9998.
- Association A, Association A, Foundation A, Pignone M, Alberts M, Colwell J, Cushman M, Inzucchi S, Mukherjee D, Rosenson R, Williams C, Wilson P, Kirkman M. Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes. Journal Of The American College Of Cardiology 2010, 55: 2878-2886. PMID: 20579547, DOI: 10.1016/j.jacc.2010.04.003.
- Inzucchi S, Kitabchi A, Rosenstock J. Diabetes monogénica. The Journal Of Clinical Endocrinology & Metabolism 2010, 95: e2-e2. DOI: 10.1210/jcem.95.5.9999.
- Inzucchi S, Kitabchi A, Rosenstock J. Monogenic Diabetes. The Journal Of Clinical Endocrinology & Metabolism 2010, 95: e1-e1. DOI: 10.1210/jcem.95.5.9998.
- Stolker J, Spertus J, McGuire D, Inzucchi S, Rathore S, Maddox T, Masoudi F, Tang F, Jones P, Kosiborod M. IN-HOSPITAL HEMOGLOBIN A1C TESTING AND ITS RELATION TO INITIATION OF GLUCOSE LOWERING THERAPY IN HYPERGLYCEMIC PATIENTS WITH ACUTE MYOCARDIAL INFARCTION. Journal Of The American College Of Cardiology 2010, 55: a143.e1340. DOI: 10.1016/s0735-1097(10)61341-1.
- VENKITACHALAM L, Riley K, Lipska K, Inzucchi S, Goyal A, Spertus J, Masoudi F, Jones P, Kosiborod M. TEMPORAL TRENDS IN THE MANAGEMENT OF SEVERE HYPERGLYCEMIA AMONG PATIENTS HOSPITALIZED WITH ACUTE MYOCARDIAL INFARCTION. Journal Of The American College Of Cardiology 2010, 55: a143.e1339. DOI: 10.1016/s0735-1097(10)61340-x.
- Bansal S, Wackers F, Inzucchi S, Young L, Chyun D. CARDIAC OUTCOMES AFTER SCREENING FOR ASYMPTOMATIC CORONARY ARTERY DISEASE IN PATIENTS WITH METABOLIC SYNDROME: POST-HOC ANALYSIS OF THE DIAD TRIAL. Journal Of The American College Of Cardiology 2010, 55: a141.e1325. DOI: 10.1016/s0735-1097(10)61326-5.
- DeMauro-Jablonski S, Inzucchi S. Management of Diabetes and Hyperglycemia in the Hospital Setting. 2009, 773-786. DOI: 10.1007/978-0-387-09841-8_47.
- Inzucchi S, Leiter L, Rosenstock J. Type 2 Diabetes and TZDs (Thiazolidinediones) Fritz 9.24.09. The Journal Of Clinical Endocrinology & Metabolism 2009, 94: e2-e2. DOI: 10.1210/jcem.94.11.9988.
- Inzucchi S, Leiter L, Rosenstock J. Diabetes de Tipo 2 y las TZD (Tiazolidinedionas) Fritz 9.24.09. The Journal Of Clinical Endocrinology & Metabolism 2009, 94: e1-e1. DOI: 10.1210/jcem.94.11.9987.
- Kosiborod M, Inzucchi S, Krumholz H, Masoudi F, Goyal A, Spertus J. Is Insulin the Preferred Compound in Lowering Glucose Levels in Patients After a Myocardial Infarction?—Reply. JAMA Internal Medicine 2009, 169: 1633-1638. DOI: 10.1001/archinternmed.2009.327.
- Lipska K, Inzucchi, Kosiborod M, Krumholz H. Intensive glucose control and cardiovascular outcomes. The Lancet 2009, 374: 522-523. PMID: 19683633, DOI: 10.1016/s0140-6736(09)61479-3.
- Alba M, Ahren B, Inzucchi S, Guan Y, Mallick M, Xu L, O'Neill E, Williams-Herman D, Kaufman K, Goldstein B. Initial combination therapy with sitagliptin and pioglitazone: complementary effects on postprandial glucose and islet cell function. Canadian Journal Of Diabetes 2009, 33: 319-320. DOI: 10.1016/s1499-2671(09)33335-3.
- Rosenstock J, Inzucchi S, Seufert J, Fleck P, Wilson C, Mekki Q. Combination alogliptin plus pioglitazone treatment in patients with type 2 diabetes inadequately controlled with diet exercise. Canadian Journal Of Diabetes 2009, 33: 212. DOI: 10.1016/s1499-2671(09)33076-2.
- Lipska K, Inzucchi S. Cardiovascular risk-benefit ratio of thiazolidinediones. Current Cardiovascular Risk Reports 2008, 3: 42-50. DOI: 10.1007/s12170-009-0008-9.
- Thomas P, Inzucchi S. An Internet Service Supporting Quality Assessment of Inpatient Glycemic Control. Journal Of Diabetes Science And Technology 2008, 2: 402-408. PMID: 19885204, PMCID: PMC2769729, DOI: 10.1177/193229680800200309.
- Hirsch I, Inzucchi S, Kirkman M. Standards of Medical Care in Diabetes—2008 Response to Dora, Kramer, and Canani. Diabetes Care 2008, 31: e45-e45. DOI: 10.2337/dc08-0285.
- Inzucchi S, Rolla A, Umpierrez G. Diabetes and New Insulins. The Journal Of Clinical Endocrinology & Metabolism 2007, 92: e2-e2. DOI: 10.1210/jcem.92.3.9996.
- Inzucchi S, Rolla A, Umpierrez G. La diabetes y las nuevas insulinas. The Journal Of Clinical Endocrinology & Metabolism 2007, 92: e1-e1. DOI: 10.1210/jcem.92.3.9995.
- Holt E, Inzucchi S. Physiology and Pathophysiology of the Parathyroid Glands and Preoperative Evaluation. 2007, 235-243. DOI: 10.1007/978-3-540-68043-7_19.
- Inzucchi S. Chapter 26 Type 2 Diabetes Therapy: Choosing Oral Agents. 2006, 332-342. DOI: 10.1016/b978-1-4160-0273-4.50031-x.
- Bax J, Bonow R, Tschöepe D, Inzucchi S, Barrett E. Early detection of coronary heart disease in diabetic patients without symptoms of coronary artery disease: implications for expanded use of myocardial perfusion imaging. British Journal Of Diabetes 2005, 5: 283-288. DOI: 10.1177/14746514050050050801.
- Goldberg P, Roussel M, Inzucchi S. Clinical Results of an Updated Insulin Infusion Protocol in Critically Ill Patients. Diabetes Spectrum 2005, 18: 188-191. DOI: 10.2337/diaspect.18.3.188.
- Masoudi F, Inzucchi S, Wang Y. Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study. ACC Current Journal Review 2005, 14: 22. DOI: 10.1016/j.accreview.2005.05.051.
- Kimmel B, Inzucchi S. Oral Agents for Type 2 Diabetes: An Update. Clinical Diabetes 2005, 23: 64-76. DOI: 10.2337/diaclin.23.2.64.
- Goldberg P, Inzucchi S. Selling Root Canals: Lessons Learned From Implementing a Hospital Insulin Infusion Protocol. Diabetes Spectrum 2005, 18: 28-33. DOI: 10.2337/diaspect.18.1.28.
- Wackers F, Young L, Inzucchi S, Chyun D. Detection of Silent Myocardial Ischemia in Asymptomatic Diabetic Subjects. Diabetes Care 2005, 28: 232-233. DOI: 10.2337/diacare.28.1.232.
- Inzucchi S, Kinder B. Chapter 87 Endocrine Emergencies: Hypoglycemic and Hyperglycemic Crises. 2005, 789-799. DOI: 10.1016/b978-0-7216-0139-7.50091-0.
- Inzucchi S, Young L, Chyun D, Wackers F. Screening for coronary artery disease in diabetic patients: The DIAD study. British Journal Of Diabetes 2004, 4: 317-319. DOI: 10.1177/14746514040040050501.
- Sudhakar S, Chyun D, Young L, Inzucchi S, Davey J, Wackers F. Abnormal heart rate response to adenosine infusion is associated with silent myocardial ischemia in asymptomatic patients with diabetes mellitus. Journal Of Nuclear Cardiology 2004, 11: s20. DOI: 10.1016/j.nuclcard.2004.06.064.
- Kosiborod M, Rathore S, Wang Y, Inzucchi S, Masoudi F, Havranek E, Foody J, Krumholz H. 885-6 Prognostic implications of admission hyperglycemia in elderly patients with acute myocardial infarction. Journal Of The American College Of Cardiology 2004, 43: a241. DOI: 10.1016/s0735-1097(04)91025-x.
- Kernan W, Inzucchi S, Viscoli C. Insulin and Membrane Microviscosity of Erythrocytes as Risk Factors for Stroke. Stroke 2003, 34: e225-e226. PMID: 14631086, DOI: 10.1161/01.str.0000103353.56177.97.
- Masoudi F, Wang Y, Inzucchi S. Metformin and thiazolidinedione use in medicare patients with heart failure. ACC Current Journal Review 2003, 12: 47. DOI: 10.1016/j.accreview.2003.08.074.
- Inzucchi S, Sherwin R. Applying the Lessons of the DPP to Clinical Practice. Clinical Diabetes 2003, 21: 91-92. DOI: 10.2337/diaclin.21.2.91.
- Wackers F, Young L, Inzucchi S, Chyun D, Davey J. Detection of ischemia in asymptomatic diabetics: Preliminary results of the DIAD study. Journal Of The American College Of Cardiology 2003, 41: 409. DOI: 10.1016/s0735-1097(03)81197-x.
- Inzucchi S. Noninvasive Assessment of the Diabetic Patient for Coronary Artery Disease. Diabetes Care 2001, 24: 1519-1521. PMID: 11522692, DOI: 10.2337/diacare.24.9.1519.
- Novella S, Inzucchi S, Goldstein J. The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. Muscle & Nerve 2001, 24: 1229-1231. PMID: 11494278, DOI: 10.1002/mus.1137.
- Nakchbandi I, Inzucchi S, Wirth J. Primary Pulmonary Hypertension and Thyroid Disease. Chest 2000, 118: 1224-1225. DOI: 10.1016/s0012-3692(15)37735-7.
- Nakchbandi I, Wirth J, Inzucchi S. Pulmonary Hypertension Caused by Graves’ Thyrotoxicosis Normal Pulmonary Hemodynamics Restored by 131I Treatment. Chest 1999, 116: 1483-1485. PMID: 10559121, DOI: 10.1378/chest.116.5.1483.
- Cline G, Petersen K, Krssak M, Shen J, Hundal R, Trajanoski Z, Inzucchi S, Dresner A, Rothman D, Shulman G. Impaired Glucose Transport as a Cause of Decreased Insulin-Stimulated Muscle Glycogen Synthesis in Type 2 Diabetes. The New England Journal Of Medicine 1999, 341: 240-246. PMID: 10413736, DOI: 10.1056/nejm199907223410404.
- Schwartz S, Raskin P, Fonseca V, Inzucchi S, Maggs D, Spollett G, Imura H. Troglitazone Improves Diabetic Control. The Nurse Practitioner 1998, 23: 96. DOI: 10.1097/00006205-199807000-00010.
- Inzucchi S, Maggs D, Spollett G, Page S, Rife F, Walton V, Shulman G. Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus. The New England Journal Of Medicine 1998, 338: 867-873. PMID: 9516221, DOI: 10.1056/nejm199803263381303.
- Inzucchi S. Growth Hormone in Adults: Indications and Implications. Hospital Practice 1997, 32: 79-96. PMID: 9006584, DOI: 10.1080/21548331.1997.11443405.
- Inzucchi S, Burrow G. Hyperthyroidism in pregnancy. Current Therapy In Endocrinology And Metabolism 1997, 6: 312-7. PMID: 9174760.
- Inzucchi S, Comite F, Burrow G. Graves’ Disease And Pregnancy. Endocrine Practice 1995, 1: 186-192. PMID: 15251592, DOI: 10.4158/ep.1.3.186.
- Inzucchi S. Clinical review 61: Effects of growth hormone on human bone biology. The Journal Of Clinical Endocrinology & Metabolism 1994, 79: 691-694. DOI: 10.1210/jc.79.3.691.
- Inzucchi S. Endocrinology clinical case seminars: a 23-year-old man with hypercalcemia, anemia, and weight loss. The Journal Of Clinical Endocrinology & Metabolism 1994, 79: 340-347. DOI: 10.1210/jc.79.2.340.
Locations
1
Yale Endocrinology
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste 4th Floor Multispecialty Care Center
New Haven, CT 06511
1 of 4
- Yale EndocrinologySmilow Cancer Hospital at Yale New Haven35 Park Street, Ste 4th Floor Multispecialty Care CenterNew Haven, CT 06511
- Yale Endocrinology & MetabolismYale New Haven Hospital20 York StreetNew Haven, CT 06510
- Yale Diabetes CenterDana Clinic Building789 Howard Avenue, Ste 2nd FloorNew Haven, CT 06519
- Yale Endocrinology & MetabolismYale Health Center55 Lock StreetNew Haven, CT 06511
Biography
Silvio E. Inzucchi, MD, director of the Yale Medicine Diabetes Center, treats patients who suffer from diabetes as well as pituitary and adrenal disorders. “Endocrinology is fascinating, and we are usually able to help patients improve their quality of life through multidisciplinary care and academic approaches to endocrine conditions,” he says.
Dr. Inzucchi is a professor or medicine (endocrinology) at Yale School of Medicine and the clinical director of the section of endocrinology. In his research, Dr. Inzucchi, studies the cardiovascular effects of diabetes medications and glucose management in the hospital. Named a “top doctor” locally and nationally, Dr. Inzucchi has also received Yale’s David J. Leffell Prize for Clinical Excellence. The prize is given to individuals who demonstrate the highest level of clinical expertise, commitment to teaching and compassion for patients.
He says he has developed an effective personal approach to treating patients, carefully honed over 30 years at Yale. It includes being on top of the latest advances, but also responding to each patient’s individual needs. “I like to try to draw people out in terms of who they are, what’s important to them, their life experiences and their family. Such an approach resonates with patients because they don’t want to be seen as a patient, they want to be treated as a person,” he says.
Titles
- Professor of Medicine (Endocrinology)
Education & Training
- MDHarvard University (1985)
- BSFordham University (1981)
Languages Spoken
- English
- Italiano (Italian)
Additional Information
Board Certifications
- AB of Internal Medicine, Endocrinology Diabetes & Metabolism (1995, recertified: 2017)
- AB of Internal Medicine, Internal Medicine (1988)
Publications
- Magvanjav O, MacLeod RS, Balasubramanian P, Mekala K, Peter PR, Inzucchi SE, Majumdar SK. Iodine for the Outpatient Management of Graves' Disease: A Case Series of 7 Patients. AACE Endocrinol Diabetes 2025, 13: 83-87. PMID: 41641309, DOI: 10.1016/j.aed.2025.10.015.
- Pop-Busui R, Rosin S, Butera N, Krause-Steinrauf H, Abou Assi H, Garg R, Inzucchi S, Katona A, McGill J, Mudaliar S, Schade D, Seaquist E, Tiktin M, Soliman E, Green J, Crandall J, McKee M, Behringer-Massera S, Brown-Friday J, Xhori E, Ballentine-Cargill K, Duran S, Estrella H, Gonzalez de la torre S, Lukin J, Phillips L, Burgess E, Olson D, Rhee M, Wilson P, Raines T, Boers J, Costello J, Maher-Albertelli M, Mungara R, Savoye L, White C, Gullett C, Holloway L, Morehead F, Person S, Sibymon M, Tanukonda S, Adams C, Ross A, Balasubramanyam A, Gaba R, Gonzalez Hattery E, Ideozu A, Jimenez J, Montes G, Wright C, Hollander P, Roe E, Jackson A, Smiley A, Burt P, Estrada L, Chionh K, Ismail-Beigi F, Falck-Ytter C, Sayyed Kassem L, Sood A, Tiktin M, Kulow T, Newman C, Stancil K, Cramer B, Iacoboni J, Kononets M, Sanders C, Tucker L, Werner A, Maxwell A, McPhee G, Patel C, Colosimo L, Krol A, Goland R, Pring J, Alfano L, Kringas P, Hausheer C, Tejada J, Gumpel K, Kirpitch A, Schneier H, Green J, AbouAssi H, Chatterjee R, Feinglos M, English Jones J, Khan S, Kimpel J, Zimmer R, Furst M, Satterwhite B, Thacker C, Evans Kreider K, Mariash C, Mather K, Ismail H, Lteif A, Mullen M, Hamilton T, Patel N, Riera G, Jackson M, Pirics V, Aguillar D, Howard D, Hurt S, Bergenstal R, Carlson A, Martens T, Johnson M, Hill R, Hyatt J, Jensen C, Madden M, Martin D, Willis H, Konerza W, Yang S, Kleeberger K, Passi R, Fortmann S, Herson M, Mularski K, Glauber H, Prihoda J, Ash B, Carlson C, Ramey P, Schield E, Torgrimson-Ojerio B, Arnold K, Kauffman B, Panos E, Sahnow S, Bays K, Berame K, Cook J, Ghioni D, Gluth J, Schell K, Criscola J, Friason C, Jones S, Nazarov S, Barzilay J, Rassouli N, Puttnam R, Ojoawo B, Nelson R, Curtis M, Hollis B, Sanders-Jones C, Stokes K, El-Haqq Z, Kolli A, Tran T, Wexler D, Larkin M, Meigs J, Chambers B, Dushkin A, Rocchio G, Yepes M, Steiner B, Dulin H, Cayford M, Chu K, DeManbey A, Hillard M, Martin K, Thangthaeng N, Gurry L, Kochis R, Raymond E, Ripley V, Stevens C, Park J, Aroda V, Ghazi A, Magee M, Ressing A, Loveland A, Hamm M, Hurtado M, Kuhn A, Leger J, Manandhar L, Mwicigi F, Sanchez O, Young T, Garg R, Lagari-Libhaber V, Florez H, Valencia W, Marks J, Casula S, Oropesa-Gonzalez L, Hue L, Cuadot A, Nieto-Martinez R, Riccio Veliz A, Gutt M, Kendal Y, Veciana B, Ahmann A, Aby-Daniel D, Joarder F, Morimoto V, Sprague C, Yamashita D, Cady N, Rivera-Eschright N, Kirchhoff P, Morales Gomez B, Adducci J, Goncharova A, Hox S, Petrovitch H, Matwichyna M, Jenkins V, Broadwater L, Ishii R, Bermudez N, Hsia D, Cefalu W, Greenway F, Waguespack C, King E, Fry G, Dragg A, Gildersleeve B, Arceneaux J, Haynes N, Thomassie A, Pavlionis M, Bourgeois B, Hazlett C, Mudaliar S, Henry R, Boeder S, Pettus J, Diaz E, Garcia-Acosta D, Maggs S, DeLue C, Stallings A, Castro E, Hernandez S, Krakoff J, Curtis J, Killean T, Khalid M, Joshevama E, Diaz E, Martin D, Tsingine K, Karshner T, Albu J, Pi-Sunyer F, Frances S, Maggio C, Ellis E, Bastawrose J, Gong X, Banerji M, August P, Lee M, Lorber D, Brown N, Josephson D, Thomas L, Tsovian M, Cherian A, Jacobson M, Mishko M, Kirkman M, Buse J, Diner J, Dostou J, Machineni S, Young L, Bergamo K, Goley A, Kerr J, Largay J, Guarda S, Cuffee J, Culmer D, Fraser R, Almeida H, Coffer S, Debnam E, Kiker L, Morton S, Josey K, Fuller G, Garvey W, Cherrington A, Dyer D, Lawson M, Griffith O, Agne A, McCullars S, Cohen R, Craig J, Rogge M, Burton K, Kersey K, Wilson C, Lipp S, Vonder Meulen M, Adkins C, Onadeko T, Rasouli N, Baker C, Schroeder E, Razzaghi M, Lyon C, Penaloza R, Underkofler C, Lorch R, Douglass S, Steiner S, Sivitz W, Cline E, Knosp L, McConnell J, Lowe T, Herman W, Pop-Busui R, Tan M, Martin C, Waltje A, Katona A, Goodhall L, Eggleston R, Kuo S, Bojescu S, Bule S, Kessler N, LaSalle E, Whitley K, Seaquist E, Bantle A, Harindhanavudhi T, Kumar A, Redmon B, Bantle J, Coe M, Mech M, Taddese A, Lesne L, Smith S, Desouza C, Kuechenmeister L, Shivaswamy V, Burbach S, Rodriguez M, Seipel K, Alfred A, Morales A, Eggert J, Lord G, Taylor W, Tillson R, Schade D, Adolphe A, Burge M, Duran-Valdez E, Martinez J, Bancroft A, Kunkel S, Ali Jamaleddin Ahmad F, Hernandez McGinnis D, Pucchetti B, Scripsick E, Zamorano A, DeFronzo R, Cersosimo E, Abdul-Ghani M, Triplitt C, Juarez D, Garza R, Verastiqui H, Wright K, Puckett C, Raskin P, Rhee C, Abraham S, Jordan L, Sao S, Morton L, Smith O, Osornio Walker L, Schnurr-Breen L, Ayala R, Kreymer R, Sturgess D, Utzschneider K, Kahn S, Alarcon-Casas Wright L, Boyko E, Tsai E, Trence D, Trikudanathan S, Fattaleh B, Montgomery B, Atkinson K, Kozedub A, Concepcion T, Moak C, Prikhodko N, Rhothisen S, Elasy T, Martin S, Shackelford L, Goidel R, Hinkle N, Lovell C, Myers J, Lipps Hogan J, McGill J, Salam M, Schweiger T, Kissel S, Recklein C, Clifton M, Tamborlane W, Camp A, Gulanski B, Inzucchi S, Pham K, Alguard M, Gatcomb P, Lessard K, Perez M, Iannone L, Magenheimer E, Montosa A, Cefalu W, Fradkin J, Burch H, Bremer A, Nathan D, Lachin J, Kahn S, Krause-Steinrauf H, Larkin M, Tiktin M, Wexler D, Burch H, Younes N, Bebu I, Butera N, Buys C, Fagan A, Gao Y, Ghosh A, Gramzinski M, Hall S, Kazemi E, Legowski E, Liu H, Suratt C, Tripputi M, Arey A, Backman M, Bethepu J, Lund C, Mangat Dhaliwal P, McGee P, Mesimer E, Ngo L, Steffes M, Seegmiller J, Saenger A, Arends V, Gabrielson D, Conner T, Warren S, Day J, Huminik J, Scrymgeour A, Soliman E, Pokharel Y, Zhang Z, Campbell C, Hu J, Keasler L, Hensley S, Li Y, Herman W, Kuo S, Martin C, Waltje A, Mihalcea R, Min D, Perez-Rosas V, Prosser L, Resnicow K, Ye W, Shao H, Zhang P, Luchsinger J, Sanchez D, Assuras S, Groessl E, Sakha F, Chong H, Hillery N. Differences in Prevalence and Incidence of Electrocardiogram Abnormalities and Cardiovascular Autonomic Neuropathy Among Randomized Glucose-Lowering Treatments in Early Type 2 Diabetes: The Glycemia Reduction Approaches in Diabetes (GRADE) Cohort. Diabetes Care 2025, 48: 1960-1970. PMID: 40986645, PMCID: PMC12583396, DOI: 10.2337/dc25-1087.
- Berg D, Patel S, Haller P, Cange A, Palazzolo M, Bellavia A, Kuder J, Desai A, Inzucchi S, McMurray J, O’Meara E, Verma S, Bělohlávek J, Drożdż J, Merkely B, Ogunniyi M, Drasnar T, Izzo J, Sarman B, McGinty J, Ramanathan K, Mulkay A, Przybylski A, Ruff C, O’Donoghue M, Murphy S, Sabatine M, Wiviott S, Committees and Investigators O. Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure. Circulation 2025, 152: 1411-1422. PMID: 40884036, DOI: 10.1161/circulationaha.125.076575.
- Lee M, Sattar N, Pop-Busui R, Deanfield J, Emerson S, Inzucchi S, Mann J, Marx N, Mulvagh S, Poulter N, Badve S, Pratley R, Perkovic V, Buse J, McGuire D. Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials. Diabetes Care 2025, 48: 846-859. PMID: 40156846, DOI: 10.2337/dc25-0241.
- Marx N, Deanfield J, Mann J, Arechavaleta R, Bain S, Bajaj H, Tanggaard K, Birkenfeld A, Buse J, Davicevic-Elez Z, Desouza C, Emerson S, Engelmann M, Hovingh G, Inzucchi S, Jhund P, Mulvagh S, Pop-Busui R, Poulter N, Rasmussen S, Tu S, McGuire D, Group O. Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial. Circulation 2025, 151: 1639-1650. PMID: 40156843, PMCID: PMC12144549, DOI: 10.1161/circulationaha.125.074545.
- Butt J, De Boer R, Hernandez A, Inzucchi S, Kosiborod M, Koeber L, Lam C, Martinez F, Ponikowski P, Sabatine M, Shah S, Vaduganathan M, Jhund P, Solomon S, Mcmurray J. Effects of dapagliflozin in heart failure according to duration of type 2 diabetes: a patient-level meta-analysis of DAPA-HF and DELIVER. European Heart Journal 2024, 45: ehae666.1097. DOI: 10.1093/eurheartj/ehae666.1097.
- Selvaraj S, Patel S, Sauer A, McGarrah R, Jones P, Kwee L, Windsor S, Ilkayeva O, Muehlbauer M, Newgard C, Borlaug B, Kitzman D, Shah S, Margulies K, Husain M, Inzucchi S, McGuire D, Lanfear D, Javaheri A, Umpierrez G, Mentz R, Sharma K, Kosiborod M, Shah S. Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction. Circulation Heart Failure 2024, 17: e011980. PMID: 39421941, PMCID: PMC11634023, DOI: 10.1161/circheartfailure.124.011980.
- Pabon M, Vaduganathan M, Claggett B, Chatur S, Siqueira S, Marti‐Castellote P, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Desai A, Jhund P, McMurray J, Solomon S, Vardeny O. In‐hospital course of patients with heart failure with improved ejection fraction in the DELIVER trial. European Journal Of Heart Failure 2024, 26: 2532-2540. PMID: 39300780, PMCID: PMC11683867, DOI: 10.1002/ejhf.3410.
- Butt J, Shen L, Inzucchi S, Docherty K, Jhund P, Martinez F, Sabatine M, Vaduganathan M, Solomon S, McMurray J, Committees and Investigators D. Dapagliflozin in Heart Failure, Type 2 Diabetes, and Neuropathy A Meta-Analysis of DAPA-HF and DELIVER. JACC Heart Failure 2024, 12: 1946-1948. PMID: 39269393, DOI: 10.1016/j.jchf.2024.07.017.
- Abdin A, Kondo T, Böhm M, Jhund P, Claggett B, Vaduganathan M, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Desai A, Køber L, Sabatine M, Petersson M, Bachus E, Solomon S, McMurray J, Committees and Investigators O. Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA‐HF and DELIVER. European Journal Of Heart Failure 2024, 26: 1952-1963. PMID: 39016033, DOI: 10.1002/ejhf.3350.
- Lassen M, Ostrominski J, Inzucchi S, Claggett B, Kulac I, Jhund P, de Boer R, Hernandez A, Kosiborod M, Lam C, Martinez F, Shah S, Desai A, Petersson M, Langkilde A, Docherty K, McMurray J, Solomon S, Vaduganathan M. Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose‐lowering therapy: A pre‐specified analysis of the DELIVER trial. European Journal Of Heart Failure 2024, 26: 1539-1548. PMID: 38745498, DOI: 10.1002/ejhf.3269.
- Yang M, Kondo T, Talebi A, Jhund P, Docherty K, Claggett B, Vaduganathan M, Bachus E, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Solomon S, McMurray J. Dapagliflozin and quality of life measured using the EuroQol 5‐dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction. European Journal Of Heart Failure 2024, 26: 1524-1538. PMID: 38700986, DOI: 10.1002/ejhf.3263.
- McDowell K, Kondo T, Talebi A, Teh K, Bachus E, de Boer R, Campbell R, Claggett B, Desai A, Docherty K, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Simpson J, Vaduganathan M, Jhund P, Solomon S, McMurray J. Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction. JAMA Cardiology 2024, 9: 457-465. PMID: 38536153, PMCID: PMC10974691, DOI: 10.1001/jamacardio.2024.0284.
- Rivier C, Acosta J, Leasure A, Forman R, Sharma R, de Havenon A, Spatz E, Inzucchi S, Kernan W, Falcone G, Sheth K. Secondary Prevention in Patients With Stroke Versus Myocardial Infarction: Analysis of 2 National Cohorts. Journal Of The American Heart Association 2024, 13: e033322. PMID: 38639369, PMCID: PMC11179946, DOI: 10.1161/jaha.123.033322.
- Pabón M, Wang X, Lam C, O'Meara E, Vaduganathan M, Claggett B, Foà A, Lu H, Langkilde A, De Boer R, Desai A, Hernandez A, Inzucchi S, Jhund P, Kosiborod M, Martinez F, Shah S, Petersson M, McMurray J, Solomon S, Vardeny O. Sex Differences in Heart Failure With Improved Ejection Fraction The DELIVER Trial. JACC Heart Failure 2024, 12: 1119-1122. PMID: 38661586, DOI: 10.1016/j.jchf.2024.03.011.
- Patel S, Kang Y, Im K, Neuen B, Anker S, Bhatt D, Butler J, Cherney D, Claggett B, Fletcher R, Herrington W, Inzucchi S, Jardine M, Mahaffey K, McGuire D, McMurray J, Neal B, Packer M, Perkovic V, Solomon S, Staplin N, Vaduganathan M, Wanner C, Wheeler D, Zannad F, Zhao Y, Heerspink H, Sabatine M, Wiviott S. Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis. Circulation 2024, 149: 1789-1801. PMID: 38583093, PMCID: PMC11149938, DOI: 10.1161/circulationaha.124.069568.
- Butt J, Jhund P, Docherty K, Claggett B, Vaduganathan M, Bachus E, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Solomon S, McMurray J. Dapagliflozin and Timing of Prior Heart Failure Hospitalization A Patient-Level Meta-Analysis of DAPA-HF and DELIVER. JACC Heart Failure 2024, 12: 1586-1599. PMID: 38573262, DOI: 10.1016/j.jchf.2024.01.018.
- Vaduganathan M, Claggett B, Kulac I, Johansen N, Reza N, Jhund P, De Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Desai A, Petersson M, Langkilde A, McMurray J, Solomon S. DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE ACROSS A RANGE OF LEFT VENTRICULAR HYPERTROPHY IN THE DELIVER TRIAL. Journal Of The American College Of Cardiology 2024, 83: 320. DOI: 10.1016/s0735-1097(24)02310-6.
- Kondo T, Mogensen U, Talebi A, Gasparyan S, Campbell R, Docherty K, de Boer R, Inzucchi S, Køber L, Kosiborod M, Martinez F, Sabatine M, Bengtsson O, Sjöstrand M, Vaduganathan M, Solomon S, Jhund P, McMurray J. Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial. Journal Of The American College Of Cardiology 2024, 83: 1973-1986. PMID: 38537918, DOI: 10.1016/j.jacc.2024.03.385.
- Peikert A, Vaduganathan M, Claggett B, Kulac I, Foà A, Desai A, Jhund P, Carberry J, Lam C, Kosiborod M, Inzucchi S, Martinez F, de Boer R, Hernandez A, Shah S, Køber L, Ponikowski P, Sabatine M, Petersson M, Langkilde A, McMurray J, Solomon S. Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant‐level pooled analysis of DAPA‐HF and DELIVER. European Journal Of Heart Failure 2024, 26: 912-924. PMID: 38487939, DOI: 10.1002/ejhf.3184.
- Vardeny O, Desai A, Jhund P, Fang J, Claggett B, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Mc Causland F, Petrie M, Vaduganathan M, McMurray J, Solomon S. Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction. JAMA Cardiology 2024, 9: 283-289. PMID: 38265835, PMCID: PMC10809142, DOI: 10.1001/jamacardio.2023.5318.
- Green J, Everett B, Ghosh A, Younes N, Krause-Steinrauf H, Barzilay J, Desouza C, Inzucchi S, Pokharel Y, Schade D, Scrymgeour A, Tan M, Utzschneider K, Mudaliar S, Crandall J, McKee M, Behringer-Massera S, Brown-Friday J, Xhori E, Ballentine-Cargill K, Duran S, Estrella H, Gonzalez de la Torre S, Lukin J, Phillips L, Burgess E, Olson D, Rhee M, Wilson P, Raines T, Boers J, Costello J, Maher-Albertelli M, Mungara R, Savoye L, White C, Gullett C, Holloway L, Morehead F, Person S, Sibymon M, Tanukonda S, Adams C, Ross A, Balasubramanyam A, Gaba R, Gonzalez Hattery E, Ideozu A, Jimenez J, Montes G, Wright C, Hollander P, Roe E, Jackson A, Smiley A, Burt P, Estrada L, Chionh K, Ismail-Beigi F, Falck-Ytter C, Sayyed Kassem L, Sood A, Tiktin M, Kulow T, Newman C, Stancil K, Cramer B, Iacoboni J, Kononets M, Sanders C, Tucker L, Werner A, Maxwell A, McPhee G, Patel C, Colosimo L, Krol A, Goland R, Pring J, Alfano L, Kringas P, Hausheer C, Tejada J, Gumpel K, Kirpitch A, Schneier H, AbouAssi H, Chatterjee R, Feinglos M, English Jones J, Khan S, Kimpel J, Zimmer R, Furst M, Satterwhite B, Thacker C, Evans Kreider K, Mariash C, Mather K, Ismail H, Lteif A, Mullen M, Hamilton T, Patel N, Riera G, Jackson M, Pirics V, Aguillar D, Howard D, Hurt S, Bergenstal R, Carlson A, Martens T, Johnson M, Hill R, Hyatt J, Jensen C, Madden M, Martin D, Willis H, Konerza W, Yang S, Kleeberger K, Passi R, Fortmann S, Herson M, Mularski K, Glauber H, Prihoda J, Ash B, Carlson C, Ramey P, Schield E, Torgrimson-Ojerio B, Arnold K, Kauffman B, Panos E, Sahnow S, Bays K, Berame K, Cook J, Ghioni D, Gluth J, Schell K, Criscola J, Friason C, Jones S, Nazarov S, Rassouli N, Puttnam R, Ojoawo B, Nelson R, Curtis M, Hollis B, Sanders-Jones C, Stokes K, El-Haqq Z, Kolli A, Tran T, Wexler D, Larkin M, Meigs J, Chambers B, Dushkin A, Rocchio G, Yepes M, Steiner B, Dulin H, Cayford M, Chu K, DeManbey A, Hillard M, Martin K, Thangthaeng N, Gurry L, Kochis R, Raymond E, Ripley V, Stevens C, Park J, Aroda V, Ghazi A, Magee M, Ressing A, Loveland A, Hamm M, Hurtado M, Kuhn A, Leger J, Manandhar L, Mwicigi F, Sanchez O, Young T, Garg R, Lagari-Libhaber V, Florez H, Valencia W, Marks J, Casula S, Oropesa-Gonzalez L, Hue L, Cuadot A, Nieto-Martinez R, Riccio Veliz A, Gutt M, Kendal Y, Veciana B, Ahmann A, Aby-Daniel D, Joarder F, Morimoto V, Sprague C, Yamashita D, Cady N, Rivera-Eschright N, Kirchhoff P, Morales Gomez B, Adducci J, Goncharova A, Hox S, Petrovitch H, Matwichyna M, Jenkins V, Broadwater L, Ishii R, Bermudez N, Hsia D, Cefalu W, Greenway F, Waguespack C, King E, Fry G, Dragg A, Gildersleeve B, Arceneaux J, Haynes N, Thomassie A, Pavlionis M, Bourgeois B, Hazlett C, Henry R, Boeder S, Pettus J, Diaz E, Garcia-Acosta D, Maggs S, DeLue C, Stallings A, Castro E, Hernandez S, Krakoff J, Curtis J, Killean T, Khalid M, Joshevama E, Diaz E, Martin D, Tsingine K, Karshner T, Albu J, Pi-Sunyer F, Frances S, Maggio C, Ellis E, Bastawrose J, Gong X, Banerji M, August P, Lee M, Lorber D, Brown N, Josephson D, Thomas L, Tsovian M, Cherian A, Jacobson M, Mishko M, Kirkman M, Buse J, Diner J, Dostou J, Machineni S, Young L, Bergamo K, Goley A, Kerr J, Largay J, Guarda S, Cuffee J, Culmer D, Fraser R, Almeida H, Coffer S, Debnam E, Kiker L, Morton S, Josey K, Fuller G, Garvey W, Cherrington A, Dyer D, Lawson M, Griffith O, Agne A, McCullars S, Cohen R, Craig J, Rogge M, Burton K, Kersey K, Wilson C, Lipp S, Vonder Meulen M, Adkins C, Onadeko T, Rasouli N, Baker C, Schroeder E, Razzaghi M, Lyon C, Penaloza R, Underkofler C, Lorch R, Douglass S, Steiner S, Sivitz W, Cline E, Knosp L, McConnell J, Lowe T, Herman W, Pop-Busui R, Martin C, Waltje A, Katona A, Goodhall L, Eggleston R, Kuo S, Bojescu S, Bule S, Kessler N, LaSalle E, Whitley K, Seaquist E, Bantle A, Harindhanavudhi T, Kumar A, Redmon B, Bantle J, Coe M, Mech M, Taddese A, Lesne L, Smith S, Kuechenmeister L, Shivaswamy V, Burbach S, Rodriguez M, Seipel K, Alfred A, Morales A, Eggert J, Lord G, Taylor W, Tillson R, Adolphe A, Burge M, Duran-Valdez E, Martinez J, Bancroft A, Kunkel S, Ali Jamaleddin Ahmad F, Hernandez McGinnis D, Pucchetti B, Scripsick E, Zamorano A, DeFronzo R, Cersosimo E, Abdul-Ghani M, Triplitt C, Juarez D, Mullen M, Garza R, Verastiqui H, Wright K, Puckett C, Raskin P, Rhee C, Abraham S, Jordan L, Sao S, Morton L, Smith O, Osornio Walker L, Schnurr-Breen L, Ayala R, Kreymer R, Sturgess D, Kahn S, Alarcon-Casas Wright L, Boyko E, Tsai E, Trence D, Trikudanathan S, Fattaleh B, Montgomery B, Atkinson K, Kozedub A, Concepcion T, Moak C, Prikhodko N, Rhothisen S, Elasy T, Martin S, Shackelford L, Goidel R, Hinkle N, Lovell C, Myers J, Lipps Hogan J, McGill J, Salam M, Schweiger T, Kissel S, Recklein C, Clifton M, Tamborlane W, Camp A, Gulanski B, Pham K, Alguard M, Gatcomb P, Lessard K, Perez M, Iannone L, Magenheimer E, Montosa A, Cefalu W, Fradkin J, Burch H, Bremer A, Nathan D, Lachin J, Buse J, Kahn S, Larkin M, Tiktin M, Wexler D, Burch H, Bremer A, Lachin J, Bebu I, Butera N, Buys C, Fagan A, Gao Y, Gramzinski M, Hall S, Kazemi E, Legowski E, Liu H, Suratt C, Tripputi M, Arey A, Backman M, Bethepu J, Lund C, Mangat Dhaliwal P, McGee P, Mesimer E, Ngo L, Steffes M, Seegmiller J, Saenger A, Arends V, Gabrielson D, Conner T, Warren S, Day J, Huminik J, Soliman E, Zhang Z, Campbell C, Hu J, Keasler L, Hensley S, Li Y, Herman W, Kuo S, Martin C, Waltje A, Mihalcea R, Min D, Perez-Rosas V, Prosser L, Resnicow K, Ye W, Shao H, Zhang P, Luchsinger J, Sanchez D, Assuras S, Groessl E, Sakha F, Chong H, Hillery N, Abdouch I, Bahtiyar G, Brantley P, Broyles F, Canaris G, Copeland P, Craine J, Fein W, Gliwa A, Hope L, Lee M, Meiners R, Meiners V, O’Neal H, Park J, Sacerdote A, Sledge Jr E, Soni L, Steppel-Reznik J, Turchin A. Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study). Circulation 2024, 149: 993-1003. PMID: 38344820, PMCID: PMC10978227, DOI: 10.1161/circulationaha.123.066604.
- Levy J, Adeyina O, Robert S, Rimmer R, Inzucchi S, Rutherford H, Omay B. Increased Anxiety and Depression after Sellar Surgery: Is Oxytocin the Culprit?? Journal Of Neurological Surgery Part B Skull Base 2024, 85: s1-s398. DOI: 10.1055/s-0044-1780103.
- Mc Causland F, Claggett B, Vaduganathan M, Desai A, Jhund P, Vardeny O, Fang J, de Boer R, Docherty K, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Saraiva J, McGrath M, Shah S, Verma S, Langkilde A, Petersson M, McMurray J, Solomon S. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiology 2024, 9: 144-152. PMID: 37952176, PMCID: PMC10641768, DOI: 10.1001/jamacardio.2023.4664.
- Chang J, Javaheri A, Sauer A, Windsor S, Fu Z, Jones P, Margulies K, Lanfear D, Nassif M, Husain M, Inzucchi S, McGuire D, Pitt B, Scirica B, Kosiborod M. Cardiac And Kidney Benefits Of Dapagliflozin Are Associated With ApoM Levels In Patients With Heart Failure With Reduced Ejection Fraction. Journal Of Cardiac Failure 2024, 30: 236. DOI: 10.1016/j.cardfail.2023.10.284.
- Butt J, Jering K, DE Boer R, Claggett B, Desai A, Hernandez A, Inzucchi S, Jhund P, Køber L, Kosiborod M, Lam C, Martinez F, Ponikowski P, Sabatine M, Shah S, Vaduganathan M, Langkilde A, Bengtsson O, Petersson M, Sjöstrand M, Wilderäng U, Solomon S, McMurray J. Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER. Journal Of Cardiac Failure 2023, 30: 436-448. PMID: 38104937, DOI: 10.1016/j.cardfail.2023.08.027.
- Wang X, Lam C, Vaduganathan M, Kondo T, Yang M, Han Y, Pham V, Chiang C, Kitakaze M, Miao Z, Jhund P, Desai A, Inzucchi S, de Boer R, Martinez F, Kosiborod M, Hernandez A, Claggett B, Langkilde A, McMurray J, Solomon S. Effects of Dapagliflozin in Patients in Asia A Post Hoc Subgroup Analysis From the DELIVER Trial. JACC Asia 2023, 4: 108-118. PMID: 38371292, PMCID: PMC10866733, DOI: 10.1016/j.jacasi.2023.10.005.
- Tan X, Liang Y, Rajpura J, Yedigarova L, Noone J, Xie L, Inzucchi S, de Havenon A. Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease. Cardiovascular Diabetology 2023, 22: 319. PMID: 37985992, PMCID: PMC10662529, DOI: 10.1186/s12933-023-02051-8.
- Kondo T, Vaduganathan V, Hernandez A, Lam C, Inzucchi S, Martinez F, De Boer R, Kosiborod M, Desai A, Kober L, Ponikowski P, Sabatine M, Shah S, Solomon S, Mcmurray J. Efficacy of dapagliflozin according to geographic regions in patients with heart failure: a patient-level pooled analysis of DAPA-HF and DELIVER. European Heart Journal 2023, 44: ehad655.979. DOI: 10.1093/eurheartj/ehad655.979.
- Butt J, Lu H, Kondo T, Bachus E, De Boer R, Hernandez A, Inzucchi S, Jhund P, Kosiborod M, Lam C, Martinez F, Shah S, Vaduganathan M, Solomon S, Mcmurray J. Effects of dapagliflozin in heart failure with preserved ejection fraction and chronic obstructive pulmonary disease: an analysis of the DELIVER trial. European Heart Journal 2023, 44: ehad655.949. DOI: 10.1093/eurheartj/ehad655.949.
- Chatur S, Vaduganathan M, Claggett B, Desai A, Docherty K, Jhund P, De Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Mcmurray J, Solomon S. Effect of dapagliflozin on outpatient worsening heart failure in patients with mildly reduced or preserved ejection fraction: the DELIVER trial. European Heart Journal 2023, 44: ehad655.751. DOI: 10.1093/eurheartj/ehad655.751.
- Kondo T, Butt J, Curtain J, Jhund P, Docherty K, Claggett B, Vaduganathan M, Bachus E, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Solomon S, McMurray J. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER. Circulation Heart Failure 2023, 16: e010898. PMID: 37886880, DOI: 10.1161/circheartfailure.123.010898.
- Kondo T, Gasparyan S, Jhund P, Bengtsson O, Claggett B, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Køber L, Lam C, Langkilde A, Martinez F, Petersson M, Ponikowski P, Sabatine M, Shah S, Sjostrand M, Wilderang U, Vaduganathan M, Solomon S, McMurray J. Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER Trials. NEJM Evidence 2023, 2: evidoa2300042. PMID: 38320525, DOI: 10.1056/evidoa2300042.
- Ostrominski J, Vaduganathan M, Selvaraj S, Claggett B, Miao Z, Desai A, Jhund P, Kosiborod M, Lam C, Inzucchi S, Martinez F, de Boer R, Hernandez A, Shah S, Petersson M, Langkilde A, McMurray J, Solomon S. Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial. Circulation 2023, 148: 1945-1957. PMID: 37830208, DOI: 10.1161/circulationaha.123.065254.
- Bhatt A, Kosiborod M, Claggett B, Miao Z, Vaduganathan M, Lam C, Hernandez A, Martinez F, Inzucchi S, Shah S, de Boer R, Jhund P, Desai A, Fang J, Han Y, Comin‐Colet J, Drożdż J, Vardeny O, Merkely B, Lindholm D, Peterson M, Langkilde A, McMurray J, Solomon S. Impact of COVID‐19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial. European Journal Of Heart Failure 2023, 25: 2177-2188. PMID: 37771274, DOI: 10.1002/ejhf.3043.
- Peikert A, Bart B, Vaduganathan M, Claggett B, Kulac I, Kosiborod M, Desai A, Jhund P, Lam C, Inzucchi S, Martinez F, de Boer R, Hernandez A, Shah S, Petersson M, Langkilde A, McMurray J, Solomon S, Vardeny O. Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF The DELIVER Trial. JACC Heart Failure 2023, 12: 631-644. PMID: 37767674, DOI: 10.1016/j.jchf.2023.09.007.
- Butt J, Lu H, Kondo T, Bachus E, de Boer R, Inzucchi S, Jhund P, Kosiborod M, Lam C, Martinez F, Vaduganathan M, Solomon S, McMurray J. Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER. European Journal Of Heart Failure 2023, 25: 2078-2090. PMID: 37634087, DOI: 10.1002/ejhf.3000.
- Chatur S, Vaduganathan M, Claggett B, Cunningham J, Docherty K, Desai A, Jhund P, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Petersson M, Langkilde A, McMurray J, Solomon S. Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial. Circulation 2023, 148: 1735-1745. PMID: 37632455, PMCID: PMC10664793, DOI: 10.1161/circulationaha.123.066506.
- Chatur S, Vaduganathan M, Claggett B, Mc Causland F, Desai A, Jhund P, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Sabatine M, Kober L, Ponikowski P, Merkely B, Petersson M, Langkilde A, McMurray J, Solomon S. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function. Journal Of The American College Of Cardiology 2023, 82: 1854-1863. PMID: 37634707, DOI: 10.1016/j.jacc.2023.08.026.
- Kondo T, Wang X, Yang M, Jhund P, Claggett B, Vaduganathan M, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Langkilde A, Petersson M, Zaozerska N, Bachus E, Solomon S, McMurray J. Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure. Journal Of The American College Of Cardiology 2023, 82: 1014-1026. PMID: 37610398, DOI: 10.1016/j.jacc.2023.05.056.
- Balasubramanian P, Kernan W, Sheth K, Ofstad A, Rosenstock J, Wanner C, Zinman B, Mattheus M, Marx N, Inzucchi S. Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials. Stroke 2023, 54: 2013-2021. PMID: 37449424, PMCID: PMC10358436, DOI: 10.1161/strokeaha.122.042053.
- Peikert A, Chandra A, Kosiborod M, Claggett B, Desai A, Jhund P, Lam C, Inzucchi S, Martinez F, de Boer R, Hernandez A, Shah S, Janssens S, Bělohlávek J, Borleffs C, Dobreanu D, Langkilde A, Bengtsson O, Petersson M, McMurray J, Solomon S, Vaduganathan M. Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiology 2023, 8: 684-690. PMID: 37208998, PMCID: PMC10200027, DOI: 10.1001/jamacardio.2023.1342.
- Wexler D, de Boer I, Ghosh A, Younes N, Bebu I, Inzucchi S, McGill J, Mudaliar S, Schade D, Steffes M, Tamborlane W, Tan M, Ismail-Beigi F, Crandall J, McKee M, Beringher-Massera S, Brown-Friday J, Xhori E, Ballentine-Cargill K, Duran S, Estrella H, Gonzalez de la torre S, Lukin J, Phillips L, Burgess E, Olson D, Rhee M, Wilson P, Raines T, Boers J, Costello J, Maher-Albertelli M, Mungara R, Savoye L, White C, Gullett C, Holloway L, Morehead F, Person S, Sibymon M, Tanukonda S, Adams C, Ross A, Balasubramanyam A, Gaba R, Gonzalez E, Ideozu A, Jimenez J, Montes G, Wright C, Hollander P, Roe E, Jackson A, Smiley A, Burt P, Estrada L, Chionh K, Ismail-Beigi F, Falck-Ytter C, Sayyed Kassem L, Sood A, Tiktin M, Cramer B, Iacoboni J, Kononets M, Kulow T, Newman C, Stancil K, Sanders C, Tucker L, Werner A, Krol A, McPhee G, Patel C, Colosimo L, Maxwell A, Goland R, Pring J, Alfano L, Kringas P, Hausheer C, Tejada J, Gumpel K, Kirpitch A, Schneier H, Green J, AbouAssi H, Chatterjee R, Feinglos M, English Jones J, Khan S, Kimpel J, Zimmer R, Furst M, Satterwhite B, Thacker C, Evans Kreider K, Mariash C, Mather K, Ismail H, Lteif A, Mullen M, Hamilton T, Patel N, Riera G, Jackson M, Pirics V, Howard D, Aguillar D, Hurt S, Bergenstal R, Carlson A, Martens T, Johnson M, Hill R, Hyatt J, Jensen C, Madden M, Martin D, Willis H, Konerza W, Yang S, Passi R, Kleeberger K, Fortmann S, Herson M, Mularski K, Glauber H, Prihoda J, Ash B, Carlson C, Ramey P, Schield E, Torgrimson-Ojerio B, Arnold K, Kauffman B, Panos E, Sahnow S, Bays K, Cook J, Gluth J, Ghioni D, Schell K, Criscola J, Friason C, Jones S, Nazarov S, Barzilay J, Rassouli N, Puttnam R, Ojoawo O, Nelson R, Curtis M, Hollis B, Sanders-Jones C, Stokes K, El-Haqq Z, Kolli A, Tran T, Wexler D, Larkin M, Meigs J, Chambers B, Dushkin A, Rocchio G, Yepes M, Steiner B, Dulin H, Cayford M, DeManbey A, Hillard M, Martin K, Thangthaeng N, Gurry L, Kochis R, Raymond E, Ripley V, Stevens C, Park J, Aroda V, Ghazi A, Magee M, Ressing A, Loveland A, Hamm M, Hurtado M, Kuhn A, Leger J, Manandhar L, Mwicigi F, Sanchez O, Young T, Garg R, Lagari-Libhaber V, Florez H, Valencia W, Mark J, Casula S, Oropesa-Gonzalez L, Hue L, Cuadot A, Nieto-Martinez R, Riccio Veliz A, Gutt M, Kendal Y, Veciana B, Ahmann A, Aby-Daniel D, Joarder F, Morimoto V, Sprague C, Yamashita D, Cady N, Rivera-Eschright N, Kirchhoff P, Morales Gonzalez B, Adducci J, Goncharova A, Hox S, Petrovich H, Matwichyna M, Jenkins V, Broadwater L, Ishii R, Bermudez N, Hsia D, Cefalu W, Greenway F, Waguespack C, King E, Fry G, Dragg A, Gildersleeve B, Arceneaux J, Haynes N, Thomassie A, Pavlionis M, Bourgeois B, Hazlett C, Mudaliar S, Robert H, Boeder S, Pettus J, Diaz E, Garcia-Acosta D, Maggs S, DeLue C, Stallings A, Castro E, Hernandez S, Krakoff J, Curtis J, Killean T, Khalid M, Joshevama E, Diaz E, Martin D, Tsingine K, Karshner T, Albu J, Pi-Sunyer F, Frances S, Maggio C, Ellis E, Bastawrose J, Gong X, Banerji M, August P, Lee M, Lorber D, Necole M. B, Josephson D, Thomas L, Tsovian M, Cherian A, Jacobson M, Mishko M, Kirkman S, Buse J, Dostou J, Machineni S, Young L, Bergamo K, Goley A, Kerr J, Largay J, Guarda S, Cuffee J, Culmer D, Fraser R, Almeida H, Coffer S, Debnam E, Kiker L, Morton S, Josey K, Fuller G, Garvey W, Cherrington A, Dyer D, Lawson M, Griffith O, Agne A, McCullars S, Cohen R, Craig J, Rogge M, Burton K, Kersey K, Wilson C, Lipp S, Vonder Meulen M, Adkins C, Onadeko T, Rasouli N, Baker C, Schroeder E, Razzaghi M, Lyon C, Penaloza R, Underkofler C, Lorch R, Douglass S, Steiner S, Sivitz W, Cline E, Knosp L, McConnell J, Lowe T, Herman W, Pop-Busui R, Tan M, Martin C, Waltje A, Katona A, Goodhall L, Eggleston R, Kuo S, Bojescu S, Bule S, Kessler N, LaSalle E, Whitley K, Seaquist E, Bantle A, Harindhanavudhi T, Kumar A, Redmon B, Bantle J, Coe M, Mech M, Taddese A, Lesne L, Smith S, Desouza C, Kuechenmeister L, Shivaswamv V, Burbach S, Rodriguez M, Seipel K, Alfred A, Morales A, Eggert J, Lord G, Taylor W, Tillson R, Schade D, Adolphe A, Burge M, Duran-Valdez E, Martinez J, Bancroft A, Kunkel S, Jamaleddin Ahmad F, Hernandez McGinnis D, Pucchetti B, Scripsick E, Zamorano A, DeFronzo R, Cersosimo E, Abdul-Ghani M, Triplitt C, Juarez D, Garza R, Verastiqui H, Wright K, Puckett C, Raskin P, Rhee C, Abraham S, Jordan L, Sao S, Morton L, Smith O, Osornio Walker L, Schnurr-Breen L, Ayala R, Kreymer R, Sturgess D, Utzschneider K, Kahn S, Alarcon-Casas Wright L, Boyko E, Tsiai E, Trence D, Trikudanathan S, Fattaleh B, Montgomery B, Atkinson K, Kozedub A, Concepcion T, Moak C, Prikhodko N, Rhothisen S, Elasy T, Martin S, Shackelford L, Goidel R, Hinkle N, Lovell C, Myers J, Lipps Hogan J, McGill J, Salam M, Schweiger T, Kissel S, Recklein C, Clifton M, Tamborlane W, Camp A, Gulanski B, Inzucchi S, Pham K, Alguard M, Gatcomb P, Lessard K, Perez M, Iannone L, Magenheimer E, Montosa A, Cefalu W, Fradkin J, Burch H, Bremer A, Nathan D, Lachin J, Krause-Steinrauf H, Younes N, Bebu I, Butera N, Buys C, Fagan A, Gao Y, Ghosh A, Gramzinski M, Hall S, Kazemi E, Legowski E, Liu H, Suratt C, Tripputi M, Arey A, Backman M, Bethepu J, Lund C, Mangat Dhaliwal P, McGee P, Mesimer E, Ngo L, Steffes M, Seegmiller J, Saenger A, Arends V, Gabrielson D, Conner T, Warren S, Day J, Huminik J, Scrymgeour A, Soliman E, Pokharel Y, Zhang Z, Campbell C, Hu J, Keasler L, Hensley S, Li Y, Mihalcea R, Min D, Perez-Rosas V, Prosser L, Resnicow K, Ye W, Shao H, Zhang P, Luchsinger J, Sanchez D, Assuras S, Groessl E, Sakha F, Chong H, Hillery N, Abdouch I, Bahityar G, Brantley P, Broyles F, Canaris G, Copeland P, Craine J, Fein W, Gliwa A, Hope L, Lee M, Meiners R, Meiners V, O'Neal H, Park J, Sacerdote A, Sledge E, Soni L, Steppel-Reznik J, Turchin A. Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes. JAMA Internal Medicine 2023, 183: 705-714. PMID: 37213109, PMCID: PMC10203973, DOI: 10.1001/jamainternmed.2023.1487.
- Butt J, Docherty K, Kosiborod M, Inzucchi S, Køber L, Langkilde A, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjöstrand M, Solomon S, Jhund P, McMurray J. Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction. JACC Heart Failure 2023, 11: 1411-1423. PMID: 37318419, DOI: 10.1016/j.jchf.2023.04.016.
- Chatur S, Cunningham J, Vaduganathan M, Mc Causland F, Claggett B, Desai A, Miao Z, Jhund P, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Petersson M, Langkilde A, McMurray J, Solomon S. Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trial. European Journal Of Heart Failure 2023, 25: 1170-1175. PMID: 37212168, DOI: 10.1002/ejhf.2915.
- Chatur S, Kondo T, Claggett B, Docherty K, Miao Z, Desai A, Jhund P, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Petersson M, Langkilde A, McMurray J, Solomon S, Vaduganathan M. Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: Insights from DELIVER and DAPA‐HF. European Journal Of Heart Failure 2023, 25: 1364-1371. PMID: 37210608, DOI: 10.1002/ejhf.2912.
- Bhatt A, Kosiborod M, Vaduganathan M, Claggett B, Miao Z, Kulac I, Lam C, Hernandez A, Martinez F, Inzucchi S, Shah S, de Boer R, Jhund P, Desai A, Petersson M, Langkilde A, McMurray J, Solomon S. Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant‐level pooled analysis from the DAPA‐HF and DELIVER trials. European Journal Of Heart Failure 2023, 25: 981-988. PMID: 37211977, DOI: 10.1002/ejhf.2909.
- Peter P, Inzucchi S. Tailoring the Treatment of Type 2 Diabetes Mellitus to the Individual. Contemporary Cardiology 2023, 1043-1070. DOI: 10.1007/978-3-031-13177-6_37.
- Jhund P, Claggett B, Talebi A, Butt J, Gasparyan S, Wei L, McCaw Z, Wilderäng U, Bengtsson O, Desai A, Petersson M, Langkilde A, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Vaduganathan M, Solomon S, McMurray J. Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiology 2023, 8: 554-563. PMID: 37099283, PMCID: PMC10134044, DOI: 10.1001/jamacardio.2023.0711.
- Ostrominski J, Thierer J, Claggett B, Miao Z, Desai A, Jhund P, Kosiborod M, Lam C, Inzucchi S, Martinez F, de Boer R, Hernandez A, Shah S, Petersson M, Langkilde A, McMurray J, Solomon S, Vaduganathan M. Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JACC Heart Failure 2023, 11: 1491-1503. PMID: 37226448, DOI: 10.1016/j.jchf.2023.05.015.
- Chatur S, Vaduganathan M, Claggett B, Vardeny O, Desai A, Jhund P, de Boer R, Lam C, Kosiborod M, Shah S, Martinez F, Inzucchi S, Hernandez A, Haddad T, Mitter S, Miao Z, Petersson M, Langkilde A, McMurray J, Solomon S. Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. European Heart Journal 2023, 44: 2930-2943. PMID: 37220093, PMCID: PMC10484057, DOI: 10.1093/eurheartj/ehad283.
- Butt J, Kondo T, Yang M, Jhund P, Docherty K, Vaduganathan M, Claggett B, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Shah S, Zaozerska N, Wilderäng U, Bengtsson O, Solomon S, McMurray J. Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. European Heart Journal 2023, 44: 2170-2183. PMID: 37220172, PMCID: PMC10290876, DOI: 10.1093/eurheartj/ehad276.
- Bhatt A, Lindholm D, Nilsson A, Zaozerska N, Claggett B, Vaduganathan M, Kosiborod M, Lam C, Hernandez A, Martinez F, Inzucchi S, Shah S, de Boer R, Desai A, Jhund P, Langkilde A, Petersson M, McMurray J, Solomon S. Operational challenges and mitigation measures during the COVID-19 pandemic–Lessons from DELIVER. American Heart Journal 2023, 263: 133-140. PMID: 37220822, PMCID: PMC10200275, DOI: 10.1016/j.ahj.2023.05.013.
- Peikert A, Goyal P, Vaduganathan M, Claggett B, Kulac I, Miao Z, Vardeny O, Kosiborod M, Desai A, Jhund P, Lam C, Inzucchi S, Martinez F, de Boer R, Hernandez A, Shah S, Petersson M, Langkilde A, McMurray J, Solomon S. Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status. JACC Heart Failure 2023, 11: 1380-1393. PMID: 37294244, DOI: 10.1016/j.jchf.2023.05.014.
- Nassif M, Windsor S, Gosch K, Borlaug B, Husain M, Inzucchi S, Kitzman D, McGuire D, Pitt B, Scirica B, Shah S, Umpierrez G, Austin B, Lamba S, Khumri T, Sharma K, Kosiborod M. Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials. Circulation Heart Failure 2023, 16: e009837. PMID: 37203441, PMCID: PMC10348645, DOI: 10.1161/circheartfailure.122.009837.
- McGuire D, Busui R, Deanfield J, Inzucchi S, Mann J, Marx N, Mulvagh S, Poulter N, Engelmann M, Hovingh G, Ripa M, Gislum M, Brown‐Frandsen K, Buse J. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial. Diabetes Obesity And Metabolism 2023, 25: 1932-1941. PMID: 36945734, DOI: 10.1111/dom.15058.
- Nargesi A, Clark C, Aminorroaya A, Chen L, Liu M, Reddy A, Amodeo S, Oikonomou E, Suchard M, McGuire D, Lin Z, Inzucchi S, Khera R. Persistence on Novel Cardioprotective Antihyperglycemic Therapies in the United States. The American Journal Of Cardiology 2023, 196: 89-98. PMID: 37012183, PMCID: PMC11007258, DOI: 10.1016/j.amjcard.2023.03.002.
- Butt J, Docherty K, Claggett B, Desai A, Petersson M, Langkilde A, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Køber L, Lam C, Martinez F, Ponikowski P, Sabatine M, Shah S, Vaduganathan M, Jhund P, Solomon S, McMurray J. Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid–Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout. JAMA Cardiology 2023, 8: 386-393. PMID: 36811901, PMCID: PMC9947801, DOI: 10.1001/jamacardio.2022.5608.
- Wojeck B, Inzucchi S, Qin L, Yaggi H. Polysomnographic predictors of incident diabetes and pre-diabetes: an analysis of the DREAM study. Journal Of Clinical Sleep Medicine 2023, 19: 703-710. PMID: 36689314, PMCID: PMC10071389, DOI: 10.5664/jcsm.10414.
- Vardeny O, Fang J, Desai A, Jhund P, Claggett B, Vaduganathan M, de Boer R, Hernandez A, Lam C, Inzucchi S, Martinez F, Kosiborod M, DeMets D, O’Meara E, Zieroth S, Comin-Colet J, Drozdz J, Chiang C, Kitakaze M, Petersson M, Lindholm D, Langkilde A, McMurray J, Solomon S. Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. Nature Medicine 2023, 29: 3269-3269. PMID: 36932245, PMCID: PMC10719083, DOI: 10.1038/s41591-023-02302-x.
- Kondo T, Jering K, Borleffs C, de Boer R, Claggett B, Desai A, Dobreanu D, Inzucchi S, Hernandez A, Janssens S, Jhund P, Kosiborod M, Lam C, Langkilde A, Martinez F, Petersson M, Vinh P, Vaduganathan M, Solomon S, McMurray J. Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial. Circulation 2023, 147: 1067-1078. PMID: 36876483, DOI: 10.1161/circulationaha.122.062918.
- Athonvarangkul D, Wang K, Deng Y, Inzucchi S, Mayerson A. Improved extremity tissue oxygenation with short-term exposure to textiles embedded with far infrared light emitting thermoactive particles in patients with diabetes mellitus. Diabetes And Vascular Disease Research 2023, 20: 14791641231170282. PMID: 37073436, PMCID: PMC10123901, DOI: 10.1177/14791641231170282.
- McMurray J, Docherty K, Jhund P, Claggett B, De Boer R, Hernandez A, Inzucchi S, Kober L, Kosiborod M, Lam C, Martinez F, Ponikowski P, Sabatine M, Shah S, Langkilde A, Petersson M, Solomon S. THE EFFECT OF DAPAGLIFLOZIN ON INSULIN INITIATION OR INTENSIFICATION IN PATIENTS IN HEART FAILURE AND DIABETES: A POOLED ANALYSIS OF DAPA-HF AND DELIVER. Journal Of The American College Of Cardiology 2023, 81: 278. DOI: 10.1016/s0735-1097(23)00722-2.
- Haider S, Templeton K, Omay S, Inzucchi S. Primary hypothyroidism presenting as neuropsychiatric symptoms and pituitary enlargement in a young woman: illustrative case. Journal Of Neurosurgery Case Lessons 2023, 5: case22496. PMID: 36794728, PMCID: PMC10550602, DOI: 10.3171/case22496.
- Butt J, Docherty K, Claggett B, Desai A, Fang J, Petersson M, Langkilde A, de Boer R, Cabrera Honorio J, Hernandez A, Inzucchi S, Kosiborod M, Køber L, Lam C, Martinez F, Ponikowski P, Sabatine M, Vardeny O, O'Meara E, Saraiva J, Shah S, Vaduganathan M, Jhund P, Solomon S, McMurray J. Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum. JACC Heart Failure 2023, 11: 375-388. PMID: 36881399, DOI: 10.1016/j.jchf.2022.11.014.
- Suthahar N, Wang K, Zwartkruis V, Bakker S, Inzucchi S, Meems L, Eijgenraam T, Ahmadizar F, Sijbrands E, Gansevoort R, Kieneker L, van Veldhuisen D, Kavousi M, de Boer R. Associations of relative fat mass, a new index of adiposity, with type-2 diabetes in the general population. European Journal Of Internal Medicine 2023, 109: 73-78. PMID: 36604231, DOI: 10.1016/j.ejim.2022.12.024.
- Brandt‐Jacobsen N, Jürgens M, Hasbak P, Gæde P, Rossing P, Rasmussen J, Andersen C, Forman J, Faber J, Inzucchi S, Gustafsson F, Schou M, Kistorp C. Reduction of cardiac adipose tissue volume with short‐term empagliflozin treatment in patients with type 2 diabetes: A substudy from the SIMPLE randomized clinical trial. Diabetes Obesity And Metabolism 2023, 25: 844-855. PMID: 36484428, PMCID: PMC10107109, DOI: 10.1111/dom.14933.
- Balasubramanian P, Inzucchi S. Chapter 13 Sodium-glucose Co-transporter-2 inhibitors: a new era of cardioprotection and renoprotection. 2023, 337-363. DOI: 10.1016/b978-0-323-99991-5.00006-1.
- Mc Causland F, Claggett B, Vaduganathan M, Desai A, Jhund P, de Boer R, Docherty K, Fang J, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Saraiva J, McGrath M, Shah S, Verma S, Langkilde A, Petersson M, McMurray J, Solomon S. Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiology 2023, 8: 56-65. PMID: 36326604, PMCID: PMC9634592, DOI: 10.1001/jamacardio.2022.4210.
- Kernan W, Forman R, Inzucchi S. Caring for Patients With Diabetes in Stroke Neurology. Stroke 2022, 54: 894-904. PMID: 36541212, DOI: 10.1161/strokeaha.122.038163.
- Vardeny O, Fang J, Desai A, Jhund P, Claggett B, Vaduganathan M, de Boer R, Hernandez A, Lam C, Inzucchi S, Martinez F, Kosiborod M, DeMets D, O’Meara E, Zieroth S, Comin-Colet J, Drozdz J, Chiang C, Kitakaze M, Petersson M, Lindholm D, Langkilde A, McMurray J, Solomon S. Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. Nature Medicine 2022, 28: 2504-2511. PMID: 36522606, PMCID: PMC9800271, DOI: 10.1038/s41591-022-02102-9.
- Kosiborod M, Bhatt A, Claggett B, Vaduganathan M, Kulac I, Lam C, Hernandez A, Martinez F, Inzucchi S, Shah S, de Boer R, Jhund P, Desai A, Fang J, Han Y, Comin-Colet J, Vardeny O, Lindholm D, Wilderäng U, Bengtsson O, McMurray J, Solomon S. Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction. Journal Of The American College Of Cardiology 2022, 81: 460-473. PMID: 36526515, DOI: 10.1016/j.jacc.2022.11.006.
- Ghazi L, O'Connor K, Yamamoto Y, Fuery M, Sen S, Samsky M, Riello R, Huang J, Olufade T, McDermott J, Inzucchi S, Velazquez E, Wilson F, Desai N, Ahmad T. Pragmatic trial of messaging to providers about treatment of acute heart failure: The PROMPT-AHF trial. American Heart Journal 2022, 257: 111-119. PMID: 36493842, DOI: 10.1016/j.ahj.2022.12.002.
- Alameddine D, Satam K, Slade M, Wang H, Mena-Hurtado C, Turner J, Inzucchi S, Chaar C. Predictors of Major Adverse Limb Events After Infrainguinal Bypass in Patients with Diabetes. American Heart Journal 2022, 254: 241. DOI: 10.1016/j.ahj.2022.10.026.
- Wojeck B, Inzucchi S, Neeland I, Mancuso J, Frederich R, Masiukiewicz U, Cater N, McGuire D, Cannon C, Yaggi H. Ertugliflozin and Incident Obstructive Sleep Apnea: An Analysis from the VERTIS CV Trial. Sleep Medicine 2022, 100: s249-s250. DOI: 10.1016/j.sleep.2022.05.671.
- Inzucchi S, Claggett B, Vaduganathan M, Desai A, Jhund P, de Boer R, Hernandez A, Kosiborod M, Lam C, Martinez F, Shah S, Verma S, Han Y, Kerr Saraiva J, Bengtsson O, Petersson M, Langkilde A, McMurray J, Solomon S. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet Diabetes & Endocrinology 2022, 10: 869-881. PMID: 36372069, DOI: 10.1016/s2213-8587(22)00308-4.
- Adamson C, Welsh P, Docherty K, de Boer R, Diez M, Drożdż J, Dukát A, Inzucchi S, Køber L, Kosiborod M, Ljungman C, Martinez F, Ponikowski P, Sabatine M, Morrow D, Lindholm D, Hammarstedt A, Boulton D, Greasley P, Langkilde A, Solomon S, Sattar N, McMurray J, Jhund P. IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction Findings From DAPA-HF. JACC Heart Failure 2022, 11: 291-304. PMID: 36592046, DOI: 10.1016/j.jchf.2022.09.004.
- Yang M, Butt J, Kondo T, Jering K, Docherty K, Jhund P, de Boer R, Claggett B, Desai A, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Langkilde A, Martinez F, Petersson M, Shah S, Vaduganathan M, Wilderäng U, Solomon S, McMurray J. Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. European Journal Of Heart Failure 2022, 24: 2307-2319. PMID: 36342375, PMCID: PMC11497302, DOI: 10.1002/ejhf.2722.
- Wang X, Vaduganathan M, Claggett B, Hegde S, Pabon M, Kulac I, Vardeny O, O’Meara E, Zieroth S, Katova T, McGrath M, Pouleur A, Jhund P, Desai A, Inzucchi S, Kosiborod M, de Boer R, Kober L, Sabatine M, Martinez F, Ponikowski P, Shah S, Hernandez A, Langkilde A, McMurray J, Solomon S, Lam C. Sex Differences in Characteristics, Outcomes and Treatment Response with Dapagliflozin across the Range of Ejection Fraction in Patients with Heart Failure: Insights from DAPA-HF and DELIVER. Circulation 2022, 147: 624-634. PMID: 36342789, PMCID: PMC9974767, DOI: 10.1161/circulationaha.122.062832.
- Baigent C, Emberson J, Haynes R, Herrington W, Judge P, Landray M, Mayne K, Ng S, Preiss D, Roddick A, Staplin N, Zhu D, Anker S, Bhatt D, Brueckmann M, Butler J, Cherney D, Green J, Hauske S, Haynes R, Heerspink H, Herrington W, Inzucchi S, Jardine M, Liu C, Mahaffey K, McCausland F, McGuire D, McMurray J, Neal B, Neuen B, Packer M, Perkovic V, Sabatine M, Solomon S, Vaduganathan M, Wanner C, Wheeler D, Wiviott S, Zannad F. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. The Lancet 2022, 400: 1788-1801. PMID: 36351458, PMCID: PMC7613836, DOI: 10.1016/s0140-6736(22)02074-8.
- Brandt-Jacobsen N, Jürgens M, Hasbak P, Gæde P, Rossing P, Rasmussen J, Andersen C, Forman J, Faber J, Inzucchi S, Gustafsson F, Schou M, Kistorp C. ODP154 Reduction of Cardiac Adipose Tissue Volume with Short-Term Empagliflozin in Patients with Type 2 Diabetes: Results from the SIMPLE Randomized Clinical Trial. Journal Of The Endocrine Society 2022, 6: a245-a245. PMCID: PMC9624604, DOI: 10.1210/jendso/bvac150.504.
- Adamson C, Welsh P, Morrow D, Docherty K, Hammarstedt A, Inzucchi S, Kober L, Kosiborod M, Martinez F, Ponikowski P, Sabatine M, Solomon S, Sattar N, Jhund P, McMurray J. Outcomes related to IGFBP-7 in patients with heart failure and reduced ejection fraction and effects of dapagliflozin: findings from DAPA-HF. European Heart Journal 2022, 43: ehac544.913. DOI: 10.1093/eurheartj/ehac544.913.
- Kondo T, Jhund P, Abraham W, Rouleau J, Packer M, Desai A, Kober L, Solomon S, Zile M, Inzucchi S, Kosiborod M, Sabatine M, Ponikowski P, Martinez F, McMurray J. Stroke in patients with heart failure and reduced ejection fraction without atrial fibrillation: external validation of a risk model. European Heart Journal 2022, 43: ehac544.869. DOI: 10.1093/eurheartj/ehac544.869.
- Yeoh S, Docherty K, Jhund P, Hammarstedt A, Inzucchi S, Kober L, Kosiborod M, Martinez F, Ponikowski P, Solomon S, Sattar N, Welsh P, Sabatine M, Morrow D, McMurray J. Relationship between endothelin-1, heart failure with reduced ejection fraction and dapagliflozin: findings from DAPA-HF. European Heart Journal 2022, 43: ehac544.833. DOI: 10.1093/eurheartj/ehac544.833.
- Selvaraj S, Vaduganathan M, Claggett B, Miao Z, Fang J, Vardeny O, Desai A, Shah S, Lam C, Martinez F, Inzucchi S, de Boer R, Petersson M, Langkilde A, McMurray J, Solomon S. Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction DELIVER. JACC Heart Failure 2022, 11: 76-89. PMID: 36599553, DOI: 10.1016/j.jchf.2022.09.002.
- Levine L, Heard A, Ignatiev J, Inzucchi S. S2229 Acquired Dextrocardia?: A Striking Consequence of Sigmoid Volvulus. The American Journal Of Gastroenterology 2022, 117: e1505-e1505. DOI: 10.14309/01.ajg.0000865556.38714.d8.
- Balasubramanian P, Wanner C, Ferreira J, Ofstad A, Elsaesser A, Zinman B, Inzucchi S. Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition? 2022, 48-52. DOI: 10.37987/1997-9894.2022.5-6(261-2).271666.
- Logeay F, Zaoui P, Inzucchi S, Zinman B, Steubl D, Ofstad A, Wanner C, Mattheus M. Effet d’empagliflozine sur le changement (aggravation/amélioration) de groupe de risque d’IRC selon KDIGO : évalué dans EMPA-REG-OUTCOME. Néphrologie & Thérapeutique 2022, 18: 355. DOI: 10.1016/j.nephro.2022.07.180.
- Myhre P, Vaduganathan M, Claggett B, Miao Z, Jhund P, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Desai A, Lindholm D, Petersson M, Langkilde A, McMurray J, Solomon S. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JACC Heart Failure 2022, 10: 902-913. PMID: 36114137, DOI: 10.1016/j.jchf.2022.08.007.
- Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O’Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilderäng U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. The New England Journal Of Medicine 2022, 387: 1089-1098. PMID: 36027570, DOI: 10.1056/nejmoa2206286.
- Aroda V, Krause-Steinrauf H, Kazemi E, Buse J, Gulanski B, Florez H, Ahmann A, Loveland A, Kuhn A, Lonier J, Wexler D, Crandall J, McKee M, Behringer-Massera S, Brown-Friday J, Xhori E, Ballentine-Cargill K, Duran S, Estrella H, Gonzalez de la torre S, Lukin J, Phillips L, Burgess E, Olson D, Rhee M, Wilson P, Raines T, Boers J, Costello J, Maher-Albertelli M, Mungara R, Savoye L, White C, Gullett C, Holloway L, Morehead F, Person S, Sibymon M, Tanukonda S, Adams C, Ross A, Balasubramanyam A, Gaba R, Gonzalez Hattery E, Ideozu A, Jimenez J, Montes G, Wright C, Hollander P, Roe E, Jackson A, Smiley A, Burt P, Estrada L, Chionh K, Ismail-Beigi F, Falck-Ytter C, Sayyed Kassem L, Sood A, Tiktin M, Kulow T, Newman C, Stancil K, Cramer B, Iacoboni J, Kononets M, Sanders C, Tucker L, Werner A, Maxwell A, McPhee G, Patel C, Colosimo L, Krol A, Goland R, Pring J, Alfano L, Kringas P, Hausheer C, Tejada J, Gumpel K, Kirpitch A, Schneier H, Green J, AbouAssi H, Chatterjee R, Feinglos M, English Jones J, Khan S, Kimpel J, Zimmer R, Furst M, Satterwhite B, Thacker C, Evans Kreider K, Mariash C, Mather K, Ismail H, Lteif A, Mullen M, Hamilton T, Patel N, Riera G, Jackson M, Pirics V, Aguillar D, Howard D, Hurt S, Bergenstal R, Carlson A, Martens T, Johnson M, Hill R, Hyatt J, Jensen C, Madden M, Martin D, Willis H, Konerza W, Yang S, Kleeberger K, Passi R, Fortmann S, Herson M, Mularski K, Glauber H, Prihoda J, Ash B, Carlson C, Ramey P, Schield E, Torgrimson-Ojerio B, Arnold K, Kauffman B, Panos E, Sahnow S, Bays K, Berame K, Cook J, Ghioni D, Gluth J, Schell K, Criscola J, Friason C, Jones S, Nazarov S, Barzilay J, Rassouli N, Puttnam R, Ojoawo B, Nelson R, Curtis M, Hollis B, Sanders-Jones C, Stokes K, El-Haqq Z, Kolli A, Tran T, Wexler D, Larkin M, Meigs J, Chambers B, Dushkin A, Rocchio G, Yepes M, Steiner B, Dulin H, Cayford M, Chu K, DeManbey A, Hillard M, Martin K, Thangthaeng N, Gurry L, Kochis R, Raymond E, Ripley V, Stevens C, Park J, Aroda V, Ghazi A, Magee M, Ressing A, Loveland A, Hamm M, Hurtado M, Kuhn A, Leger J, Manandhar L, Sanchez O, Young T, Mofor F, Garg R, Lagari-Libhaber V, Florez H, Valencia W, Marks J, Casula S, Oropesa-Gonzalez L, Hue L, Cuadot A, Nieto-Martinez R, Riccio Veliz A, Gutt M, Kendal Y, Veciana B, Ahmann A, Aby-Daniel D, Joarder F, Morimoto V, Sprague C, Yamashita D, Cady N, Rivera-Eschright N, Kirchhoff P, Morales Gomez B, Adducci J, Goncharova A, Hox S, Petrovitch H, Matwichyna M, Jenkins V, Broadwater L, Ishii R, Bermudez N, Hsia D, Cefalu W, Greenway F, Waguespack C, King E, Fry G, Dragg A, Gildersleeve B, Arceneaux J, Haynes N, Thomassie A, Pavlionis M, Bourgeois B, Hazlett C, Mudaliar S, Henry R, Boeder S, Pettus J, Diaz E, Garcia-Acosta D, Maggs S, DeLue C, Stallings A, Castro E, Hernandez S, Krakoff J, Curtis J, Killean T, Khalid M, Joshevama E, Diaz E, Martin D, Tsingine K, Karshner T, Albu J, Pi-Sunyer F, Frances S, Maggio C, Ellis E, Bastawrose J, Gong X, Banerji M, August P, Lee M, Lorber D, Brown N, Josephson D, Thomas L, Tsovian M, Cherian A, Jacobson M, Mishko M, Kirkman M, Buse J, Dostou J, Machineni S, Young L, Bergamo K, Goley A, Kerr J, Largay J, Guarda S, Cuffee J, Culmer D, Fraser R, Almeida H, Coffer S, Debnam E, Kiker L, Morton S, Josey K, Fuller G, Garvey W, Cherrington A, Dyer D, Lawson M, Griffith O, Agne A, McCullars S, Cohen R, Craig J, Rogge M, Burton K, Kersey K, Wilson C, Lipp S, Vonder Meulen M, Adkins C, Onadeko T, Rasouli N, Baker C, Schroeder E, Razzaghi M, Lyon C, Penaloza R, Underkofler C, Lorch R, Douglass S, Steiner S, Sivitz W, Cline E, Knosp L, McConnell J, Lowe T, Herman W, Pop-Busui R, Tan M, Martin C, Waltje A, Katona A, Goodhall L, Eggleston R, Kuo S, Bojescu S, Bule S, Kessler N, LaSalle E, Whitley K, Seaquist E, Bantle A, Harindhanavudhi T, Kumar A, Redmon B, Bantle J, Coe M, Mech M, Taddese A, Lesne L, Smith S, Desouza C, Kuechenmeister L, Shivaswamy V, Burbach S, Rodriguez M, Seipel K, Alfred A, Morales A, Eggert J, Lord G, Taylor W, Tillson R, Schade D, Adolphe A, Burge M, Duran-Valdez E, Martinez J, Bancroft A, Kunkel S, Ali Jamaleddin Ahmad F, Hernandez McGinnis D, Pucchetti B, Scripsick E, Zamorano A, DeFronzo R, Cersosimo E, Abdul-Ghani M, Triplitt C, Juarez D, Mullen M, Garza R, Verastiqui H, Wright K, Puckett C, Raskin P, Rhee C, Abraham S, Jordan L, Sao S, Morton L, Smith O, Osornio Walker L, Schnurr-Breen L, Ayala R, Kreymer R, Sturgess D, Utzschneider K, Kahn S, Alarcon-Casas L, Wright L, Boyko E, Tsai E, Trence D, Trikudanathan S, Fattaleh B, Montgomery B, Atkinson K, Kozedub A, Concepcion T, Moak C, Prikhodko N, Rhothisen S, Elasy T, Martin S, Shackelford L, Goidel R, Hinkle N, Lovell C, Myers J, Lipps Hogan J, McGill J, Salam M, Schweiger T, Kissel S, Recklein C, Clifton M, Tamborlane W, Camp A, Gulanski B, Inzucchi S, Pham K, Alguard M, Gatcomb P, Lessard K, Perez M, Iannone L, Magenheimer E, Montosa A, Burch H, Bremer A, Fradkin J, Nathan D, Lachin J, Krause-Steinrauf H, Younes N, Backman M, Bebu I, Butera N, Buys C, Fagan Murphy A, Gao Y, Ghosh A, Gramzinski M, Kazemi E, Hall S, Legowski E, Suratt C, Tripputi M, Arey A, Bethepu J, Lund C, Mangat Dhaliwal P, McGee P, Mesimer E, Ngo L, Steffes M, Seegmiller J, Saenger A, Arends V, Gabrielson D, Conner T, Warren S, Day J, Huminik J, Scrymgeour A, Soliman E, Pokharel Y, Zhang Z, Campbell C, Hu J, Keasler L, Hensley S, Li Y, Herman W, Kuo S, Martin C, Waltje A, Mihalcea R, Min D, Perez-Rosas V, Prosser L, Resnicow K, Ye W, Shao H, Zhang P, Luchsinger J, Sanchez D, Assuras S, Groessl E, Sakha F, Chong H, Hillery N, Everett B, Abdouch I, Bahtiyar G, Brantley P, Broyles F, Canaris G, Copeland P, Craine J, Fein W, Gliwa A, Hope L, Lee M, Meiners R, Meiners V, O’Neal H, Park J, Sacerdote A, Sledge E, Soni L, Steppel-Reznik J, Turchin A, Brooks-Worrell B, Hampe C, Newgard C, Palmer J, Shojaie A, Higgins J, Fischer L, Golden S, Gonzalez J, Naik A, Walker E, Doner Lotenberg L, Gallivan J, Lim J, Tuncer D, Behringer-Massera S. Clinical and Metabolic Characterization of Adults With Type 2 Diabetes by Age in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) Cohort. Diabetes Care 2022, 45: 1512-1521. PMID: 40315175, PMCID: PMC9375440, DOI: 10.2337/dc21-2659.
- INZUCCHI S, BHATT D, PITT B, SZAREK M, CANNON C, LEWIS J, RIDDLE M, KOSIBOROD M, CHERNEY D, DWYER J, SCIRICA B, BAILEY C, BANKS P, DIAZ R, RAY K, UDELL J, LOPES R, LEITER L, STEG P. 864-P: Glycemic Control across eGFR Categories with the Dual SGLT1 and 2 Inhibitor Sotagliflozin in SCORED. Diabetes 2022, 71 DOI: 10.2337/db22-864-p.
- Sharma A, Inzucchi S, Testani J, Ofstad A, Fitchett D, Mattheus M, Verma S, Zannad F, Wanner C, Kraus B, Wagner-Golbs A. Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2022, 17: s31-s32. DOI: 10.1055/s-0042-1746295.
- Ferreira J, Inzucchi S, Zinman B, Mattheus M, Meinicke T, Steubl D, Wanner C, Gotsch U. Effects of empagliflozin on uric acid levels and gout: observations from the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2022, 17: s62-s62. DOI: 10.1055/s-0042-1746380.
- Anam A, Inzucchi S. Newer Glucose-Lowering Medications and Potential Role in Metabolic Management of PCOS. 2022, 527-553. DOI: 10.1007/978-3-030-92589-5_26.
- Sharma A, Inzucchi S, Testani J, Ofstad A, Fitchett D, Mattheus M, Verma S, Zannad F, Wanner C, Kraus B. Association Of Kidney And Cardiovascular Outcomes: Insights From The Empagliflozin Cardiovascular Outcome Event Trial In Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) Trial. Journal Of Cardiac Failure 2022, 28: s103. DOI: 10.1016/j.cardfail.2022.03.262.
- Docherty K, Anand I, Chiang C, Chopra V, Desai A, Kitakaze M, Verma S, Vinh P, Inzucchi S, Køber L, Kosiborod M, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjöstrand M, Solomon S, Langkilde A, Jhund P, McMurray J. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. JACC Asia 2022, 2: 139-153. PMID: 36339117, PMCID: PMC9627879, DOI: 10.1016/j.jacasi.2022.02.004.
- Leasure A, Acosta J, Schwartz A, Forman R, Sharma R, de Havenon A, Falcone G, Inzucchi S, Kernan W, Sheth K. WORSE VASCULAR RISK FACTOR CONTROL IN PATIENTS WITH STROKE COMPARED TO PATIENTS WITH MYOCARDIAL INFARCTION. Journal Of The American College Of Cardiology 2022, 79: 1504. DOI: 10.1016/s0735-1097(22)02495-0.
- Brooks-Worrell B, Hampe C, Hattery E, Palomino B, Zangeneh S, Utzschneider K, Kahn S, Larkin M, Johnson M, Mather K, Younes N, Rasouli N, Desouza C, Cohen R, Park J, Florez H, Valencia W, Shojaie A, Palmer J, Balasubramanyam A, Crandall J, McKee M, Brown-Friday J, Xhori E, Ballentine-Cargill K, Duran S, Lukin J, Beringher S, Gonzalez de la Torre S, Phillips L, Burgess E, Olson D, Rhee M, Wilson P, Raines T, Costello J, Gullett C, Maher-Albertelli M, Morehead F, Mungara R, Person S, Savoye L, Sibymon M, Tanukonda S, White C, Holloway L, Adams C, Ross A, Balasubramanyam A, Gonzalez Hattery E, Gaba R, Montes G, Wright C, Hollander P, Roe E, Uy A, Burt P, Estrada L, Chionh K, Ismail-Beigi F, Falck-Ytter C, Sayyed Kassem L, Sood A, Tiktin M, Cramer B, Iacoboni J, Kononets M, Kulow T, Newman C, Stancil K, Sanders C, Tucker L, Werner A, Krol A, McPhee G, Patel C, Colosimo L, Goland R, Pring J, Kringas P, Tejada J, Hausheer C, Schneier H, Gumpel K, Kirpitch A, Green J, AbouAssi H, Chatterjee R, Feinglos M, English Jones J, Khan S, Kimpel J, Zimmer R, Furst M, Satterwhite B, Thacker C, Evans Kreider K, Mather K, Lteif A, Hamilton T, Patel N, Riera G, Jackson M, Pirics V, Howard D, Aguillar D, Hurt S, Bergenstal R, Carlson A, Martens T, Johnson M, Hill R, Hyatt J, Jensen C, Madden M, Martin D, Willis H, Konerza W, Passi R, Kleeberger K, Fortmann S, Herson M, Mularski K, Glauber H, Prihoda J, Ash B, Carlson C, Ramey P, Schield E, Torgrimson-Ojerio B, Arnold K, Kauffman B, Panos E, Sahnow S, Bays K, Cook J, Gluth J, Sasaki D, Schell K, Criscola J, Friason C, Jones S, Nazarov S, Barzilay J, Rassouli N, Puttnam R, Curtis M, Stokes K, Hollis B, Sanders-Jones C, Nelson R, El-Haqq Z, Kolli A, Tran T, Wexler D, Larkin M, Meigs J, Dushkin A, Rocchio G, Chambers B, Yepes M, Steiner B, Dulin H, Cayford M, DeManbey A, Gurry L, Hillard M, Martin K, Stevens C, Thangthaeng N, Kochis R, Raymond E, Ripley V, Park J, Aroda V, Ghazi A, Loveland A, Hurtado M, Kuhn A, Mofor F, Florez H, Valencia W, Marks J, Oropesa-Gonzalez L, Riccio Veliz A, Nieto-Martinez R, Gutt M, Ahmann A, Aby-Daniel D, Joarder F, Morimoto V, Sprague C, Yamashita D, Cady N, Kirchhoff P, Rivera-Eschright N, Adducci J, Morales Gomez B, Goncharova A, Hox S, Petrovitch H, Matwichyna M, Jenkins V, Bermudez N, Ishii R, Hsia D, Cefalu W, Greenway F, Waguespack C, King E, Haynes N, Thomassie A, Bourgeois B, Hazlett C, Henry R, Mudaliar S, Boeder S, Pettus J, Diaz E, DeLue C, Castro E, Hernandez S, Krakoff J, Curtis J, Killean T, Joshevama E, Diaz E, Martin D, Karshner T, Albu J, Pi-Sunyer F, Frances S, Maggio C, Ellis E, Bastawrose J, Gong X, Banerji M, August P, Lorber D, Brown N, Josephson D, Thomas L, Tsovian M, Cherian A, Jacobson M, Mishko M, Kirkman M, Bergamo K, Buse J, Dostou J, Young L, Goley A, Kerr J, Largay J, Guarda S, Cuffee J, Culmer D, Fraser R, Almeida H, Coffer S, Debnam E, Kiker L, Morton S, Josey K, Fuller G, Garvey W, Cherrington A, Golson D, Griffith O, Robertson M, Agne A, McCullars S, Cohen R, Craig J, Kersey K, Rogge M, Wilson C, Burton K, Lipp S, Vonder Meulen M, Rasouli N, Schroeder E, Steiner S, Baker C, Underkofler C, Douglass S, Sivitz W, Cline E, Knosp L, McConnell J, Lowe T, Herman W, Pop-Busui R, Tan M, Martin C, Waltje A, Goodhall L, Eggleston R, Kuo S, Bule S, Kessler N, LaSalle E, Seaquist E, Bantle A, Kumar A, Redmon B, Bantle J, Harindhanavudhi T, Coe M, Mech M, Taddese A, Lesne L, Smith S, Desouza C, Kuechenmeister L, Shivaswamy V, Morales A, Rodriguez M, Seipel K, Alfred A, Eggert J, Lord G, Taylor W, Tillson R, Schade D, Adolphe A, Burge M, Duran-Valdez E, Martinez J, Hernandez McGinnis D, Pucchetti B, Scripsick E, DeFronzo R, Cersosimo E, Abdul-Ghani M, Triplitt C, Verastiqui H, Garza R, Wright K, Puckett C, Raskin P, Rhee C, Abraham S, Jordan L, Sao S, Morton L, Smith O, Osornio Walker L, Schnurr-Breen L, Ayala R, Kraymer R, Sturgess D, Utzschneider K, Kahn S, Alarcon-Casas Wright L, Boyko E, Tsai E, Trence D, Fattaleh B, Montgomery B, Atkinson K, Concepcion T, Kozedub A, Moak C, Rhothisen S, Elasy T, Martin S, Shackelford L, Goidel R, Hinkle N, Lipps Hogan J, Lovell C, Myers J, McGill J, Salam M, Kissel S, Schweiger T, Recklein C, Tamborlane W, Gatcomb P, Camp A, Gulanski B, Inzucchi S, Pham K, Alguard M, Lessard K, Perez M, Magenheimer E, Montoza A, Nathan D, Lachin J, Buse J, Kahn S, Krause-Steinrauf H, Larkin M, Wexler D, Burch H, Linder B, Bremer A, Lachin J, Younes N, Backman M, Bebu I, Buys C, Fagan Murphy A, Gao Y, Gramzinski M, Hall S, Legowski E, Arey A, Bethepu J, Lund C, Mangat Dhaliwal P, McGee P, Mesimer E, Ngo L, Steffes M, Seegmiller J, Saenger A, Arends V, Gabrielson D, Conner T, Stuart W, Day J, Scrymgeour A, Soliman E, Zhang Z, Campbell C, Hu J, Keasler L, Hensley S, Li Y, Herman W, Martin C, Waltje A, Mihalcea R, Perez-Rosas V, Prosser L, Resnicow K, Ye W, Shao H, Zhang P, Luchsinger J, Sanchez D, Burch H, Bremer A, Linder B, Fradkin J, Groessl E, Chong H, Hillery N, Abdouch I, Brantley P, Broyles F, Canaris G, Copeland P, Craine J, Fein W, Lee M, Meiners R, Meiners V, O’Neal H, Park J, Sledge E, Steppel-Resnick J, Turchin A, Brooks-Worrell B, Hampe C, Palmer J, Shojaie A, Higgins J, Fischer L, Golden S, Gonzalez J, Naik A, Walker E, Doner Lotenberg L, Gallivan J, Lim J, Tuncer D, Behringer-Massera S. Islet Autoimmunity is Highly Prevalent and Associated With Diminished β-Cell Function in Patients With Type 2 Diabetes in the Grade Study. Diabetes 2022, 71: 1261-1271. PMID: 35061024, PMCID: PMC9375448, DOI: 10.2337/db21-0590.
- Ding Q, Qin L, Wojeck B, Inzucchi SE, Ibrahim A, Bravata DM, Strohl KP, Yaggi HK, Zinchuk AV. Polysomnographic Phenotypes of Obstructive Sleep Apnea and Incident Type 2 Diabetes: Results from the DREAM Study. Annals Of The American Thoracic Society 2021, 18: 2067-2078. PMID: 34185617, PMCID: PMC8641817, DOI: 10.1513/annalsats.202012-1556oc.
- Holt E, Inzucchi S. Update in Endocrinology. 2021, 105: i. DOI: 10.1016/s0025-7125(21)00125-5.
- Cowan L, Adamson C, Docherty K, Inzucchi S, Koeber L, Kosiborod M, Martinez F, Ponikowski P, Sabatine M, Solomon S, Bengtsson O, Sjostrand M, Langkilde A, Jhund P, McMurray J. Elevated markers of liver function are associated with poorer outcomes in HFREF: an analysis of DAPA-HF. European Heart Journal 2021, 42: ehab724.0911. DOI: 10.1093/eurheartj/ehab724.0911.
- Hadjadj S, Kahl S, Ofstad A, Zinman B, Wanner C, Schüler E, Inzucchi S, Roden M. Effets de l’empagliflozine sur les marqueurs de la stéatose et de la fibrose hépatique et lien avec les résultats cardiorénaux dans l’étude EMPA-REG OUTCOME. Annales D Endocrinologie 2021, 82: 269-270. DOI: 10.1016/j.ando.2021.08.045.
- Sharma A, Inzucchi S, Testani J, Ofstad A, Fitchett D, Mattheus M, Verma S, Zannad F, Wanner C, Kraus B. ASSOCIATION OF KIDNEY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL. Canadian Journal Of Cardiology 2021, 37: s62-s63. DOI: 10.1016/j.cjca.2021.07.130.
- Wanner C, Nangaku M, Kraus B, Zinman B, Mattheus M, Ohneberg K, Hajmessaoud N, Zaoui P, Schmoor C, Inzucchi S. Médiateurs de l’effet du traitement par empagliflozine sur les résultats rénaux dans l’essai EMPA-REG OUTCOME. Néphrologie & Thérapeutique 2021, 17: 339. DOI: 10.1016/j.nephro.2021.07.233.
- Luchsinger J, Younes N, Manly J, Barzilay J, Valencia W, Larkin M, Falck-Ytter C, Krause-Steinrauf H, Pop-Busui R, Florez H, Seaquist E, Crandall J, McKee M, Brown-Friday J, Xhori E, Ballentine-Cargill K, Duran S, Lukin J, Beringher S, Gonzalez de la torre S, Phillips L, Burgess E, Olson D, Rhee M, Wilson P, Raines T, Costello J, Gullett C, Maher-Albertelli M, Morehead F, Mungara R, Person S, Savoye L, Sibymon M, Tanukonda S, White C, Holloway L, Adams C, Ross A, Balasubramanyam A, Gonzalez E, Wright C, Hollander P, Roe E, Uy A, Burt P, Estrada L, Chionh K, Ismail-Beigi F, Falck-Ytter C, Sayyed Kassem L, Sood A, Tiktin M, Cramer B, Iacoboni J, Kononets M, Kulow T, Newman C, Stancil K, Sanders C, Tucker L, Werner A, Krol A, McPhee G, Patel C, Colosimo L, Goland R, Pring J, Kringas P, Tejada J, Hausheer C, Schneier H, Gumpel K, Kirpitch A, Green J, AbouAssi H, Chatterjee R, Feinglos M, English Jones J, Khan S, Kimpel J, Zimmer R, Furst M, Satterwhite B, Thacker C, Evans Kreider K, Mather K, Lteif A, Hamilton T, Patel N, Riera G, Jackson M, Pirics V, Howard D, Aguillar D, Hurt S, Bergenstal R, Carlson A, Martens T, Johnson M, Hill R, Hyatt J, Jensen C, Madden M, Martin D, Willis H, Konerza W, Passi R, Kleeberger K, Fortmann S, Herson M, Mularski K, Glauber H, Prihoda J, Ash B, Carlson C, Ramey P, Schield E, Torgrimson-Ojerio B, Arnold K, Kauffman B, Panos E, Sahnow S, Bays K, Cook J, Gluth J, Sasaki D, Schell K, Criscola J, Friason C, Jones S, Nazarov S, Barzilay J, Rassouli N, Puttnam R, Curtis M, Stokes K, Hollis B, Sanders-Jones C, Nelson R, El-Haqq Z, Kolli A, Tran T, Wexler D, Larkin M, Meigs J, Dushkin A, Rocchio G, Chambers B, Yepes M, Steiner B, Dulin H, Cayford M, DeManbey A, Gurry L, Hillard M, Martin K, Stevens C, Thangthaeng N, Kochis R, Raymond E, Ripley V, Park J, Aroda V, Ghazi A, Loveland A, Hurtado M, Kuhn A, Mofor F, Florez H, Valencia W, Marks J, Oropesa-Gonzalez L, Riccio Veliz A, Nieto-Martinez R, Gutt M, Ahmann A, Aby-Daniel D, Joarder F, Morimoto V, Sprague C, Yamashita D, Cady N, Kirchhoff P, Rivera- Eschright N, Adducci J, Morales Gomez B, Goncharova A, Hox S, Petrovitch H, Matwichyna M, Jenkins V, Bermudez N, Ishii R, Hsia D, Cefalu W, Greenway F, Waguespack C, King E, Haynes N, Thomassie A, Bourgeois B, Hazlett C, Henry R, Mudaliar S, Boeder S, Pettus J, Diaz E, DeLue C, Castro E, Hernandez S, Krakoff J, Curtis J, Killean T, Joshevama E, Diaz E, Martin D, Karshner T, Albu J, Pi-Sunyer F, Frances S, Maggio C, Ellis E, Bastawrose J, Gong X, Banerji M, August P, Lorber D, Brown N, Josephson D, Thomas L, Tsovian M, Cherian A, Jacobson M, Mishko M, Kirkman M, Bergamo K, Buse J, Dostou J, Young L, Goley A, Kerr J, Largay J, Guarda S, Cuffee J, Culmer D, Fraser R, Almeida H, Coffer S, Debnam E, Kiker L, Morton S, Josey K, Fuller G, Garvey W, Cherrington A, Golson D, Griffith O, Robertson M, Agne A, McCullars S, Cohen R, Craig J, Kersey K, Rogge M, Wilson C, Burton K, Lipp S, Vonder Meulen M, Rasouli N, Schroeder E, Steiner S, Baker C, Underkofler C, Douglass S, Sivitz W, Cline E, Knosp L, McConnell J, Lowe T, Herman W, Pop-Busui R, Tan M, Martin C, Waltje A, Goodhall L, Eggleston R, Kuo S, Bule S, Kessler N, LaSalle E, Seaquist E, Bantle A, Kumar A, Redmon B, Bantle J, Harindhanavudhi T, Coe M, Mech M, Taddese A, Lesne L, Smith S, Desouza C, Kuechenmeister L, Shivaswamy V, Morales A, Rodriguez M, Seipel K, Alfred A, Eggert J, Lord G, Taylor W, Tillson R, Schade D, Adolphe A, Burge M, Duran-Valdez E, Martinez J, Hernandez McGinnis D, Pucchetti B, Scripsick E, DeFronzo R, Cersosimo E, Abdul-Ghani M, Triplitt C, Verastiqui H, Garza R, Wright K, Puckett C, Raskin P, Rhee C, Abraham S, Jordan L, Sao S, Morton L, Smith O, Osornio Walker L, Schnurr-Breen L, Ayala R, Kraymer R, Sturgess D, Utzschneider K, Kahn S, Alarcon-Casas Wright L, Boyko E, Tsai E, Trence D, Fattaleh B, Montgomery B, Atkinson K, Concepcion T, Kozedub A, Moak C, Rhothisen S, Elasy T, Martin S, Shackelford L, Goidel R, Hinkle N, Lipps Hogan J, Lovell C, Myers J, McGill J, Salam M, Kissel S, Schweiger T, Recklein Carol Tamborlane W, Gatcomb P, Camp A, Gulanski B, Inzucchi S, Pham K, Alguard M, Lessard K, Perez M, Magenheimer E, Montoza A, Nathan D, Lachin J, Buse J, Kahn S, Krause-Steinrauf H, Larkin M, Tiktin M, Wexler D, Burch H, Linder B, Bremer A, Younes N, Backman M, Bebu I, Buys C, Fagan Murphy A, Gao Y, Gramzinski M, Hall S, Legowski E, Arey A, Bethepu J, Lund C, Mangat Dhaliwal P, McGee P, Mesimer E, Ngo L, Steffes M, Seegmiller J, Saenger A, Arends V, Gabrielson D, Conner T, Warren S, Day J, Scrymgeour A, Soliman E, Zhang Z, Campbell C, Hu J, Keasler L, Hensley S, Li Y, Herman W, Martin C, Waltje A, Kuo S, Mihalcea R, Perez-Rosas V, Prosser L, Resnicow K, Ye W, Shao H, Zhang P, Luchsinger J, Sanchez D, Burch H, Bremer A, Linder B, Fradkin J, Groessl E, Chong H, Hillery N, Abdouch I, Brantley P, Broyles F, Canaris G, Copeland P, Craine J, Fein W, Lee M, Meiners R, Meiners V, O’Neal H, Park J, Sledge E, Steppel-Resnick J, Turchin A, Brooks-Worrell B, Hampe C, Newgard C, Palmer J, Shojaie A, Higgins J, Fischer L, Golden S, Gonzalez J, Naik A, Walker E, Doner Lotenberg L, Gallivan J, Lim J, Tuncer D, Behringer-Massera S. Association of Glycemia, Lipids, and Blood Pressure With Cognitive Performance in People With Type 2 Diabetes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care 2021, 44: 2286-2292. PMID: 34285097, PMCID: PMC8740937, DOI: 10.2337/dc20-2858.
- ATHONVARANGKUL D, BAK L, ZHENG C, D’AMBROSI J, SINER J, HONIDEN S, INZUCCHI S. 873-P: Modified Insulin Infusion Protocol for COVID-19 Patients Is Safe and Effective for Controlling Hyperglycemia. Diabetes 2021, 70 DOI: 10.2337/db21-873-p.
- INZUCCHI S, WANNER C, FITCHETT D, ZINMAN B, ANKER S, MATTHEUS M, VEDIN O, HANTEL S, LUND S. 790-P: Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalization in EMPA-REG OUTCOME. Diabetes 2021, 70 DOI: 10.2337/db21-790-p.
- KAHL S, OFSTAD A, ZINMAN B, WANNER C, SCHUELER E, INZUCCHI S, RODEN M. 319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial. Diabetes 2021, 70 DOI: 10.2337/db21-319-or.
- Vaduganathan M, Sattar N, Fitchett D, George J, Ofstad A, Verma S, Mattheus M, Wanner C, Inzucchi, Zinman B, Butler J. Empagliflozin facilitates sustained insulin dose reductions in patients with type 2 diabetes and cardiovascular disease: the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2021, 16: s18-s19. DOI: 10.1055/s-0041-1727336.
- Fitchett D, Inzucchi, Zinman B, Wanner C, Anker S, Pocock S, Kaspers S, George J, Johansen O, Jamal W, Hantel S, Lund S. Empagliflozin reduces the total burden of cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2021, 16: s51. DOI: 10.1055/s-0041-1727464.
- Kraus B, Weir, Bakris G, Mattheus M, Cherney D, Sattar N, Heerspink H, Ritter I, von Eynatten M, Zinman B, Inzucchi, Wanner C, Koitka-Webe A. Cardiovascular and kidney implications of the initial response in estimated glomerular filtration rate to sodium glucose cotransporter-2 inhibition with empagliflozin: the ‘eGFR dip’ in EMPA-REG OUTCOME. Diabetologie Und Stoffwechsel 2021, 16: s52. DOI: 10.1055/s-0041-1727466.
- Inzucchi, Zinman B, Wanner C, Fitchett D, Anker S, Pocock S, Kaspers S, George J, Johansen O, Jamal W, Hantel S, Lund S. Empagliflozin Reduces the Total Burden of All-cause Hospitalisations and All-cause Mortality in the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2021, 16: s51-s52. DOI: 10.1055/s-0041-1727465.
- Ding Q, Qin L, Wojeck B, Inzucchi S, Ibrahim A, Bravata D, Strohl K, Yaggi H, Zinchuk A. Associations Between Polysomnographic Phenotypes of Obstructive Sleep Apnea and Incident Type 2 Diabetes. 2021, a4679-a4679. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4679.
- Wojeck B, Gossmann M, Zeidan A, Inzucchi S. Acute Myeloid Leukemia Leading to Central Diabetes Insipidus. Journal Of The Endocrine Society 2021, 5: a570-a571. PMCID: PMC8090637, DOI: 10.1210/jendso/bvab048.1163.
- Lupsa B, Inzucchi S. Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic Syndrome. Contemporary Endocrinology 2021, 9-25. DOI: 10.1007/978-3-030-67455-7_2.
- Hong CS, Omuro A, An Y, Inzucchi S, Kohli AA, McGuone D, Vining EM, Omay SB, Erson-Omay E. Sporadic adamantinomatous craniopharyngioma with double-hit somatic APC mutations. Neuro-Oncology Advances 2021, 3: vdab124. PMID: 34549183, PMCID: PMC8446933, DOI: 10.1093/noajnl/vdab124.
- Hamilton A, Inzucchi S, Wanner C, Fitchett D, Zinman B, Anker S, Mattheus M, Vedin O, Hantel S, Lund S. Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalisation in EMPA-REG OUTCOME. Heart Lung And Circulation 2021, 30: s221-s222. DOI: 10.1016/j.hlc.2021.06.281.
- Hamilton A, Fitchett D, Zinman B, Inzucchi S, Wanner C, Anker S, Pocock S, Kaspers S, Mattheus M, Vedin O, Hantel S, Lund S. Effect of Empagliflozin on Total Events of Myocardial Infarctions by Subtype in the EMPA-REG OUTCOME Trial. Heart Lung And Circulation 2021, 30: s220-s221. DOI: 10.1016/j.hlc.2021.06.278.
- Hamilton A, Sharma A, Inzucchi S, Testani J, Ofstad A, Fitchett D, Mattheus M, Verma S, Zannad F, Wanner C, Kraus B. Association of Kidney and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus: Insights From the EMPA-REG OUTCOME Trial. Heart Lung And Circulation 2021, 30: s212-s213. DOI: 10.1016/j.hlc.2021.06.259.
- Yaggi H, Eliasson B, Kasai T, Marx N, Zinman B, Inzucchi S, Wanner C, Zwiener I, Wojeck B, Neeland I, Johansen O. Obstructive sleep apnoe and cardiovascular, heart failure and mortality outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial. European Heart Journal 2020, 41: ehaa946.2883. DOI: 10.1093/ehjci/ehaa946.2883.
- Kristensen S, Docherty K, Jhund P, Bengtsson O, Demets D, Inzucchi S, Kober L, Kosiborod M, Langkilde A, Martinez F, Ponikowski P, Sabatine M, Sjostrand M, Solomon S, McMurray J. Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF. European Heart Journal 2020, 41: ehaa946.0939. DOI: 10.1093/ehjci/ehaa946.0939.
- Docherty K, Jhund P, Bengtsson O, Demets D, Inzucchi S, Kober L, Kosiborod M, Langkilde A, Lindholm D, Martinez F, Ponikowski P, Sabatine M, Sjostrand M, Solomon S, McMurray J. The effect of dapagliflozin across the spectrum of baseline risk: a post-hoc analysis of DAPA-HF. European Heart Journal 2020, 41: ehaa946.0931. DOI: 10.1093/ehjci/ehaa946.0931.
- Dewan P, Jhund P, Bengtsson O, Demets D, Inzucchi S, Kober L, Kosiborod M, Langkilde A, Lindholm D, Martinez F, Ponikowski P, Sabatine M, Sjostrand M, Solomon S, McMurray J. The effect of dapagliflozin in patients with HFrEF and COPD: a post-hoc analysis of DAPA-HF. European Heart Journal 2020, 41: ehaa946.0932. DOI: 10.1093/ehjci/ehaa946.0932.
- Verma S, Mazer C, Inzucchi S, Wanner C, Ofstad A, Johansen O, Zwiener I, George J, Butler J, Zinman B. Impact of polyvascular disease and renal dysfunction on cardiovascular outcomes in diabetes: post hoc analyses from EMPA-REG OUTCOME. European Heart Journal 2020, 41: ehaa946.3352. DOI: 10.1093/ehjci/ehaa946.3352.
- Kristensen S, Docherty K, Jhund P, Bengtsson O, Inzucchi S, Kosiborod M, Langkilde A, Martinez F, Ponikowski P, Sabatine M, Sjostrand M, Solomon S, McMurray J. Dapagliflozin Reduces the Risk of Hyperkalaemia in Patients with Heart Failure and Reduced Ejection Fraction: A Secondary Analysis from DAPA-HF. Journal Of The American Society Of Nephrology 2020, 31: 21-21. DOI: 10.1681/asn.20203110s121b.
- Docherty KF, Jhund PS, Anand I, Bengtsson O, Böhm M, de Boer RA, DeMets DL, Desai AS, Drozdz J, Howlett J, Inzucchi SE, Johanson P, Katova T, Køber L, Kosiborod MN, Langkilde AM, Lindholm D, Martinez FA, Merkely B, Nicolau J, O’Meara E, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Tereshchenko S, Verma S, McMurray JJV. Effect of Dapagliflozin on Outpatient Worsening of Patients with Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. Circulation 2020, 142: 1623-1632. PMID: 32883108, PMCID: PMC7580857, DOI: 10.1161/circulationaha.120.047480.
- Jackson AM, Dewan P, Anand IS, Bělohlávek J, Bengtsson O, de Boer RA, Böhm M, Boulton DW, Chopra VK, DeMets DL, Docherty KF, Dukát A, Greasley PJ, Howlett JG, Inzucchi SE, Katova T, Køber L, Kosiborod MN, Langkilde AM, Lindholm D, Ljungman CEA, Martinez FA, O’Meara E, Sabatine MS, Sjöstrand M, Solomon SD, Tereshchenko S, Verma S, Jhund PS, McMurray JJV. Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. Circulation 2020, 142: 1040-1054. PMID: 32673497, PMCID: PMC7664959, DOI: 10.1161/circulationaha.120.047077.
- LIPSKA K, DOYLE M, CENGIZ E, DROZDOWICZ B, GILL T, MURPHY T, INZUCCHI S. 380-P: Hypoglycemia among Nursing Home Residents with Diabetes Detected by Continuous Glucose Monitoring (CGM). Diabetes 2020, 69 DOI: 10.2337/db20-380-p.
- PRATLEY R, BAUER R, INZUCCHI S, KHUNTI K, KREINER E, LAURSEN P, MEIER J. 927-P: Effect of Oral Semaglutide with or without Background SGLT2i in Patients with T2D: Subgroup Analysis of PIONEER 4. Diabetes 2020, 69 DOI: 10.2337/db20-927-p.
- VADUGANATHAN M, SATTAR N, FITCHETT D, OFSTAD A, BRUECKMANN M, GEORGE J, VERMA S, MATTHEUS M, WANNER C, INZUCCHI S, ZINMAN B, BUTLER J. 30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME. Diabetes 2020, 69 DOI: 10.2337/db20-30-or.
- VERMA S, LEITER L, SHARMA A, ZINMAN B, MATTHEUS M, FITCHETT D, GEORGE J, OFSTAD A, WANNER C, INZUCCHI S. 28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME. Diabetes 2020, 69 DOI: 10.2337/db20-28-or.
- INZUCCHI S, DOCHERTY K, KOBER L, KOSIBOROD M, MARTINEZ F, PONIKOWSKI P, SABATINE M, SOLOMON S, BELOHLAVEK J, BÖHM M, CHIANG C, DE BOER R, DIEZ M, DUKAT A, LJUNGMAN C, VERMA S, DEMETS D, BENGTSSON O, LANGKILDE A, SJÖSTRAND M, JHUND P, MCMURRAY J. 271-OR: ADA Presidents’ Select Abstract: Effect of Dapagliflozin on the Incidence of Diabetes: A Prespecified Exploratory Analysis from DAPA-HF. Diabetes 2020, 69 DOI: 10.2337/db20-271-or.
- BAK L, FANDEL T, BOZZO J, DEWITT M, CHEN P, PANDO R, FERRO L, KAPLAN R, HENDRICKSON K, AMPORT S, SUSSMAN L, INZUCCHI S. 23-OR: EHR-Based Blood Glucose Alerts Improve Inpatient Glycemic Control at a Large Academic Medical Center. Diabetes 2020, 69 DOI: 10.2337/db20-23-or.
- INZUCCHI S, KRAUS B, WEIR M, BAKRIS G, MATTHEUS M, CHERNEY D, SATTAR N, HEERSPINK H, RITTER I, EYNATTEN M, ZINMAN B, WANNER C, KOITKA-WEBER A. 132-LB: Implications of Initial EGFR Response to Empagliflozin Treatment Effects. Diabetes 2020, 69 DOI: 10.2337/db20-132-lb.
- INZUCCHI S, ZINMAN B, WANNER C, FITCHETT D, ANKER S, POCOCK S, KASPERS S, GEORGE J, JOHANSEN O, JAMAL W, HANTEL S, LUND S. 131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome. Diabetes 2020, 69 DOI: 10.2337/db20-131-lb.
- NEELAND I, ELIASSON B, KASAI T, MARX N, ZINMAN B, INZUCCHI S, WANNER C, ZWIENER I, WOJECK B, YAGGI H, JOHANSEN O. 1128-P: Empagliflozin and Obstructive Sleep Apnea (OSA): Exploratory Analysis from the EMPA-REG OUTCOME Trial. Diabetes 2020, 69 DOI: 10.2337/db20-1128-p.
- DOCHERTY K, INZUCCHI S, KOSIBOROD M, KOBER L, LANGKILDE A, MARTINEZ F, BENGTSSON O, DEMETS D, SJÖSTRAND M, SABATINE M, SOLOMON S, JHUND P, MCMURRAY J. 1112-P: Does Background T2D Therapy Modify the Benefits of Dapagliflozin in Heart Failure? Analysis of the DAPA-HF Trial. Diabetes 2020, 69 DOI: 10.2337/db20-1112-p.
- Kraus B, Weir M, Bakris G, Mattheus M, Cherney D, Sattar N, Heerspink H, Ritter I, Von Eynatten M, Zinman B, Inzucchi S, Wanner C, Koitka-Weber A. LB005KIDNEY IMPLICATIONS OF THE INITIAL EGFR RESPONSE TO SGLT2 INHIBITION WITH EMPAGLIFLOZIN: THE ‘EGFR DIP’ IN EMPA-REG OUTCOME. Nephrology Dialysis Transplantation 2020, 35: gfaa146.lb005. DOI: 10.1093/ndt/gfaa146.lb005.
- Inzucchi S, Davies M, Khunti K, Trivedi P, George J, Zwiener I, Johansen O, Sattar N. MON-645 Association of Baseline Cardio-Metabolic Parameters on the Treatment Effects of Empagliflozin When Added to Metformin in Patients with T2D. Journal Of The Endocrine Society 2020, 4: mon-645. PMCID: PMC7209010, DOI: 10.1210/jendso/bvaa046.414.
- Athonvarangkul D, Hosier H, Wojeck B, Inzucchi S. SAT-258 Surprising Transformation of a Microprolactinoma to a Macroprolactinoma. Journal Of The Endocrine Society 2020, 4: sat-258. PMCID: PMC7207434, DOI: 10.1210/jendso/bvaa046.1057.
- Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett J, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Vinh PN, Schou M, Tereshchenko S, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Johanson P, Greasley PJ, Boulton D, Bengtsson O, Jhund PS, McMurray JJV. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA: The Journal Of The American Medical Association 2020, 323: 1353-1368. PMID: 32219386, PMCID: PMC7157181, DOI: 10.1001/jama.2020.1906.
- Buse J, Caprio S, Cefalu W, Ceriello A, Del Prato S, Inzucchi S, McLaughlin S, Phillips G, Robertson R, Rubino F, Kahn R, Kirkman M. Partial remission of diabetes mellitus (type 1 or type 2). 2020 DOI: 10.32388/d002ka.
- Buse J, Caprio S, Cefalu W, Ceriello A, Del Prato S, Inzucchi S, McLaughlin S, Phillips G, Robertson R, Rubino F, Kahn R, Kirkman M. Complete remission of diabetes mellitus (type 1 or type 2). 2020 DOI: 10.32388/bg3azp.
- Buse J, Caprio S, Cefalu W, Ceriello A, Del Prato S, Inzucchi S, McLaughlin S, Phillips G, Robertson R, Rubino F, Kahn R, Kirkman M. Remission of diabetes mellitus (type 1 or type 2). 2020 DOI: 10.32388/2q5q1f.
- Sivitz W, Phillips L, Wexler D, Fortmann S, Camp A, Tiktin M, Perez M, Craig J, Hollander P, Cherrington A, Aroda V, Tan M, Krakoff J, Rasouli N, Butera N, Younes N, Crandall J, Diane McKee M, Brown-Friday J, Xhori E, Ballentine-Cargill K, Duran S, Lukin J, Beringher S, Gonzalez de la torre S, Phillips L, Burgess E, Olson D, Rhee M, Wilson P, Stephanie Raines T, Costello J, Gullett C, Maher-Albertelli M, Morehead F, Mungara R, Person S, Savoye L, Sibymon M, Tanukonda S, Ann White C, Holloway L, Adams C, Ross A, Balasubramanyam A, Gonzalez E, Wright C, Hollander P, Roe E, Uy A, Burt P, Estrada L, Chionh K, Ismail-Beigi F, Falck-Ytter C, Sayyed Kassem L, Sood A, Tiktin M, Cramer B, Iacoboni J, Kononets M, Kulow T, Newman C, Stancil K, Sanders C, Tucker L, Werner A, Krol A, McPhee G, Patel C, Colosimo L, Goland R, Pring J, Kringas P, Tejada J, Hausheer C, Schneier H, Gumpel K, Kirpitch A, Green J, AbouAssi H, Chatterjee R, Feinglos M, English Jones J, Khan S, Kimpel J, Zimmer R, Furst M, Satterwhite B, Thacker C, Evans Kreider K, Mather K, Lteif A, Hamilton T, Patel N, Riera G, Jackson M, Pirics V, Howard D, Aguillar D, Hurt S, Bergenstal R, Carlson A, Martens T, Johnson M, Hill R, Hyatt J, Jensen C, Madden M, Martin D, Willis H, Konerza W, Passi R, Kleeberger K, Fortmann S, Herson M, Mularski K, Glauber H, Prihoda J, Ash B, Carlson C, Anne Ramey P, Schield E, Torgrimson-Ojerio B, Arnold K, Kauffman B, Panos E, Sahnow S, Bays K, Cook J, Gluth J, Sasaki D, Schell K, Criscola J, Friason C, Jones S, Nazarov S, Barzilay J, Rassouli N, Puttnam R, Curtis M, Stokes K, Hollis B, Sanders-Jones C, Nelson R, El-Haqq Z, Kolli A, Tran T, Wexler D, Mary L, Meigs J, Dushkin A, Rocchio G, Chambers B, Yepes M, Steiner B, Dulin H, Cayford M, DeManbey A, Gurry L, Hillard M, Martin K, Stevens C, Thangthaeng N, Kochis R, Raymond E, Ripley V, Park J, Aroda V, Ghazi A, Loveland A, Hurtado M, Kuhn A, Mofor F, Florez H, Valencia W, Marks J, Oropesa-Gonzalez L, Riccio Veliz A, Nieto-Martinez R, Gutt M, Ahmann A, Aby-Daniel D, Joarder F, Morimoto V, Sprague C, Yamashita D, Cady N, Kirchhoff P, Rivera-Eschright N, Adducci J, Gomez B, Goncharova A, Hox S, Petrovitch H, Matwichyna M, Jenkins V, Bermudez N, Ishii R, Hsia D, Cefalu W, Greenway F, Waguespack C, King E, Haynes N, Thomassie A, Bourgeois B, Hazlett C, Henry R, Mudaliar S, Boeder S, Pettus J, Diaz E, DeLue C, Castro E, Hernandez S, Krakoff J, Curtis J, Killean T, Joshevama E, Diaz E, Martin D, Karshner T, Albu J, Pi-Sunyer F, Frances S, Maggio C, Ellis E, Bastawrose J, Gong X, Ann Banerji M, August P, Lorber D, Brown N, Josephson D, Thomas L, Tsovian M, Cherian A, Jacobson M, Mishko M, Kirkman M, Bergamo K, Buse J, Dostou J, Young L, Goley A, Kerr J, Largay J, Guarda S, Cuffee J, Culmer D, Fraser R, Almeida H, Coffer S, Debnam E, Kiker L, Morton S, Josey K, Fuller G, Garvey W, Cherrington A, Golson D, Griffith O, Catherine Robertson M, Agne A, McCullars S, Cohen R, Craig J, Kersey K, Rogge M, Wilson C, Burton K, Lipp S, Vonder Meulen M, Rasouli N, Schroeder E, Steiner S, Baker C, Underkofler C, Douglass S, Sivitz W, Cline E, Knosp L, McConnell J, Lowe T, Herman W, Pop-Busui R, Tan M, Martin C, Waltje A, Goodhall L, Eggleston R, Kuo S, Bule S, Kessler N, LaSalle E, Seaquist E, Bantle A, Kumar A, Redmon B, Bantle J, Harindhanavudhi T, Coe M, Mech M, Taddese A, Lesne L, Smith S, Desouza C, Kuechenmeister L, Shivaswamy V, Laura Morales A, Rodriguez M, Seipel K, Alfred A, Eggert J, Lord G, Taylor W, Tillson R, Schade D, Adolphe A, Burge M, Duran-Valdez E, Martinez J, McGinnis D, Pucchetti B, Scripsick E, DeFronzo R, Cersosimo E, Abdul-Ghani M, Triplitt C, Verastiqui H, Irene Garza R, Wright K, Puckett C, Raskin P, Rhee C, Abraham S, Fan Jordan L, Sao S, Morton L, Smith O, Osornio Walker L, Schnurr-Breen L, Ayala R, Brian Kraymer R, Sturgess D, Utzschneider K, Kahn S, Alarcon-Casas Wright L, Boyko E, Tsai E, Trence D, Fattaleh B, Montgomery B, Atkinson K, Concepcion T, Kozedub A, Moak C, Rhothisen S, Elasy T, Martin S, Shackelford L, Goidel R, Hinkle N, Lipps Hogan J, Lovell C, Myers J, McGill J, Salam M, Kissel S, Schweiger T, Recklein C, Tamborlane W, Gatcomb P, Camp A, Gulanski B, Inzucchi S, Pham K, Alguard M, Lessard K, Perez M, Magenheimer E, Montoza A, Nathan D, Lachin J, Buse J, Kahn S, Krause-Steinrauf H, Larkin M, Tiktin M, Wexler D, Burch H, Linder B, Bremer A, Lachin J, Krause-Steinrauf H, Younes N, Backman M, Bebu I, Buys C, Fagan Murphy A, Gao Y, Gramzinski M, Hall S, Legowski E, Arey A, Bethepu J, Lund C, Mangat Dhaliwal P, McGee P, Mesimer E, Ngo L, Steffes M, Seegmiller J, Saenger A, Arends V, Gabrielson D, Conner T, Warren S, Day J, Scrymgeour A, Soliman E, Zhang Z, Campbell C, Hu J, Keasler L, Hensley S, Li Y, Herman W, Martin C, Waltje A, Kuo S, Mihalcea R, Perez-Rosas V, Prosser L, Resnicow K, Ye W, Shao H, Zhang P, Luchsinger J, Sanchez D, Burch H, Bremer A, Linder B, Fradkin J, Groessl E, Chong H, Hillery N, Abdouch I, Brantley P, Broyles F, Canaris G, Copeland P, Craine J, Fein W, Lee M, Meiners R, Meiners V, O’Neal H, Park J, Sledge E, Steppel-Resnick J, Turchin A, Brooks-Worrell B, Hampe C, Newgard C, Palmer J, Shojaie A, Higgins J, Fischer L, Golden S, Gonzalez J, Naik A, Walker E, Doner Lotenberg L, Gallivan J, Lim J, Tuncer D, Behringer-Massera S. Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. Diabetes Care 2020, 43: 940-947. PMID: 32139384, PMCID: PMC7171946, DOI: 10.2337/dc19-1769.
- Docherty K, Jackson A, Inzucchi S, Jhund P, Kober L, Kosiborod M, Langkilde A, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjoestrand M, Solomon S, Desai A, Diez M, Howlett J, Ljungman C, O'Meara E, Petrie M, Schou M, Pham V, McMurray J. CONSISTENT BENEFIT OF DAPAGLIFLOZIN ACCORDING TO BACKGROUND THERAPY IN PATIENTS WITH HFREF: AN ANALYSIS OF THE DAPA-HF TRIAL. Journal Of The American College Of Cardiology 2020, 75: 656. DOI: 10.1016/s0735-1097(20)31283-3.
- Jhund P, Adamson C, Inzucchi S, Kosiborod M, Langkilde A, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjoestrand M, Solomon S, McMurray J. EFFECT OF TREATMENT WITH DAPAGLIFLOZIN IS CONSISTENT ACROSS THE RANGE OF BODY MASS INDEX IN PATIENTS WITH HFREF: AN ANALYSIS OF THE DAPA-HF TRIAL. Journal Of The American College Of Cardiology 2020, 75: 673. DOI: 10.1016/s0735-1097(20)31300-0.
- Køber L, Docherty K, Inzucchi S, Jhund P, Kosiborod M, Langkilde A, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjoestrand M, Solomon S, McMurray J. DAPAGLIFLOZIN IMPROVES OUTCOMES IRRESPECTIVE OF NT-PROBNP CONCENTRATION IN PATIENTS WITH HFREF: AN ANALYSIS OF THE DAPA-HF TRIAL. Journal Of The American College Of Cardiology 2020, 75: 675. DOI: 10.1016/s0735-1097(20)31302-4.
- McMurray J, Boehm M, Serenelli M, Inzucchi S, Jhund P, Kober L, Kosiborod M, Langkilde A, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjoestrand M, Solomon S. EFFECT OF TREATMENT WITH DAPAGLIFLOZIN ACCORDING TO BASELINE SYSTOLIC BLOOD PRESSURE IN PATIENTS WITH HFREF: AN ANALYSIS OF THE DAPA-HF TRIAL. Journal Of The American College Of Cardiology 2020, 75: 849. DOI: 10.1016/s0735-1097(20)31476-5.
- Verma S, Mazer C, Inzucchi S, Wanner C, Ofstad A, Johansen O, Zwiener I, George J, Butler J, Zinman B. THE ASSOCIATION BETWEEN POLYVASCULAR DISEASE AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME. Journal Of The American College Of Cardiology 2020, 75: 1859. DOI: 10.1016/s0735-1097(20)32486-4.
- Verma S, Sharma A, Zinman B, Ofstad A, Fitchett D, Brueckmann M, Wanner C, Zwiener I, George J, Inzucchi S, Butler J, Mazer C. APPLICATION OF THE TIMI HEART FAILURE RISK SCORE TO THE EMPA-REG OUTCOME POPULATION. Journal Of The American College Of Cardiology 2020, 75: 1851. DOI: 10.1016/s0735-1097(20)32478-5.
- Inzucchi S, Khunti K, Fitchett D, Wanner C, Mattheus M, George J, Ofstad A, Zinman B. Consistent cardiovascular (CV) benefit of empagliflozin over the spectrum of CV risk factor control in EMPA-REG OUTCOME. Metabolism 2020, 104: 154125. DOI: 10.1016/j.metabol.2019.12.071.
- Murari K, Gossman M, Mahajan A, Erson Z, Inzucchi S, Omay S. A Case of the Use of Genomic Signatures in the Diagnosis of Cushing Disease. Journal Of Neurological Surgery Part B Skull Base 2020, 81: s1-s272. DOI: 10.1055/s-0040-1702681.
- Kosiborod M, Nassif M, Windsor S, Tang F, Khariton Y, Austin B, Umpierrez G, Lamba S, Katz S, Fong M, Husain M, Inzucchi S, Mcguire D, Pitt B, Scirica B. Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients with Heart Failure with Reduced Ejection Fraction with and without Diabetes - The Define-HF Trial. Journal Of Cardiac Failure 2019, 25: 937-938. DOI: 10.1016/j.cardfail.2019.11.005.
- McGuire D, Zinman B, Inzucchi S, Anker S, Wanner C, Kaspers S, Von Eynatten M, Johansen O, Elsasser U, Pocock S, Fitchett D, Jamal W, Hantel S, Lund S. P6270Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease. European Heart Journal 2019, 40: ehz746.0869. DOI: 10.1093/eurheartj/ehz746.0869.
- Verma S, Böhm M, Brueckmann M, Fitchett D, George J, Inzucchi S, Marx N, Mattheus M, Ofstad A, Slawik J, Wanner C, Zinman B. HEART FAILURE OUTCOMES IN PATIENTS WITH DIABETES WITH AND WITHOUT ATRIAL FIBRILLATION - DATA FROM THE EMPA-REG OUTCOME STUDY. Canadian Journal Of Cardiology 2019, 35: s197. DOI: 10.1016/j.cjca.2019.07.619.
- Verma S, Qiuhe J, Bhatt D, Mazer C, Al-Omran M, Inzucchi S, Wanner C, Ofstad A, Zwiener I, George J, Zinman B, Fitchett D. URIC ACID LEVELS PREDICT CARDIORENAL OUTCOMES AND CARDIOVASCULAR DEATH IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME. Canadian Journal Of Cardiology 2019, 35: s139. DOI: 10.1016/j.cjca.2019.07.554.
- Nassif ME, Windsor S, Tang F, Khariton Y, Husain M, Inzucchi SE, McGuire D, Pitt B, Scirica BM, Austin B, Drazner M, Fong M, Givertz MM, Gordon R, Jermyn R, Katz S, Lamba S, Lanfear D, LaRue S, Lindenfeld J, Malone M, Margulies K, Mentz R, Mutharasan RK, Pursley M, Umpierrez G, Kosiborod M, Malik A, Wenger N, Ogunniyi M, Vellanki P, Murphy B, Newman J, Hartupee J, Gupta C, Goldsmith M, Baweja P, Montero M, Gottlieb S, Costanzo M, Hoang T, Warnock A, Allen L, Tang W, Chen H, Cox J. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. Circulation 2019, 140: 1463-1476. PMID: 31524498, DOI: 10.1161/circulationaha.119.042929.
- Larkin M, Nathan D, Bebu I, Krause-Steinrauf H, Herman W, Higgins J, Tiktin M, Cohen R, Lund C, Bergenstal R, Johnson M, Arends V, Crandall J, McKee M, Brown-Friday J, Xhori E, Ballentine-Cargill K, Duran S, Lukin J, Beringher S, de la torre S, Phillips L, Burgess E, Olson D, Rhee M, Wilson P, Raines T, Costello J, Gullett C, Maher-Albertelli M, Morehead F, Mungara R, Person S, Savoye L, Sibymon M, Tanukonda S, White C, Holloway L, Adams C, Ross A, Balasubramanyam A, Gonzalez E, Wright C, Hollander P, Roe E, Uy A, Burt P, Estrada L, Chionh K, Ismail-Beigi F, Falck-Ytter C, Kassem L, Sood A, Cramer B, Iacoboni J, Kononets M, Kulow T, Newman C, Stancil K, Sanders C, Tucker L, Werner A, Krol A, McPhee G, Patel C, Colosimo L, Goland R, Pring J, Kringas P, Tejada J, Hausheer C, Schneier H, Gumpel K, Kirpitch A, Green J, AbouAssi H, Chatterjee R, Feinglos M, Jones J, Khan S, Kimpel J, Zimmer R, Furst M, Satterwhite B, Thacker C, Kreider K, Mather K, Lteif A, Hamilton T, Patel N, Riera G, Jackson M, Pirics V, Howard D, Aguillar D, Hurt S, Bergenstal R, Carlson A, Martens T, Johnson M, Hill R, Hyatt J, Jensen C, Madden M, Martin D, Willis H, Konerza W, Passi R, Kleeberger K, Fortmann S, Herson M, Mularski K, Glauber H, Prihoda J, Ash B, Carlson C, Ramey P, Schield E, Torgrimson-Ojerio B, Arnold K, Kauffman B, Panos E, Sahnow S, Bays K, Cook J, Gluth J, Sasaki D, Schell K, Criscola J, Friason C, Jones S, Nazarov S, Barzilay J, Rassouli N, Puttnam R, Curtis M, Stokes K, Hollis B, Sanders-Jones C, Nelson R, El-Haqq Z, Kolli A, Tran T, Wexler D, Meigs J, Dushkin A, Rocchio G, Chambers B, Yepes M, Steiner B, Dulin H, Cayford M, DeManbey A, Gurry L, Hillard M, Martin K, Stevens C, Thangthaeng N, Kochis R, Raymond E, Ripley V, Park J, Aroda V, Ghazi A, Loveland A, Hurtado M, Kuhn A, Mofor F, Florez H, Valencia W, Marks J, Oropesa-Gonzalez L, Riccio Veliz A, Nieto-Martinez R, Gutt M, Ahmann A, Aby-Daniel D, Joarder F, Morimoto V, Sprague C, Yamashita D, Cady N, Kirchhoff P, Rivera-Eschright N, Adducci J, Gomez B, Goncharova A, Hox S, Petrovitch H, Matwichyna M, Jenkins V, Bermudez N, Ishii R, Hsia D, Cefalu W, Greenway F, Waguespack C, King E, Haynes N, Thomassie A, Bourgeois B, Hazlett C, Henry R, Mudaliar S, Boeder S, Pettus J, Diaz E, DeLue C, Castro E, Hernandez S, Krakoff J, Curtis J, Killean T, Joshevama E, Diaz E, Martin D, Karshner T, Albu J, Pi-Sunyer F, Frances S, Maggio C, Ellis E, Bastawrose J, Gong X, Banerji M, August P, Lorber D, Brown N, Josephson D, Thomas L, Tsovian M, Cherian A, Jacobson M, Mishko M, Kirkman M, Bergamo K, Buse J, Dostou J, Young L, Goley A, Kerr J, Largay J, Guarda S, Cuffee J, Culmer D, Fraser R, Almeida H, Coffer S, Debnam E, Kiker L, Morton S, Josey K, Fuller G, Garvey W, Cherrington A, Golson D, Griffith O, Robertson M, Agne A, McCullars S, Craig J, Kersey K, Rogge M, Wilson C, Burton K, Lipp S, Meulen M, Rasouli N, Schroeder E, Steiner S, Baker C, Underkofler C, Douglass S, Sivitz W, Cline E, Knosp L, McConnell J, Lowe T, Pop-Busui R, Tan M, Martin C, Waltje A, Goodhall L, Eggleston R, Kuo S, Bule S, Kessler N, LaSalle E, Seaquist E, Bantle A, Kumar A, Redmon B, Bantle J, Harindhanavudhi T, Coe M, Mech M, Taddese A, Lesne L, Smith S, Desouza C, Kuechenmeister L, Shivaswamy V, Morales A, Rodriguez M, Seipel K, Alfred A, Eggert J, Lord G, Taylor W, Tillson R, Schade D, Adolphe A, Burge M, Duran-Valdez E, Martinez J, McGinnis D, Pucchetti B, Scripsick E, DeFronzo R, Cersosimo E, Abdul-Ghani M, Triplitt C, Verastiqui H, Garza R, Wright K, Puckett C, Raskin P, Rhee C, Abraham S, Jordan L, Sao S, Morton L, Smith O, Walker L, Schnurr-Breen L, Ayala R, Kraymer R, Sturgess D, Utzschneider K, Kahn S, Wright L, Boyko E, Tsai E, Trence D, Fattaleh B, Montgomery B, Atkinson K, Concepcion T, Kozedub A, Moak C, Rhothisen S, Elasy T, Martin S, Shackelford L, Goidel R, Hinkle N, Hogan J, Lovell C, Myers J, McGill J, Salam M, Kissel S, Schweiger T, Recklein C, Tamborlane W, Gatcomb P, Camp A, Gulanski B, Inzucchi S, Pham K, Alguard M, Lessard K, Perez M, Magenheimer E, Montoza A, Burch H, Bremer A, Linder B, Fradkin J, Lachin J, Kahn S, Burch H, Younes N, Backman M, Buys C, Murphy A, Gao Y, Gramzinski M, Hall S, Legowski E, Arey A, Bethepu J, Dhaliwal P, McGee P, Mesimer E, Ngo L, Steffes M, Seegmiller J, Saenger A, Gabrielson D, Conner T, Warren S, Day J, Scrymgeour A, Soliman E, Zhang Z, Campbell C, Hu J, Keasler L, Hensley S, Li Y, Herman W, Mihalcea R, Perez-Rosas V, Prosser L, Resnicow K, Ye W, Shao H, Zhang P, Luchsinger J, Sanchez D, Groessl E, Chong H, Hillery N, Abdouch I, Brantley P, Broyles F, Canaris G, Copeland P, Craine J, Fein W, Lee M, Meiners R, Meiners V, O'Neal H, Park J, Sledge E, Steppel-Resnick J, Turchin A, Higgins J. Rationale and Design for a GRADE Substudy of Continuous Glucose Monitoring. Diabetes Technology & Therapeutics 2019, 21: 682-690. PMID: 31393176, PMCID: PMC7207016, DOI: 10.1089/dia.2019.0202.
- INZUCCHI S, ZINMAN B, GEORGE J, MATTHEUS M, EYNATTEN M, WANNER C, HAUSKE S. 248-OR: Empagliflozin and Cardiorenal Outcomes in Patients with Nonproteinuric Kidney Disease in the EMPA-REG OUTCOME Trial. Diabetes 2019, 68 DOI: 10.2337/db19-248-or.
- INZUCCHI S, KHUNTI K, FITCHETT D, WANNER C, MATTHEUS M, GEORGE J, PERNILLE OFSTAD A, ZINMAN B. 19-LB: Consistent Cardiovascular (CV) Benefits from Empagliflozin across the Spectrum of CV Risk Factor Control: Post Hoc Analysis from EMPA-REG OUTCOME. Diabetes 2019, 68 DOI: 10.2337/db19-19-lb.
- ZINMAN B, FITCHETT D, MATTHEUS M, WANNER C, GEORGE J, VEDIN O, INZUCCHI S, JOHANSEN O. 159-LB: Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME. Diabetes 2019, 68 DOI: 10.2337/db19-159-lb.
- Inzucchi S, Wanner C, Hehnke U, Lee J, Kaspers S, Clark D, George J, Zinman B. Composite retinopathy outcome in patients treated with empagliflozin versus placebo in the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2019, 14: s53-s53. DOI: 10.1055/s-0039-1688261.
- Sambevski S, Fitchett D, Inzucchi S, Kaspers S, Pfarr E, George J, Zinman B. Empagliflozin reduces mortality and hospitalisation for heart failure in patients with or without a history of myocardial infarction or stroke at baseline. Diabetologie Und Stoffwechsel 2019, 14: s65-s66. DOI: 10.1055/s-0039-1688297.
- Wanner C, Cooper M, Inzucchi S, Zinman B, Zwiener I, Eynatten M, Koitka-Weber A. Empagliflozin Improves Kidney Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol and HbA1c. Diabetologie Und Stoffwechsel 2019, 14: s80-s80. DOI: 10.1055/s-0039-1688342.
- Gunawan F, Partridge C, Kosiborod M, Inzucchi S. SUN-149 Cardiologist vs. Endocrinologist Encounters in Patients with T2D and CVD: Potential Implications for Glucose-Lowering Therapy Use and Education. Journal Of The Endocrine Society 2019, 3: sun-149. PMCID: PMC6553036, DOI: 10.1210/js.2019-sun-149.
- Verma S, Ji Q, Bhatt D, Mazer C, Al-Omran M, Inzucchi S, Wanner C, Ofstad A, Zwiener I, George J, Zinman B, Fitchett D. THE ASSOCIATION BETWEEN URIC ACID LEVELS AND CARDIORENAL OUTCOMES AND DEATH IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME. Journal Of The American College Of Cardiology 2019, 73: 1754. DOI: 10.1016/s0735-1097(19)32360-5.
- Qamar A, Scirica B, Wiviott S, Fanola C, Im K, Inzucchi S, McGuire D, Keech A, Smith S, Murphy S, Perdomo C, Miao W, Patel T, Sabatine M, Bohula E, Group S. INTERINDIVIDUAL VARIABILITY IN WEIGHT LOSS WITH LORCASERIN: AN ANALYSIS FROM THE CAMELLIA-TIMI 61 STUDY. Journal Of The American College Of Cardiology 2019, 73: 1811. DOI: 10.1016/s0735-1097(19)32417-9.
- Fanola C, Bohula E, Weissman N, Wiviott S, Qamar A, Kuder J, Im K, Inzucchi S, McGuire D, Keech A, Smith S, Perdomo C, Miao W, Patel T, Sabatine M, Scirica B. PERSISTENCE OF VALVULOPATHY IN THE CAMELLIA-TIMI 61 TRIAL OF LORCASERIN IN OBESE OR OVERWEIGHT PATIENTS AT INCREASED CARDIOVASCULAR RISK. Journal Of The American College Of Cardiology 2019, 73: 2023. DOI: 10.1016/s0735-1097(19)32629-4.
- Butler J, Savarese G, Sattar N, Januzzi J, Verma S, Lund L, Fitchett D, Zeller C, George J, Brueckmann M, Ofstad A, Inzucchi S, Wanner C, Zinman B. EMPAGLIFLOZIN IS ASSOCIATED WITH A LOWER RISK OF POST-ACUTE HEART FAILURE RE-HOSPITALIZATION AND MORTALITY: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL. Journal Of The American College Of Cardiology 2019, 73: 663. DOI: 10.1016/s0735-1097(19)31271-9.
- Böhm M, Brueckmann M, Fitchett D, George J, Inzucchi S, Marx N, Mattheus M, Ofstad A, Slawik J, Verma S, Wanner C, Zinman B. Heart Failure Outcomes in Patients with Diabetes With and Without Atrial Fibrillation – Data From the EMPA-REG OUTCOME Study. Heart Lung And Circulation 2019, 28: s172. DOI: 10.1016/j.hlc.2019.06.091.
- Verma S, Mazer C, Fitchett D, Inzucchi S, George J, Pfarr E, Woerle H, Zinman B. 124 Empagliflozin Reduces Mortality and Hospitalization for Heart Failure in Patients with Type 2 Diabetes and Peripheral Artery Disease: A Sub-Analysis of the EMPA-REG OUTCOME Trial. Canadian Journal Of Diabetes 2018, 42: s43. DOI: 10.1016/j.jcjd.2018.08.129.
- Fitchett D, Inzucchi S, Sambevski S, Kaspers S, Pfarr E, George J, Zinman B. EMPAGLIFLOZIN REDUCES MORTALITY AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH OR WITHOUT A HISTORY OF MYOCARDIAL INFARCTION OR STROKE AT BASELINE. Canadian Journal Of Cardiology 2018, 34: s80-s81. DOI: 10.1016/j.cjca.2018.07.288.
- Verma S, Mazer C, Fitchett D, Inzucchi S, George J, Pfarr E, Woerle H, Zinman B. EMPAGLIFLOZIN REDUCES MORTALITY AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH TYPE 2 DIABETES AND PERIPHERAL ARTERY DISEASE: A SUB-ANALYSIS OF THE EMPA-REG OUTCOME TRIAL. Canadian Journal Of Cardiology 2018, 34: s81. DOI: 10.1016/j.cjca.2018.07.289.
- McGuire D, Zinman B, Inzucchi S, Anker S, Wanner C, Kaspers S, George J, Elsasser U, Woerle H, Lund S, Fitchett D. P5334Effect of empagliflozin on cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial. European Heart Journal 2018, 39: ehy566.p5334. DOI: 10.1093/eurheartj/ehy566.p5334.
- Fitchett D, Inzucchi S, Cannon C, McGuire D, Johansen O, Sambevski S, Hehnke U, George J, Zinman B. P1879Empagliflozin reduces mortality and hospitalisation for heart failure irrespective of cardiovascular risk score at baseline. European Heart Journal 2018, 39: ehy565.p1879. DOI: 10.1093/eurheartj/ehy565.p1879.
- INZUCCHI S, VISCOLI C, YOUNG L, GORMAN M, CONWIT R, SCHWARTZ G, KERNAN W. What Mediated Pioglitazone's Cardiovascular (CV) Benefit in the IRIS Trial? Diabetes 2018, 67 DOI: 10.2337/db18-17-lb.
- WANNER C, COOPER M, INZUCCHI S, ZINMAN B, HEHNKE U, EYNATTEN M, KOITKA-WEBER A. Empagliflozin Improves Renal Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol, and HbA1c. Diabetes 2018, 67 DOI: 10.2337/db18-524-p.
- RASOULI N, COHEN R, DEFRONZO R, INZUCCHI S, ISMAIL-BEIGI F, KAHN S, UTZSCHNEIDER K, LACHIN J, YOUNES N. Relationship between Baseline Phenotype and Measures of Insulin Sensitivity and Beta-Cell Responses in the GRADE Cohort. Diabetes 2018, 67 DOI: 10.2337/db18-1822-p.
- WONG N, SONG Y, ARNOLD S, SPERLING L, CANNON C, INZUCCHI S, KOSIBOROD M. Composite Cardiovascular Risk Factor Target Achievement and Its Indicators in U.S. Adults with Diabetes—The Diabetes Collaborative Registry. Diabetes 2018, 67 DOI: 10.2337/db18-1487-p.
- FITCHETT D, SCIRICA B, INZUCCHI S, CANNON C, MCGUIRE D, JOHANSEN O, SAMBEVSKI S, HEHNKE U, GEORGE J, ZINMAN B. Empagliflozin (EMPA) Reduces Mortality and Hospitalization for Heart Failure (HHF) Irrespective of Cardiovascular (CV) Risk Score at Baseline. Diabetes 2018, 67 DOI: 10.2337/db18-1123-p.
- Ruggenenti P, Inzucchi S, Zinman B, Hantel S, Koitka-Weber A, von Eynatten M, Wanner C. SP415EMPAGLIFLOZIN AND PROGRESSION OF CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES COMPLICATED BY NEPHROTIC-RANGE PROTEINURIA: INSIGHTS FROM THE EMPA-REG OUTCOME® TRIAL. Nephrology Dialysis Transplantation 2018, 33: i487-i487. DOI: 10.1093/ndt/gfy104.sp415.
- Fitchett D, Lee J, George J, Woerle H, Inzucchi. Empagliflozin reduces heart failure irrespective of control of blood pressure, low density lipoprotein cholesterol and HbA1c. Diabetologie Und Stoffwechsel 2018, 13: s52-s52. DOI: 10.1055/s-0038-1641913.
- Inzucchi, Fitchett D, Wanner C, George J, Woerle H, Zinman B. Reduction in cardiovascular death with empagliflozin is consistent across categories of baseline HbA1c and change in HbA1c: Results from EMPA-REG OUTCOME. Diabetologie Und Stoffwechsel 2018, 13: s51-s51. DOI: 10.1055/s-0038-1641909.
- Fitchett D, Inzucchi S, Sambevski S, Kaspers S, Pfarr E, George J, Zinman B. EMPAGLIFLOZIN REDUCES MORTALITY AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH OR WITHOUT A HISTORY OF MYOCARDIAL INFARCTION OR STROKE AT BASELINE. Journal Of The American College Of Cardiology 2018, 71: a1719. DOI: 10.1016/s0735-1097(18)32260-5.
- Fitchett D, McKnight J, Lee J, George J, Mattheus M, Woerle H, Inzucchi S. P4903Empagliflozin reduces heart failure irrespective of control of blood pressure, low density lipoprotein cholesterol and HbA1c. European Heart Journal 2017, 38: ehx493.p4903. DOI: 10.1093/eurheartj/ehx493.p4903.
- Chilton R, Gullestad L, Fitchett D, Inzucchi S, Mattheus M, Woerle H, Johansen O. 5935Effects of empagliflozin on cardiac and vascular hemodynamic markers by subgroups of age, sex and hypertension in patients with T2DM and high CV risk: EMPA-reg outcome. European Heart Journal 2017, 38: ehx493.5935. DOI: 10.1093/eurheartj/ehx493.5935.
- DeMauro-Jablonski S, Inzucchi S. Management of Diabetes and Hyperglycemia in the Hospital Setting. 2017, 983-998. DOI: 10.1007/978-3-319-18741-9_47.
- Jurišić-Eržen D, Johansen O, George J, Mattheus M, Zinman B, Inzucchi. Effect of empagliflozin when added to insulin in patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2017, 12: s1-s84. DOI: 10.1055/s-0037-1601614.
- Zinman B, Inzucchi, Lachin J, George J, Mattheus M, Woerle H, Fitchett D. Consistent effect of empagliflozin on cardiovascular death in subgroups by type of cardiovascular disease: results from EMPA-REG OUTCOME. Diabetologie Und Stoffwechsel 2017, 12: s1-s84. DOI: 10.1055/s-0037-1601787.
- Inzucchi S, Zinman B, McGinniss J, Schnee J, George J, Fitchett D. CONSISTENT EFFECT OF EMPAGLIFLOZIN ON COMPOSITE OUTCOMES RELATED TO HEART FAILURE: RESULTS FROM EMPA-REG OUTCOME. Journal Of The American College Of Cardiology 2017, 69: 1656. DOI: 10.1016/s0735-1097(17)35045-3.
- Arnold S, Inzucchi S, Tang F, McGuire D, Mehta S, Goyal A, Maddox T, Sperling L, Einhorn D, Wong N, Kosiborod M. USING THE DIABETES COLLABORATIVE REGISTRY (DCR) TO ESTIMATE THE POTENTIAL REAL-WORLD IMPACT OF THE LEADER TRIAL ON IMPROVING CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIABETES AT HIGH CARDIOVASCULAR RISK. Journal Of The American College Of Cardiology 2017, 69: 47. DOI: 10.1016/s0735-1097(17)33436-8.
- Inzucchi S, Matthews D. How to Use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies. 2016, 471-492. DOI: 10.1002/9781118924853.ch33.
- Fitchett D, Inzucchi S, Lachin J, Wanner C, Mattheus M, Johansen O, Woerle H, Broedl U, Zinman B. EFFECT OF EMPAGLIFLOZIN ON MORTALITY AND CAUSES OF DEATH IN PATIENTS WITH TYPE 2 DIABETES AT HIGH CARDIOVASCULAR RISK. Canadian Journal Of Cardiology 2016, 32: s122-s123. DOI: 10.1016/j.cjca.2016.07.182.
- Fitchett D, Zinman B, Lachin J, Mattheus M, George J, Johansen O, Inzucchi S. EFFECTS OF EMPAGLIFLOZIN ON OVERALL HEART FAILURE BURDEN IN EMPA-REG OUTCOME. Canadian Journal Of Cardiology 2016, 32: s175-s176. DOI: 10.1016/j.cjca.2016.07.272.
- Fitchett D, Zinman B, Lachin J, Mattheus M, George J, Johansen O, Inzucchi S. EFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR MORTALITY BY PREVALENT OR INCIDENT HEART FAILURE IN THE EMPA-REG OUTCOME TRIAL. Canadian Journal Of Cardiology 2016, 32: s90-s91. DOI: 10.1016/j.cjca.2016.07.124.
- Fitchett D, Inzucchi S, Lachin J, Wanner C, Mattheus M, Johansen O, Woerle H, Broedl U, Zinman B. 10 Effect of Empagliflozin on Mortality and Causes of Death in Patients with Type 2 Diabetes at High Cardiovascular Risk. Canadian Journal Of Diabetes 2016, 40: s4-s5. DOI: 10.1016/j.jcjd.2016.08.013.
- Lee D, Monteiro P, Clark D, Hantel S, Woerle H, Inzucchi S, Fitchett D. LBPS 02-52 EFFECT OF EMPAGLIFLOZIN ON HEART FAILURE OUTCOMES IN SUBGROUPS BY AGE. Journal Of Hypertension 2016, 34: e520. DOI: 10.1097/01.hjh.0000501423.64635.bd.
- Fitchett D, Inzucchi S, Lachin J, Wanner C, Mattheus M, Johansen O, Woerle H, Broedl U, Zinman B. EFFECT OF EMPAGLIFLOZIN ON MORTALITY AND CAUSES OF DEATH IN PATIENTS WITH TYPE 2 DIABETES AT HIGH CARDIOVASCULAR RISK. Journal Of The American College Of Cardiology 2016, 67: 1869. DOI: 10.1016/s0735-1097(16)31870-8.
- Moghissi E, Inzucchi S. 1: The Evolution of Glycemic Control in the Hospital Setting. 2016, 1-10. DOI: 10.2337/9781580406086.01.
- Peter P, Inzucchi S. 25: Continuous Glucose Monitoring in the Hospital. 2016, 323-335. DOI: 10.2337/9781580406086.25.
- Shuman J, Inzucchi S. Revisiting the Role of Intensive Glucose Control on Cardiovascular Outcomes. MD Conference Express 2015, 15: 4-7. DOI: 10.1177/1559897715581830.
- DeMauro-Jablonski S, Inzucchi S. Management of Diabetes and Hyperglycemia in the Hospital Setting. 2015, 1-16. DOI: 10.1007/978-3-319-20797-1_47-1.
- Lleva RR, Thomas P, Bozzo JE, Hendrickson KC, Inzucchi SE. Using the Glucometrics Website to Benchmark ICU Glucose Control Before and After the NICE-SUGAR Study. Journal Of Diabetes Science And Technology 2014, 8: 918-922. PMID: 25013157, PMCID: PMC4455376, DOI: 10.1177/1932296814540871.
- Lee G, Inzucchi S, Holt E. Endocrine Perturbations in Critical Illness. 2014, 247-272. DOI: 10.1007/978-1-4939-1121-9_14.
- Hoang QN, Pisani MA, Inzucchi S, Hu B, Honiden S. The prevalence of undiagnosed diabetes mellitus and the association of baseline glycemic control on mortality in the intensive care unit: A prospective observational study. Journal Of Critical Care 2014, 29: 1052-1056. PMID: 25092614, DOI: 10.1016/j.jcrc.2014.06.007.
- Zinman B, Inzucchi S, Lachin J, Wanner C, Ferrari R, Fitchett D, Bluhmki E, Kempthorne-Rawson J, Newman J, Johansen O, Woerle H, Broedl U. Baseline characteristics of participants enrolled in the empagliflozin cardiovascular outcome trial (EMPA-REG OUTCOME™) in patients with type 2 diabetes. Diabetologie Und Stoffwechsel 2014, 9 DOI: 10.1055/s-0034-1374995.
- Inzucchi S. Personalizing Diabetes Management. 2014, 59-64. DOI: 10.1210/mtp3.9781936704835.ch13.
- Lupsa B, Inzucchi S. Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic Syndrome. Contemporary Endocrinology 2013, 15-31. DOI: 10.1007/978-1-62703-697-9_2.
- Zinman B, Inzucchi S, Lachin J, Wanner C, Ferrari R, Bluhmki E, Hantel S, Johansen O, Woerle H, Broedl U. Design of the Empagliflozin Cardiovascular (CV) Outcome Event Trial in Type 2 Diabetes (T2D). Canadian Journal Of Diabetes 2013, 37: s29-s30. DOI: 10.1016/j.jcjd.2013.08.088.
- Inzucchi, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M, Peters A, Tsapas A, Wender R, Matthews. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379. Diabetes Care 2013, 36: 490-490. PMCID: PMC3554319, DOI: 10.2337/dc13-er02.
- Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M, Peters A, Tsapas A, Wender R, Matthews D. Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 56: 680-680. DOI: 10.1007/s00125-012-2785-9.
- Matthews D, Inzucchi S. Response to Comments on: Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379. Diabetes Care 2012, 35: e72-e73. PMCID: PMC3447838, DOI: 10.2337/dc12-1184.
- Matthews D, Inzucchi S, for the Position Statement Writing Group. ADA/EASD position statement of the treatment of type 2 diabetes: Reply to Rodbard HW and Jellinger PS [letter], Scheen AJ [letter] and Ceriello A, Gallo M, Gentile S et al [letter]. Diabetologia 2012, 55: 2856-2857. PMID: 22854891, DOI: 10.1007/s00125-012-2669-z.
- Buckley R, Inzucchi S. New ADA/EASD Position Statement Endorses a Patient-Centered Approach. MD Conference Express 2012, 12: 35-36. DOI: 10.1177/155989771210019.
- Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M, Peters A, Tsapas A, Wender R, Matthews D. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Spectrum 2012, 25: 154-171. DOI: 10.2337/diaspect.25.3.154.
- Inzucchi S, Rosenstock J, Umpierrez G. Diabetic Neuropathy. The Journal Of Clinical Endocrinology & Metabolism 2012, 97: 35a-35a. PMID: 22563114, DOI: 10.1210/jcem.97.5.zeg35a.
- Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M, Peters A, Tsapas A, Wender R, Matthews D. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 55: 1577-1596. PMID: 22526604, DOI: 10.1007/s00125-012-2534-0.
- Hage F, Wackers F, Bansal S, Chyun D, Young L, Inzucchi S, Iskandrian A. THE HEART RATE RESPONSE TO ADENOSINE AS A PREDICTOR OF ADVERSE CARDIAC OUTCOMES IN THE DETECTION OF ISCHEMIA IN ASYMPTOMATIC DIABETICS STUDY. Journal Of The American College Of Cardiology 2012, 59: e1162. DOI: 10.1016/s0735-1097(12)61163-2.
- Inzucchi S, Sherwin R. 237 Type 2 Diabetes Mellitus. 2012, 1489-1499. DOI: 10.1016/b978-1-4377-1604-7.00237-2.
- Inzucchi S, Sherwin R. 237 Type 2 Diabetes Mellitus. 2012, e95-e108. DOI: 10.1016/b978-1-4377-1604-7.00562-5.
- Inzucchi S, Sherwin R. 236 Type 1 Diabetes Mellitus. 2012, e78-e94. DOI: 10.1016/b978-1-4377-1604-7.00561-3.
- Inzucchi S, Sherwin R. 236 Type 1 Diabetes Mellitus. 2012, 1475-1489. DOI: 10.1016/b978-1-4377-1604-7.00236-0.
- Tandon S, Bansal S, Inzucchi S, Staib L, Davey J, Chyun D, Young L, Wackers F. SCREENING ASYMPTOMATIC PATIENTS WITH TYPE 2 DIABETES FOR SILENT MYOCARDIAL ISCHEMIA: IMPORTANT GENDER DIFFERENCES FROM THE DETECTION OF ISCHEMIA IN ASYMPTOMATIC DIABETICS (DIAD) STUDY. Journal Of The American College Of Cardiology 2011, 57: e745. DOI: 10.1016/s0735-1097(11)60745-6.
- Gore M, Inzucchi S, McGuire D. CHAPTER 21 Diabetes and Cardiovascular Disease. 2011, 345-370. DOI: 10.1016/b978-1-4377-1366-4.00021-4.
- Vinall M, Inzucchi S. Glucose Lowering: New Options. MD Conference Express 2010, 10: 35-35. DOI: 10.1177/155989771010023.
- Inzucchi S, Rosenstock J, Umpiérrez G. Control continuo de la glucosa. The Journal Of Clinical Endocrinology & Metabolism 2010, 95: e2-e2. DOI: 10.1210/jcem.95.10.9999.
- Inzucchi S, Rosenstock J, Umpierrez G. Continuous Glucose Monitoring. The Journal Of Clinical Endocrinology & Metabolism 2010, 95: e1-e1. DOI: 10.1210/jcem.95.10.9998.
- Association A, Association A, Foundation A, Pignone M, Alberts M, Colwell J, Cushman M, Inzucchi S, Mukherjee D, Rosenson R, Williams C, Wilson P, Kirkman M. Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes. Journal Of The American College Of Cardiology 2010, 55: 2878-2886. PMID: 20579547, DOI: 10.1016/j.jacc.2010.04.003.
- Inzucchi S, Kitabchi A, Rosenstock J. Diabetes monogénica. The Journal Of Clinical Endocrinology & Metabolism 2010, 95: e2-e2. DOI: 10.1210/jcem.95.5.9999.
- Inzucchi S, Kitabchi A, Rosenstock J. Monogenic Diabetes. The Journal Of Clinical Endocrinology & Metabolism 2010, 95: e1-e1. DOI: 10.1210/jcem.95.5.9998.
- Stolker J, Spertus J, McGuire D, Inzucchi S, Rathore S, Maddox T, Masoudi F, Tang F, Jones P, Kosiborod M. IN-HOSPITAL HEMOGLOBIN A1C TESTING AND ITS RELATION TO INITIATION OF GLUCOSE LOWERING THERAPY IN HYPERGLYCEMIC PATIENTS WITH ACUTE MYOCARDIAL INFARCTION. Journal Of The American College Of Cardiology 2010, 55: a143.e1340. DOI: 10.1016/s0735-1097(10)61341-1.
- VENKITACHALAM L, Riley K, Lipska K, Inzucchi S, Goyal A, Spertus J, Masoudi F, Jones P, Kosiborod M. TEMPORAL TRENDS IN THE MANAGEMENT OF SEVERE HYPERGLYCEMIA AMONG PATIENTS HOSPITALIZED WITH ACUTE MYOCARDIAL INFARCTION. Journal Of The American College Of Cardiology 2010, 55: a143.e1339. DOI: 10.1016/s0735-1097(10)61340-x.
- Bansal S, Wackers F, Inzucchi S, Young L, Chyun D. CARDIAC OUTCOMES AFTER SCREENING FOR ASYMPTOMATIC CORONARY ARTERY DISEASE IN PATIENTS WITH METABOLIC SYNDROME: POST-HOC ANALYSIS OF THE DIAD TRIAL. Journal Of The American College Of Cardiology 2010, 55: a141.e1325. DOI: 10.1016/s0735-1097(10)61326-5.
- DeMauro-Jablonski S, Inzucchi S. Management of Diabetes and Hyperglycemia in the Hospital Setting. 2009, 773-786. DOI: 10.1007/978-0-387-09841-8_47.
- Inzucchi S, Leiter L, Rosenstock J. Type 2 Diabetes and TZDs (Thiazolidinediones) Fritz 9.24.09. The Journal Of Clinical Endocrinology & Metabolism 2009, 94: e2-e2. DOI: 10.1210/jcem.94.11.9988.
- Inzucchi S, Leiter L, Rosenstock J. Diabetes de Tipo 2 y las TZD (Tiazolidinedionas) Fritz 9.24.09. The Journal Of Clinical Endocrinology & Metabolism 2009, 94: e1-e1. DOI: 10.1210/jcem.94.11.9987.
- Kosiborod M, Inzucchi S, Krumholz H, Masoudi F, Goyal A, Spertus J. Is Insulin the Preferred Compound in Lowering Glucose Levels in Patients After a Myocardial Infarction?—Reply. JAMA Internal Medicine 2009, 169: 1633-1638. DOI: 10.1001/archinternmed.2009.327.
- Lipska K, Inzucchi, Kosiborod M, Krumholz H. Intensive glucose control and cardiovascular outcomes. The Lancet 2009, 374: 522-523. PMID: 19683633, DOI: 10.1016/s0140-6736(09)61479-3.
- Alba M, Ahren B, Inzucchi S, Guan Y, Mallick M, Xu L, O'Neill E, Williams-Herman D, Kaufman K, Goldstein B. Initial combination therapy with sitagliptin and pioglitazone: complementary effects on postprandial glucose and islet cell function. Canadian Journal Of Diabetes 2009, 33: 319-320. DOI: 10.1016/s1499-2671(09)33335-3.
- Rosenstock J, Inzucchi S, Seufert J, Fleck P, Wilson C, Mekki Q. Combination alogliptin plus pioglitazone treatment in patients with type 2 diabetes inadequately controlled with diet exercise. Canadian Journal Of Diabetes 2009, 33: 212. DOI: 10.1016/s1499-2671(09)33076-2.
- Lipska K, Inzucchi S. Cardiovascular risk-benefit ratio of thiazolidinediones. Current Cardiovascular Risk Reports 2008, 3: 42-50. DOI: 10.1007/s12170-009-0008-9.
- Thomas P, Inzucchi S. An Internet Service Supporting Quality Assessment of Inpatient Glycemic Control. Journal Of Diabetes Science And Technology 2008, 2: 402-408. PMID: 19885204, PMCID: PMC2769729, DOI: 10.1177/193229680800200309.
- Hirsch I, Inzucchi S, Kirkman M. Standards of Medical Care in Diabetes—2008 Response to Dora, Kramer, and Canani. Diabetes Care 2008, 31: e45-e45. DOI: 10.2337/dc08-0285.
- Inzucchi S, Rolla A, Umpierrez G. Diabetes and New Insulins. The Journal Of Clinical Endocrinology & Metabolism 2007, 92: e2-e2. DOI: 10.1210/jcem.92.3.9996.
- Inzucchi S, Rolla A, Umpierrez G. La diabetes y las nuevas insulinas. The Journal Of Clinical Endocrinology & Metabolism 2007, 92: e1-e1. DOI: 10.1210/jcem.92.3.9995.
- Holt E, Inzucchi S. Physiology and Pathophysiology of the Parathyroid Glands and Preoperative Evaluation. 2007, 235-243. DOI: 10.1007/978-3-540-68043-7_19.
- Inzucchi S. Chapter 26 Type 2 Diabetes Therapy: Choosing Oral Agents. 2006, 332-342. DOI: 10.1016/b978-1-4160-0273-4.50031-x.
- Bax J, Bonow R, Tschöepe D, Inzucchi S, Barrett E. Early detection of coronary heart disease in diabetic patients without symptoms of coronary artery disease: implications for expanded use of myocardial perfusion imaging. British Journal Of Diabetes 2005, 5: 283-288. DOI: 10.1177/14746514050050050801.
- Goldberg P, Roussel M, Inzucchi S. Clinical Results of an Updated Insulin Infusion Protocol in Critically Ill Patients. Diabetes Spectrum 2005, 18: 188-191. DOI: 10.2337/diaspect.18.3.188.
- Masoudi F, Inzucchi S, Wang Y. Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study. ACC Current Journal Review 2005, 14: 22. DOI: 10.1016/j.accreview.2005.05.051.
- Kimmel B, Inzucchi S. Oral Agents for Type 2 Diabetes: An Update. Clinical Diabetes 2005, 23: 64-76. DOI: 10.2337/diaclin.23.2.64.
- Goldberg P, Inzucchi S. Selling Root Canals: Lessons Learned From Implementing a Hospital Insulin Infusion Protocol. Diabetes Spectrum 2005, 18: 28-33. DOI: 10.2337/diaspect.18.1.28.
- Wackers F, Young L, Inzucchi S, Chyun D. Detection of Silent Myocardial Ischemia in Asymptomatic Diabetic Subjects. Diabetes Care 2005, 28: 232-233. DOI: 10.2337/diacare.28.1.232.
- Inzucchi S, Kinder B. Chapter 87 Endocrine Emergencies: Hypoglycemic and Hyperglycemic Crises. 2005, 789-799. DOI: 10.1016/b978-0-7216-0139-7.50091-0.
- Inzucchi S, Young L, Chyun D, Wackers F. Screening for coronary artery disease in diabetic patients: The DIAD study. British Journal Of Diabetes 2004, 4: 317-319. DOI: 10.1177/14746514040040050501.
- Sudhakar S, Chyun D, Young L, Inzucchi S, Davey J, Wackers F. Abnormal heart rate response to adenosine infusion is associated with silent myocardial ischemia in asymptomatic patients with diabetes mellitus. Journal Of Nuclear Cardiology 2004, 11: s20. DOI: 10.1016/j.nuclcard.2004.06.064.
- Kosiborod M, Rathore S, Wang Y, Inzucchi S, Masoudi F, Havranek E, Foody J, Krumholz H. 885-6 Prognostic implications of admission hyperglycemia in elderly patients with acute myocardial infarction. Journal Of The American College Of Cardiology 2004, 43: a241. DOI: 10.1016/s0735-1097(04)91025-x.
- Kernan W, Inzucchi S, Viscoli C. Insulin and Membrane Microviscosity of Erythrocytes as Risk Factors for Stroke. Stroke 2003, 34: e225-e226. PMID: 14631086, DOI: 10.1161/01.str.0000103353.56177.97.
- Masoudi F, Wang Y, Inzucchi S. Metformin and thiazolidinedione use in medicare patients with heart failure. ACC Current Journal Review 2003, 12: 47. DOI: 10.1016/j.accreview.2003.08.074.
- Inzucchi S, Sherwin R. Applying the Lessons of the DPP to Clinical Practice. Clinical Diabetes 2003, 21: 91-92. DOI: 10.2337/diaclin.21.2.91.
- Wackers F, Young L, Inzucchi S, Chyun D, Davey J. Detection of ischemia in asymptomatic diabetics: Preliminary results of the DIAD study. Journal Of The American College Of Cardiology 2003, 41: 409. DOI: 10.1016/s0735-1097(03)81197-x.
- Inzucchi S. Noninvasive Assessment of the Diabetic Patient for Coronary Artery Disease. Diabetes Care 2001, 24: 1519-1521. PMID: 11522692, DOI: 10.2337/diacare.24.9.1519.
- Novella S, Inzucchi S, Goldstein J. The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. Muscle & Nerve 2001, 24: 1229-1231. PMID: 11494278, DOI: 10.1002/mus.1137.
- Nakchbandi I, Inzucchi S, Wirth J. Primary Pulmonary Hypertension and Thyroid Disease. Chest 2000, 118: 1224-1225. DOI: 10.1016/s0012-3692(15)37735-7.
- Nakchbandi I, Wirth J, Inzucchi S. Pulmonary Hypertension Caused by Graves’ Thyrotoxicosis Normal Pulmonary Hemodynamics Restored by 131I Treatment. Chest 1999, 116: 1483-1485. PMID: 10559121, DOI: 10.1378/chest.116.5.1483.
- Cline G, Petersen K, Krssak M, Shen J, Hundal R, Trajanoski Z, Inzucchi S, Dresner A, Rothman D, Shulman G. Impaired Glucose Transport as a Cause of Decreased Insulin-Stimulated Muscle Glycogen Synthesis in Type 2 Diabetes. The New England Journal Of Medicine 1999, 341: 240-246. PMID: 10413736, DOI: 10.1056/nejm199907223410404.
- Schwartz S, Raskin P, Fonseca V, Inzucchi S, Maggs D, Spollett G, Imura H. Troglitazone Improves Diabetic Control. The Nurse Practitioner 1998, 23: 96. DOI: 10.1097/00006205-199807000-00010.
- Inzucchi S, Maggs D, Spollett G, Page S, Rife F, Walton V, Shulman G. Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus. The New England Journal Of Medicine 1998, 338: 867-873. PMID: 9516221, DOI: 10.1056/nejm199803263381303.
- Inzucchi S. Growth Hormone in Adults: Indications and Implications. Hospital Practice 1997, 32: 79-96. PMID: 9006584, DOI: 10.1080/21548331.1997.11443405.
- Inzucchi S, Burrow G. Hyperthyroidism in pregnancy. Current Therapy In Endocrinology And Metabolism 1997, 6: 312-7. PMID: 9174760.
- Inzucchi S, Comite F, Burrow G. Graves’ Disease And Pregnancy. Endocrine Practice 1995, 1: 186-192. PMID: 15251592, DOI: 10.4158/ep.1.3.186.
- Inzucchi S. Clinical review 61: Effects of growth hormone on human bone biology. The Journal Of Clinical Endocrinology & Metabolism 1994, 79: 691-694. DOI: 10.1210/jc.79.3.691.
- Inzucchi S. Endocrinology clinical case seminars: a 23-year-old man with hypercalcemia, anemia, and weight loss. The Journal Of Clinical Endocrinology & Metabolism 1994, 79: 340-347. DOI: 10.1210/jc.79.2.340.
Locations
1
Yale Endocrinology
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste 4th Floor Multispecialty Care Center
New Haven, CT 06511
1 of 4
- Yale EndocrinologySmilow Cancer Hospital at Yale New Haven35 Park Street, Ste 4th Floor Multispecialty Care CenterNew Haven, CT 06511
- Yale Endocrinology & MetabolismYale New Haven Hospital20 York StreetNew Haven, CT 06510
- Yale Diabetes CenterDana Clinic Building789 Howard Avenue, Ste 2nd FloorNew Haven, CT 06519
- Yale Endocrinology & MetabolismYale Health Center55 Lock StreetNew Haven, CT 06511
1
Yale Endocrinology
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste 4th Floor Multispecialty Care Center
New Haven, CT 06511
1 of 4
- Yale EndocrinologySmilow Cancer Hospital at Yale New Haven35 Park Street, Ste 4th Floor Multispecialty Care CenterNew Haven, CT 06511
- Yale Endocrinology & MetabolismYale New Haven Hospital20 York StreetNew Haven, CT 06510
- Yale Diabetes CenterDana Clinic Building789 Howard Avenue, Ste 2nd FloorNew Haven, CT 06519
- Yale Endocrinology & MetabolismYale Health Center55 Lock StreetNew Haven, CT 06511